The condensed heteroaryl compound acts as a calcium-dependent / calmodulin-dependent protein kinase II inhibitor, and pharmaceutical preparations containing it are also used.

Abstract

The invention proposes a condensed heteroaryl compound acting as a CaMKII inhibitor, which is expected to be useful as a substance for the prevention or treatment of heart diseases (especially polymorphic ventricular tachycardias associated with catecholamines, postoperative atrial fibrillation, heart failure, fatal arrhythmias) and similar diseases. The invention relates to a compound of formula (I), in which each member is as defined in the description, or its pharmaceutical salt. A drug containing it is also proposed.

Description

DESCRIPTION Title of the Invention: Fused heteroaryl compounds and their use as CaMKII inhibitors Technical Field

[0001] The present invention relates to a fused heteroaryl compound having a calcium / calmodulin-dependent protein kinase II (sometimes to be abbreviated as “CaMKII” in the present specification) inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like.

[0002] (Background of the Invention) Cardiac diseases include heart failure, arrhythmia, myocardial infarction, angina, valvular heart disease and the like, and they are high-mortality diseases. In treatment of cardiac diseases with a drug, the symptoms are improved by control of each risk factor and symptomatic therapy. However, the satisfaction with treatment remains low level, and there is now no definitive therapy. Calcium-calmodulin complex binds to Ca2+ / calmodulin- dependent protein kinase (CaMK) included in serine / threonine protein kinase, and activates the kinase. The CaMK family includes CaMKII, and four isoforms (α, β, γ and δ) exist as CaMKII. CaMKII α and CaMKII β are expressed mainly in cerebral tissue, and CaMKII γ and CaMKII δ are expressed in many tissues including heart. CaMKII is activated by amino acid-modification due to oxidative stress or hyperglycemia, in addition to the binding of calcium-calmodulin complex. CaMKII regulates cell functions by phosphorylation of a transcription factor which is a substrate, a protein that plays a function in organelle uptake / excretion of Ca2+, a protein that regulates contract and relax of muscles, a channel that regulates an intracellular ion concentration, and the like, due to its kinase activation.Some documents suggest that CaMKII plays a harmful role in progress of cardiac disease conditions. Expression and activity of CaMKII are increased in heart of human patient or animal with heart failure (Non-Patent Documents 1-4). In transgenic mouse overexpressing CaMKII δ in heart, onsets of cardiac hypertrophy and heart failure are reported (Non-Patent Document 4). By studies using an inhibitor by a pharmacological method, and studies using a gene deletion by genetic method, protecting effects on heart failure, cardiac hypertrophy, myocardial infarction and arrhythmia by an inhibition of CaMKII and an overexpression of CaMKII inhibitory protein are reported in mouse (Non-Patent Documents 5-7). For catecholaminergic polymorphic ventricular tachycardia, improving effects on disease conditions by CaMKII inhibitor in mutant ryanodine knock-in mouse (RyR2R4496C+ / -mouse) are reported (Non-Patent Document 8). These findings suggest availabilities of CaMKII inhibitors in the prophylaxis and / or treatment of cardiac diseases including heart failure, cardiac hypertrophy, myocardial infarction and cardiac arrhythmia. Recently, CaMKII exacerbating action on growth or metastasis of a certain type of cancer is suggested (Non-Patent Document 9). In addition, therapeutic effect on acute renal failure, intimal hypertrophy, hepatic fibrosis, stroke, pain, rheumatoid arthritis and the like by CaMKII inhibition are also indicated (Non-Patent Documents 10-15). However, genetic methods achieve only deficiency of protein or overexpression of inhibitory protein, and they are different from a mechanism which inhibits temporarily kinase activity, and therefore, effects by kinase inhibitor cannot be always expected. In addition, inhibitors which have been already reported are not suitable for application as a medicament for a CaMKII selective inhibitor, because they have a low kinase selectivity to CaMKII, or they are not suitable for oral administration or chronic administration.

[0003] As a heterocyclic compound, the following compounds are known. Patent Document 1 describes that a compound represented bythe following formula (I):

[0004]

[0005] wherein each symbol is as defined in Patent Document 1, is a FLT3 inhibitor and useful for the treatment of acute myelogenous leukemia and the like.

[0006] Patent Document 2 describes that a compound represented by the following formula (I):

[0007]

[0008] wherein each symbol is as defined in Patent Document 2, is a Syk (Spleen tyrosine kinase) inhibitor and useful for the treatment of diseases or conditions mediated by Syk (e.g., rheumatism).

[0009] Patent Document 3 describes that a compound represented by the following formula (I):

[0010]

[0011] wherein each symbol is as defined in Patent Document 3, is a mGluR (metabotropic glutamate receptors)5 modulator anduseful for the treatment or prophylaxis of diseases or conditions in which mGluR5 is involved (e.g., pain disorder, anxiety, depression, Alzheimer's disease, Parkinson’s disease, etc.).

[0012] Patent Document 4 describes that a compound represented by the following formula (I):

[0013]

[0014] wherein each symbol is as defined in Patent Document 4, is a kinase inhibitor (particularly an inhibitor of kinase domain in VEGF receptor (VEGF receptor tyrosine kinase inhibitor)) and useful for the treatment of vascular abnormality, tumor, diabetic retinopathy, rheumatism, endometriosis, psoriasis and the like.

[0015] Patent Document 5 describes that a compound represented by the following formula (I):

[0016]

[0017] wherein each symbol is as defined in Patent Document 5, is a kinase (p38 kinase, etc.) inhibitor and useful for reduction of ischemic cell death (particularly reduction of traumatic neuronalcell death).

[0018] Patent Document 6 describes that a compound represented by the following formula (I):

[0019]

[0020] wherein each symbol is as defined in Patent Document 6, is a calcium / calmodulin-dependent protein kinase II inhibitor and useful for the prophylaxis or treatment of cardiac diseases. Document List Patent Document

[0021] Patent Document 1: WO 2013 / 157540 Patent Document 2: WO 2013 / 052394 Patent Document 3: WO 2005 / 021529 Patent Document 4: WO 2002 / 024681 Patent Document 5: WO 2002 / 011724 Patent Document 6: WO 2018 / 183112 Non-Patent Document

[0022] Non-Patent Document 1: European Journal of Heart Failure, vol.16, p.1292-1300 Non-Patent Document 2: Circulation Research, vol.84, p.713-721 Non-Patent Document 3: Molecular Endocrinology, vol.17, p.183-192 Non-Patent Document 4: Circulation Research, vol.92, p.912-919 Non-Patent Document 5: Proceedings of the National Academy of Sciences, vol.106, p.2342-2347 Non-Patent Document 6: Circulation Research, vol.112, p.935-944 Non-Patent Document 7: Nature, vol.502, p.372-376 Non-Patent Document 8: Journal of Molecular and Cellular Cardiology, vol.50, p.214-222 Non-Patent Document 9: Oncotarget, vol.20, p.11725-11734 Non-Patent Document 10: Arterioscler Thromb Vasc Biol, vol.28, p.441-447 Non-Patent Document 11: Cell Calcium, vol.45, p.284-292 Non-Patent Document 12: J Clin Invest, vol.119, p.2925-2941 Non-Patent Document 13: J Biol Chem, vol.285, p.20675-20682Non-Patent Document 14: J Pharmacol Exp Ther, vol.325, p.267-275 Non-Patent Document 15: BMC Musculoskelet Disord, vol.30, p.61 Summary of the Invention Problems to be Solved by the Invention

[0023] An object of the present invention is to provide a fused heteroaryl compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. Means of Solving the Problems

[0024] The present inventors have conducted intensive studies in an attempt to solve the above-mentioned problems and found that a compound represented by the following formula (I) has a CaMKII inhibitory action, and therefore, is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like, which resulted in the completion of the present invention.

[0025] Accordingly, the present invention provides the following. [1] A compound represented by the formula (I):

[0026]

[0027] wherein X1is N or CRX1wherein RX1is a hydrogen atom, a halogen atom or aC1-6alkyl group; X2, X3and X4are each independently C or N, and one of X2, X3and X4is N, and the other two are C; X5is N or CRX5wherein RX5is a hydrogen atom; X6is N or CRX6wherein RX6is a hydrogen atom; Ring A1is an optionally further substituted C6-14aromatic hydrocarbon, an optionally further substituted aromatic heterocycle, or an optionally further substituted non-aromatic heterocycle, each of which is optionally fused with an optionally substituted 5- or 6-membered ring; Y1is N or CRY1wherein RY1is a hydrogen atom; Y2is N or CRY2wherein RY2is a hydrogen atom, a halogen atom or a cyano group; Y3is N or CRY3wherein RY3is a hydrogen atom or a halogen atom; Y4is N or CRY4wherein RY4is a hydrogen atom or a halogen atom; Ring B1is an optionally further substituted aromatic heterocycle; V is O, S, S(O), S(O)2or N(RV) wherein RVis a hydrogen atom or an optionally substituted C1-6alkyl group; and Z is an optionally substituted C1-6alkylene group; or a pharmaceutically acceptable salt thereof (hereinafter sometimes to be referred to as compound (I)).

[0028] [2] The compound or pharmaceutically acceptable salt according to the above-mentioned [1], wherein V is O. [3] The compound or pharmaceutically acceptable salt according to the above-mentioned [1], wherein Ring B1is an optionally further substituted 5-membered aromatic heterocycle. [4] The compound or pharmaceutically acceptable salt according to the above-mentioned [1], wherein Z is an optionally substituted ethylene group. [5] The compound or pharmaceutically acceptable salt according to the above-mentioned [1], wherein X5is N. [6] The compound or pharmaceutically acceptable salt according to the above-mentioned [1], wherein X6is CH. [7] The compound or pharmaceutically acceptable salt according to the above-mentioned [1], wherein at least one of Y1, Y2, Y3and Y4are N.

[0029] [8] The compound or pharmaceutically acceptable salt according to the above-mentioned [1], which is a compound represented by the formula (I-1):

[0030]

[0031] wherein each symbol is as defined in the above-mentioned [1], or a pharmaceutically acceptable salt thereof (hereinafter sometimes to be referred to as compound (I-1)).

[0032] [9] A compound represented by the formula (II):

[0033]

[0034] wherein X1is N or CRX1wherein RX1is a hydrogen atom, a halogen atom or aC1-6alkyl group; X2, X3and X4are each independently C or N, and one of X2, X3and X4is N, and the other two are C; Ring A2is an optionally further substituted benzene ring, an optionally further substituted 5- or 6-membered aromaticheterocycle, or an optionally further substituted 5- or 6- membered non-aromatic heterocycle, each of which is optionally fused with an optionally substituted 5- or 6-membered ring; Y1is N or CRY1wherein RY1is a hydrogen atom; Y2is N or CRY2wherein RY2is a hydrogen atom, a halogen atom or a cyano group; Y3is N or CRY3wherein RY3is a hydrogen atom or a halogen atom; Y4is N or CRY4wherein RY4is a hydrogen atom or a halogen atom; Ring B2is an optionally further substituted 5-membered aromatic heterocycle; and R1is a C1-6alkyl group; or a pharmaceutically acceptable salt thereof (hereinafter sometimes to be referred to as compound (II)).

[0035]

[0010] The compound or pharmaceutically acceptable salt according to the above-mentioned [9], wherein X1is CH.

[0011] The compound or pharmaceutically acceptable salt according to the above-mentioned [9], wherein Ring B2is tetrazole or triazole, each of which is bonded at its nitrogen.

[0012] The compound or pharmaceutically acceptable salt according to the above-mentioned [9], wherein R1is methyl.

[0013] The compound or pharmaceutically acceptable salt according to the above-mentioned [9], wherein Ring A2is a benzene ring, a 6-membered aromatic heterocycle, or a 6-membered non-aromatic heterocycle, each of which is further substituted by one cyano group and optionally further substituted.

[0014] The compound or pharmaceutically acceptable salt according to the above-mentioned [9], wherein at least one of Y1, Y2, Y3and Y4are N.

[0036]

[0015] The compound or pharmaceutically acceptable salt according to the above-mentioned [9], which is a compound represented by the formula (II-1):

[0037]

[0038] wherein each symbol is as defined in the above-mentioned [9], or a pharmaceutically acceptable salt thereof (hereinafter sometimes to be referred to as compound (II-1)).

[0039]

[0016] A compound represented by the formula (III):

[0040]

[0041] X2, X3and X4are each independently C or N, and one of X2, X3and X4is N, and the other two are C; Ring A3is an optionally further substituted benzene ring, an optionally further substituted 6-membered nitrogen-containing aromatic heterocycle, or an optionally further substituted 6- membered nitrogen-containing non-aromatic heterocycle; Y1is N or CRY1wherein RY1is a hydrogen atom; Y2is N or CRY2wherein RY2is a hydrogen atom, a halogen atom or a cyano group; Y3is N or CRY3wherein RY3is a hydrogen atom or a halogen atom; Y4is N or CRY4wherein RY4is a hydrogen atom or a halogen atom; andW is N or CH; or a pharmaceutically acceptable salt thereof (hereinafter sometimes to be referred to as compound (III)).

[0042]

[0017] The compound or pharmaceutically acceptable salt according to the above-mentioned

[0016] , wherein the partial structure represented by the formula;

[0043]

[0044] is a partial structure represented by the formula (A3-1)-(A3-9);

[0045]

[0046] wherein Q1is N or CRQ1wherein RQ1is(a) a hydrogen atom, (b) a cyano group, (c) a halogen atom, (d) a hydroxy group, (e) a carboxy group, (f) an amino group, (g) an optionally substituted C1-6alkyl group, (h) an optionally substituted C1-6alkoxy group, (i) a C1-6alkyl-carbonyl group, (j) a C1-6alkoxy-carbonyl group, (k) an optionally substituted mono- or di-C1-6alkylamino group, (l) an optionally substituted mono- or di-C1-6alkyl- carbonylamino group, (m) a mono- or di-C1-6alkoxy-carbonylamino group, (n) a mono- or di-C1-6alkyl-carbamoyl group, (o) a di-C1-6alkylsulfinylidenamino group, (p) a C3-10cycloalkyl group, (q) an optionally substituted C3-10cycloalkyloxy group, (r) a 3- to 8-membered monocyclic non-aromatic heterocyclic group, (s) an optionally substituted 3- to 8-membered monocyclic non- aromatic heterocyclyloxy, (t) an optionally substituted 3- to 8-membered monocyclic non- aromatic heterocyclylcarbonyl group, or (u) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group, Q2is N or CRQ2wherein RQ2is (a) a hydrogen atom, (b) a halogen atom, or (c) a C1-6alkoxy group, Q3is N or CRQ3wherein RQ3is (a) a hydrogen atom, (b) a cyano group, (c) a halogen atom, (d) a carboxy group, (e) an optionally substituted C1-6alkyl group,(f) an optionally substituted C1-6alkoxy group, (g) a C1-6alkyl-carbonyl group, (h) a C1-6alkoxy-carbonyl group, (i) a mono- or di-C1-6alkylamino group, (j) an optionally substituted mono- or di-C1-6alkyl-carbamoyl group, (k) a di-C1-6alkylsulfinylidenamino group, or (l) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group, Q4is N or CRQ4wherein RQ4is (a) a hydrogen atom, or (b) a halogen atom, and N of Q1, Q2, Q3and Q4is each optionally oxidized; RN1is a hydrogen atom or a C1-6alkyl group; RN2is a hydrogen atom or a C1-6alkyl group; RN3is a hydrogen atom or a C1-6alkyl group; and RN4is a hydrogen atom or a C1-6alkyl group optionally substituted by 1 to 3 halogen atoms.

[0018] The compound or pharmaceutically acceptable salt according to the above-mentioned

[0016] , wherein at least one of Y1, Y2, Y3and Y4are N.

[0047]

[0019] The compound or pharmaceutically acceptable salt according to the above-mentioned

[0016] , which is a compound represented by the formula (III-1):

[0048]

[0049] wherein each symbol is as defined in the above-mentioned

[0016] ,or a pharmaceutically acceptable salt thereof (hereinafter sometimes to be referred to as compound (III-1)).

[0050]

[0020] A compound selected from the group consisting of 2-[6-(4-fluoro-3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]benzonitrile, 2-[6-(4-fluoro-3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]pyridine-3- carbonitrile, 2-[6-(3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]pyridine-3- carbonitrile, 2-[5-(3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2-yl]oxy}phenyl)-3H- imidazo[4,5-b]pyridin-3-yl]pyridine-3-carbonitrile, 4-fluoro-2-[6-(5-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}pyridin-3-yl)imidazo[1,2-b]pyridazin-3-yl]benzonitrile, 4-methoxy-2-[6-(3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]pyridine-3- carbonitrile, 2-[6-(4-fluoro-3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]-4-methoxypyridine-3- carbonitrile, 4-fluoro-2-[5-(6-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}pyridin-2-yl)-3H-imidazo[4,5-b]pyridin-3-yl]benzonitrile, 4-fluoro-2-methoxy-6-[6-(6-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}pyrazin-2-yl)imidazo[1,2-b]pyridazin-3-yl]benzonitrile, 4-fluoro-2-methoxy-6-[5-(6-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}pyridin-2-yl)-3H-imidazo[4,5-b]pyridin-3-yl]benzonitrile, and 4-fluoro-2-methoxy-6-[6-(6-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}pyridin-2-yl)imidazo[1,2-b]pyridazin-3-yl]benzonitrile, or a pharmaceutically acceptable salt.

[0051]

[0021] A medicament comprising the compound or pharmaceutically acceptable salt according to the above-mentioned [1].

[0022] The medicament according to the above-mentioned

[0021] , which is a calcium / calmodulin-dependent protein kinase II inhibitor.

[0023] The medicament according to the above-mentioned

[0021] , which is an agent for the prophylaxis or treatment of cardiac diseases.

[0024] The medicament according to the above-mentioned

[0023] , wherein the cardiac disease is selected from catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure and fatal arrhythmia.

[0052]

[0025] The compound or pharmaceutically acceptable salt according to the above-mentioned [1] for use in the prophylaxis or treatment of cardiac diseases.

[0026] The compound or pharmaceutically acceptable salt according to the above-mentioned

[0025] , wherein the cardiac disease is selected from catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure and fatal arrhythmia.

[0053]

[0027] A method for inhibiting calcium / calmodulin-dependent protein kinase II in a mammal, which comprises administering an effective amount of the compound or pharmaceutically acceptable salt according to the above-mentioned [1] to the mammal.

[0028] A method for preventing or treating cardiac diseases in a mammal, which comprises administering an effective amount of the compound or pharmaceutically acceptable salt according to the above-mentioned [1] to the mammal.

[0029] The method according to the above-mentioned

[0028] , wherein the cardiac disease is selected from catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure and fatal arrhythmia.

[0054]

[0030] Use of the compound or pharmaceutically acceptable salt according to the above-mentioned [1] for the production of an agent for the prophylaxis or treatment of cardiac diseases.

[0031] The use according to the above-mentioned

[0030] , wherein the cardiac disease is selected from catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure and fatal arrhythmia. Effect of the Invention

[0055] According to the present invention, a fused heteroaryl compound having a superior CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like can be provided.

[0056] (Detailed Description of the Invention) The present invention is explained in detail in the following.

[0057] The definition of each substituent used in the present specification is described in detail in the following. Unless otherwise specified, each substituent has the following definition. In the present specification, examples of the “halogen atom” include fluorine, chlorine, bromine and iodine. In the present specification, examples of the “C1-6alkyl group” include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1- ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2- dimethylbutyl, 3,3-dimethylbutyl and 2-ethylbutyl. In the present specification, examples of the “optionally halogenated C1-6alkyl group” include a C1-6alkyl group optionally having 1 to 7, preferably 1 to 5, halogen atoms. Specific examples thereof include methyl, chloromethyl, difluoromethyl, trichloromethyl, trifluoromethyl, ethyl, 2-bromoethyl, 2,2,2- trifluoroethyl, tetrafluoroethyl, pentafluoroethyl, propyl, 2,2- difluoropropyl, 3,3,3-trifluoropropyl, isopropyl, butyl, 4,4,4- trifluorobutyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 5,5,5-trifluoropentyl, hexyl and 6,6,6- trifluorohexyl. In the present specification, examples of the “C2-6alkenyl group” include ethenyl, 1-propenyl, 2-propenyl, 2-methyl-1- propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 3-methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3- pentenyl, 1-hexenyl, 3-hexenyl and 5-hexenyl. In the present specification, examples of the “C2-6alkynyl group” include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2- butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4- pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl and 4-methyl-2-pentynyl. In the present specification, examples of the “C3-10cycloalkyl group” include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl and adamantyl. In the present specification, examples of the “optionally halogenated C3-10cycloalkyl group” include a C3-10cycloalkyl group optionally having 1 to 7, preferably 1 to 5, halogen atoms. Specific examples thereof include cyclopropyl, 2,2- difluorocyclopropyl, 2,3-difluorocyclopropyl, cyclobutyl, difluorocyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. In the present specification, examples of the “C3-10cycloalkenyl group” include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl. In the present specification, examples of the “C6-14aryl group” include phenyl, 1-naphthyl, 2-naphthyl, 1-anthryl, 2- anthryl and 9-anthryl. In the present specification, examples of the “C7-16aralkyl group” include benzyl, phenethyl, naphthylmethyl and phenylpropyl.

[0058] In the present specification, examples of the “C1-6alkoxy group” include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy and hexyloxy. In the present specification, examples of the “optionally halogenated C1-6alkoxy group” include a C1-6alkoxy group optionally having 1 to 7, preferably 1 to 5, halogen atoms. Specific examples thereof include methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, 2,2,2-trifluoroethoxy, propoxy, isopropoxy, butoxy, 4,4,4-trifluorobutoxy, isobutoxy, sec-butoxy,pentyloxy and hexyloxy. In the present specification, examples of the “C3-10cycloalkyloxy group” include cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy and cyclooctyloxy. In the present specification, examples of the “C1-6alkylthio group” include methylthio, ethylthio, propylthio, isopropylthio, butylthio, sec-butylthio, tert-butylthio, pentylthio and hexylthio. In the present specification, examples of the “optionally halogenated C1-6alkylthio group” include a C1-6alkylthio group optionally having 1 to 7, preferably 1 to 5, halogen atoms. Specific examples thereof include methylthio, difluoromethylthio, trifluoromethylthio, ethylthio, propylthio, isopropylthio, butylthio, 4,4,4-trifluorobutylthio, pentylthio and hexylthio. In the present specification, examples of the “C1-6alkyl- carbonyl group” include acetyl, propanoyl, butanoyl, 2- methylpropanoyl, pentanoyl, 3-methylbutanoyl, 2-methylbutanoyl, 2,2-dimethylpropanoyl, hexanoyl and heptanoyl. In the present specification, examples of the “optionally halogenated C1-6alkyl-carbonyl group” include a C1-6alkyl- carbonyl group optionally having 1 to 7, preferably 1 to 5, halogen atoms. Specific examples thereof include acetyl, chloroacetyl, trifluoroacetyl, trichloroacetyl, propanoyl, butanoyl, pentanoyl and hexanoyl. In the present specification, examples of the “C1-6alkoxy- carbonyl group” include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl and hexyloxycarbonyl. In the present specification, examples of the “C6-14aryl- carbonyl group” include benzoyl, 1-naphthoyl and 2-naphthoyl. In the present specification, examples of the “C7-16aralkyl-carbonyl group” include phenylacetyl and phenylpropionyl. In the present specification, examples of the “5- to 14- membered aromatic heterocyclylcarbonyl group” include nicotinoyl, isonicotinoyl, thenoyl and furoyl. In the present specification, examples of the “3- to 14-membered non-aromatic heterocyclylcarbonyl group” include morpholinylcarbonyl, piperidinylcarbonyl and pyrrolidinylcarbonyl.

[0059] In the present specification, examples of the “mono- or di-C1-6alkyl-carbamoyl group” include methylcarbamoyl, ethylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl and N-ethyl- N-methylcarbamoyl. In the present specification, examples of the “mono- or di- C7-16aralkyl-carbamoyl group” include benzylcarbamoyl and phenethylcarbamoyl. In the present specification, examples of the “C1-6alkylsulfonyl group” include methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, sec- butylsulfonyl and tert-butylsulfonyl. In the present specification, examples of the “optionally halogenated C1-6alkylsulfonyl group” include a C1-6alkylsulfonyl group optionally having 1 to 7, preferably 1 to 5, halogen atoms. Specific examples thereof include methylsulfonyl, difluoromethylsulfonyl, trifluoromethylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, 4,4,4- trifluorobutylsulfonyl, pentylsulfonyl and hexylsulfonyl. In the present specification, examples of the “C6-14arylsulfonyl group” include phenylsulfonyl, 1-naphthylsulfonyl and 2-naphthylsulfonyl.

[0060] In the present specification, examples of the “substituent” include a halogen atom, a cyano group, a nitro group, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an acyl group, an optionally substituted amino group, an optionally substituted carbamoyl group, an optionally substituted thiocarbamoyl group, an optionally substituted sulfamoyl group, an optionally substituted hydroxy group, an optionally substituted sulfanyl (SH) group and an optionally substituted silyl group. In the present specification, examples of the “hydrocarbon group” (including “hydrocarbon group” of “optionally substitutedhydrocarbon group”) include a C1-6alkyl group, a C2-6alkenyl group, a C2-6alkynyl group, a C3-10cycloalkyl group, a C3-10cycloalkenyl group, a C6-14aryl group and a C7-16aralkyl group.

[0061] In the present specification, examples of the “optionally substituted hydrocarbon group” include a hydrocarbon group optionally having substituent(s) selected from the following Substituent Group A. [Substituent Group A] (1) a halogen atom, (2) a nitro group, (3) a cyano group, (4) an oxo group, (5) a hydroxy group, (6) an optionally halogenated C1-6alkoxy group, (7) a C6-14aryloxy group (e.g., phenoxy, naphthoxy), (8) a C7-16aralkyloxy group (e.g., benzyloxy), (9) a 5- to 14-membered aromatic heterocyclyloxy group (e.g., pyridyloxy), (10) a 3- to 14-membered non-aromatic heterocyclyloxy group (e.g., morpholinyloxy, piperidinyloxy), (11) a C1-6alkyl-carbonyloxy group (e.g., acetoxy, propanoyloxy), (12) a C6-14aryl-carbonyloxy group (e.g., benzoyloxy, 1- naphthoyloxy, 2-naphthoyloxy), (13) a C1-6alkoxy-carbonyloxy group (e.g., methoxycarbonyloxy, ethoxycarbonyloxy, propoxycarbonyloxy, butoxycarbonyloxy), (14) a mono- or di-C1-6alkyl-carbamoyloxy group (e.g., methylcarbamoyloxy, ethylcarbamoyloxy, dimethylcarbamoyloxy, diethylcarbamoyloxy), (15) a C6-14aryl-carbamoyloxy group (e.g., phenylcarbamoyloxy, naphthylcarbamoyloxy), (16) a 5- to 14-membered aromatic heterocyclylcarbonyloxy group (e.g., nicotinoyloxy), (17) a 3- to 14-membered non-aromatic heterocyclylcarbonyloxy group (e.g., morpholinylcarbonyloxy, piperidinylcarbonyloxy), (18) an optionally halogenated C1-6alkylsulfonyloxy group (e.g., methylsulfonyloxy, trifluoromethylsulfonyloxy),(19) a C6-14arylsulfonyloxy group optionally substituted by a C1-6alkyl group (e.g., phenylsulfonyloxy, toluenesulfonyloxy), (20) an optionally halogenated C1-6alkylthio group, (21) a 5- to 14-membered aromatic heterocyclic group, (22) a 3- to 14-membered non-aromatic heterocyclic group, (23) a formyl group, (24) a carboxy group, (25) an optionally halogenated C1-6alkyl-carbonyl group, (26) a C6-14aryl-carbonyl group, (27) a 5- to 14-membered aromatic heterocyclylcarbonyl group, (28) a 3- to 14-membered non-aromatic heterocyclylcarbonyl group, (29) a C1-6alkoxy-carbonyl group, (30) a C6-14aryloxy-carbonyl group (e.g., phenyloxycarbonyl, 1- naphthyloxycarbonyl, 2-naphthyloxycarbonyl), (31) a C7-16aralkyloxy-carbonyl group (e.g., benzyloxycarbonyl, phenethyloxycarbonyl), (32) a carbamoyl group, (33) a thiocarbamoyl group, (34) a mono- or di-C1-6alkyl-carbamoyl group, (35) a C6-14aryl-carbamoyl group (e.g., phenylcarbamoyl), (36) a 5- to 14-membered aromatic heterocyclylcarbamoyl group (e.g., pyridylcarbamoyl, thienylcarbamoyl), (37) a 3- to 14-membered non-aromatic heterocyclylcarbamoyl group (e.g., morpholinylcarbamoyl, piperidinylcarbamoyl), (38) an optionally halogenated C1-6alkylsulfonyl group, (39) a C6-14arylsulfonyl group, (40) a 5- to 14-membered aromatic heterocyclylsulfonyl group (e.g., pyridylsulfonyl, thienylsulfonyl), (41) an optionally halogenated C1-6alkylsulfinyl group, (42) a C6-14arylsulfinyl group (e.g., phenylsulfinyl, 1- naphthylsulfinyl, 2-naphthylsulfinyl), (43) a 5- to 14-membered aromatic heterocyclylsulfinyl group (e.g., pyridylsulfinyl, thienylsulfinyl), (44) an amino group, (45) a mono- or di-C1-6alkylamino group (e.g., methylamino, ethylamino, propylamino, isopropylamino, butylamino, dimethylamino, diethylamino, dipropylamino, dibutylamino, N-ethyl-N-methylamino), (46) a mono- or di-C6-14arylamino group (e.g., phenylamino), (47) a 5- to 14-membered aromatic heterocyclylamino group (e.g., pyridylamino), (48) a C7-16aralkylamino group (e.g., benzylamino), (49) a formylamino group, (50) a C1-6alkyl-carbonylamino group (e.g., acetylamino, propanoylamino, butanoylamino), (51) a (C1-6alkyl)(C1-6alkyl-carbonyl) amino group (e.g., N- acetyl-N-methylamino), (52) a C6-14aryl-carbonylamino group (e.g., phenylcarbonylamino, naphthylcarbonylamino), (53) a C1-6alkoxy-carbonylamino group (e.g., methoxycarbonylamino, ethoxycarbonylamino, propoxycarbonylamino, butoxycarbonylamino, tert-butoxycarbonylamino), (54) a C7-16aralkyloxy-carbonylamino group (e.g., benzyloxycarbonylamino), (55) a C1-6alkylsulfonylamino group (e.g., methylsulfonylamino, ethylsulfonylamino), (56) a C6-14arylsulfonylamino group optionally substituted by a C1-6alkyl group (e.g., phenylsulfonylamino, toluenesulfonylamino), (57) an optionally halogenated C1-6alkyl group, (58) a C2-6alkenyl group, (59) a C2-6alkynyl group, (60) a C3-10cycloalkyl group, (61) a C3-10cycloalkenyl group, and (62) a C6-14aryl group.

[0062] The number of the above-mentioned substituents in the “optionally substituted hydrocarbon group” is, for example, 1 to 5, preferably 1 to 3. When the number of the substituents is two or more, the respective substituents may be the same or different. In the present specification, examples of the “heterocyclic group” (including “heterocyclic group” of “optionally substituted heterocyclic group”) include (i) an aromatic heterocyclic group,(ii) a non-aromatic heterocyclic group and (iii) a 7- to 10- membered bridged heterocyclic group, each containing, as a ring- constituting atom besides carbon atom, 1 to 4 heteroatoms selected from a nitrogen atom, a sulfur atom and an oxygen atom.

[0063] In the present specification, examples of the “aromatic heterocyclic group” (including “5- to 14-membered aromatic heterocyclic group”) include a 5- to 14-membered (preferably 5- to 10-membered) aromatic heterocyclic group containing, as a ring-constituting atom besides carbon atom, 1 to 4 heteroatoms selected from a nitrogen atom, a sulfur atom and an oxygen atom. Preferable examples of the “aromatic heterocyclic group” include 5- or 6-membered monocyclic aromatic heterocyclic groups such as thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1,2,4-oxadiazolyl, 1,3,4- oxadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, triazolyl, tetrazolyl, triazinyl and the like; and 8- to 14-membered fused polycyclic (preferably bi or tricyclic) aromatic heterocyclic groups such as benzothiophenyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, imidazopyridinyl, thienopyridinyl, furopyridinyl, pyrrolopyridinyl, pyrazolopyridinyl, oxazolopyridinyl, thiazolopyridinyl, imidazopyrazinyl, imidazopyrimidinyl, thienopyrimidinyl, furopyrimidinyl, pyrrolopyrimidinyl, pyrazolopyrimidinyl, oxazolopyrimidinyl, thiazolopyrimidinyl, pyrazolotriazinyl, naphtho[2,3-b]thienyl, phenoxathiinyl, indolyl, isoindolyl, 1H-indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, β-carbolinyl, phenanthridinyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl and the like.

[0064] In the present specification, examples of the “non-aromatic heterocyclic group” (including “3- to 14-membered non-aromatic heterocyclic group”) include a 3- to 14-membered (preferably 4-to 10-membered) non-aromatic heterocyclic group containing, as a ring-constituting atom besides carbon atom, 1 to 4 heteroatoms selected from a nitrogen atom, a sulfur atom and an oxygen atom. Preferable examples of the “non-aromatic heterocyclic group” include 3- to 8-membered monocyclic non-aromatic heterocyclic groups such as aziridinyl, oxiranyl, thiiranyl, azetidinyl, oxetanyl, thietanyl, tetrahydrothienyl, tetrahydrofuranyl, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, oxazolinyl, oxazolidinyl, pyrazolinyl, pyrazolidinyl, thiazolinyl, thiazolidinyl, tetrahydroisothiazolyl, tetrahydrooxazolyl, tetrahydroisooxazolyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydropyridinyl, dihydrothiopyranyl, tetrahydropyrimidinyl, tetrahydropyridazinyl, dihydropyranyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholinyl, thiomorpholinyl, azepanyl, diazepanyl, azepinyl, oxepanyl, azocanyl, diazocanyl and the like; and 9- to 14-membered fused polycyclic (preferably bi or tricyclic) non-aromatic heterocyclic groups such as dihydrobenzofuranyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, dihydrobenzothiazolyl, dihydrobenzisothiazolyl, dihydronaphtho[2,3-b]thienyl, tetrahydroisoquinolyl, tetrahydroquinolyl, 4H-quinolizinyl, indolinyl, isoindolinyl, tetrahydrothieno[2,3-c]pyridinyl, tetrahydrobenzazepinyl, tetrahydroquinoxalinyl, tetrahydrophenanthridinyl, hexahydrophenothiazinyl, hexahydrophenoxazinyl, tetrahydrophthalazinyl, tetrahydronaphthyridinyl, tetrahydroquinazolinyl, tetrahydrocinnolinyl, tetrahydrocarbazolyl, tetrahydro-β-carbolinyl, tetrahydroacrydinyl, tetrahydrophenazinyl, tetrahydrothioxanthenyl, octahydroisoquinolyl and the like.

[0065] In the present specification, preferable examples of the “7- to 10-membered bridged heterocyclic group” include quinuclidinyl and 7-azabicyclo[2.2.1]heptanyl. In the present specification, examples of the “nitrogen- containing heterocyclic group” include a “heterocyclic group”containing at least one nitrogen atom as a ring-constituting atom. In the present specification, examples of the “optionally substituted heterocyclic group” include a heterocyclic group optionally having substituent(s) selected from the above- mentioned Substituent Group A. The number of the substituents in the “optionally substituted heterocyclic group” is, for example, 1 to 3. When the number of the substituents is two or more, the respective substituents may be the same or different.

[0066] In the present specification, examples of the “acyl group” include a formyl group, a carboxy group, a carbamoyl group, a thiocarbamoyl group, a sulfino group, a sulfo group, a sulfamoyl group and a phosphono group, each optionally having “1 or 2 substituents selected from a C1-6alkyl group, a C2-6alkenyl group, a C3-10cycloalkyl group, a C3-10cycloalkenyl group, a C6-14aryl group, a C7-16aralkyl group, a 5- to 14-membered aromatic heterocyclic group and a 3- to 14-membered non-aromatic heterocyclic group, each of which optionally has 1 to 3 substituents selected from a halogen atom, an optionally halogenated C1-6alkoxy group, a hydroxy group, a nitro group, a cyano group, an amino group and a carbamoyl group”. Examples of the “acyl group” also include a hydrocarbon- sulfonyl group, a heterocyclylsulfonyl group, a hydrocarbon- sulfinyl group and a heterocyclylsulfinyl group. Here, the hydrocarbon-sulfonyl group means a hydrocarbon group-bonded sulfonyl group, the heterocyclylsulfonyl group means a heterocyclic group-bonded sulfonyl group, the hydrocarbon- sulfinyl group means a hydrocarbon group-bonded sulfinyl group and the heterocyclylsulfinyl group means a heterocyclic group- bonded sulfinyl group. Preferable examples of the “acyl group” include a formyl group, a carboxy group, a C1-6alkyl-carbonyl group, a C2-6alkenyl-carbonyl group (e.g., crotonoyl), a C3-10cycloalkyl- carbonyl group (e.g., cyclobutanecarbonyl, cyclopentanecarbonyl, cyclohexanecarbonyl, cycloheptanecarbonyl), a C3-10cycloalkenyl-carbonyl group (e.g., 2-cyclohexenecarbonyl), a C6-14aryl-carbonyl group, a C7-16aralkyl-carbonyl group, a 5- to 14-membered aromatic heterocyclylcarbonyl group, a 3- to 14-membered non-aromatic heterocyclylcarbonyl group, a C1-6alkoxy-carbonyl group, a C6-14aryloxy-carbonyl group (e.g., phenyloxycarbonyl, naphthyloxycarbonyl), a C7-16aralkyloxy-carbonyl group (e.g., benzyloxycarbonyl, phenethyloxycarbonyl), a carbamoyl group, a mono- or di-C1-6alkyl-carbamoyl group, a mono- or di-C2-6alkenyl- carbamoyl group (e.g., diallylcarbamoyl), a mono- or di-C3-10cycloalkyl-carbamoyl group (e.g., cyclopropylcarbamoyl), a mono- or di-C6-14aryl-carbamoyl group (e.g., phenylcarbamoyl), a mono- or di-C7-16aralkyl-carbamoyl group, a 5- to 14-membered aromatic heterocyclylcarbamoyl group (e.g., pyridylcarbamoyl), a thiocarbamoyl group, a mono- or di-C1-6alkyl-thiocarbamoyl group (e.g., methylthiocarbamoyl, N-ethyl-N-methylthiocarbamoyl), a mono- or di-C2-6alkenyl-thiocarbamoyl group (e.g., diallylthiocarbamoyl), a mono- or di-C3-10cycloalkyl-thiocarbamoyl group (e.g., cyclopropylthiocarbamoyl, cyclohexylthiocarbamoyl), a mono- or di-C6-14aryl-thiocarbamoyl group (e.g., phenylthiocarbamoyl), a mono- or di-C7-16aralkyl-thiocarbamoyl group (e.g., benzylthiocarbamoyl, phenethylthiocarbamoyl), a 5- to 14-membered aromatic heterocyclylthiocarbamoyl group (e.g., pyridylthiocarbamoyl), a sulfino group, a C1-6alkylsulfinyl group (e.g., methylsulfinyl, ethylsulfinyl), a sulfo group, a C1-6alkylsulfonyl group, a C6-14arylsulfonyl group, a phosphono group and a mono- or di-C1-6alkylphosphono group (e.g., dimethylphosphono, diethylphosphono, diisopropylphosphono, dibutylphosphono).

[0067] In the present specification, examples of the “optionally substituted amino group” include an amino group optionally having “1 or 2 substituents selected from a C1-6alkyl group, a C2-6alkenyl group, a C3-10cycloalkyl group, a C6-14aryl group, a C7-16aralkyl group, a C1-6alkyl-carbonyl group, a C6-14aryl-carbonyl group, a C7-16aralkyl-carbonyl group, a 5- to 14-membered aromatic heterocyclylcarbonyl group, a 3- to 14-membered non-aromatic heterocyclylcarbonyl group, a C1-6alkoxy-carbonyl group, a 5- to14-membered aromatic heterocyclic group, a carbamoyl group, a mono- or di-C1-6alkyl-carbamoyl group, a mono- or di-C7-16aralkyl- carbamoyl group, a C1-6alkylsulfonyl group and a C6-14arylsulfonyl group, each of which optionally has 1 to 3 substituents selected from Substituent Group A”. Preferable examples of the optionally substituted amino group include an amino group, a mono- or di-(optionally halogenated C1-6alkyl) amino group (e.g., methylamino, trifluoromethylamino, dimethylamino, ethylamino, diethylamino, propylamino, dibutylamino), a mono- or di-C2-6alkenylamino group (e.g., diallylamino), a mono- or di-C3-10cycloalkylamino group (e.g., cyclopropylamino, cyclohexylamino), a mono- or di-C6-14arylamino group (e.g., phenylamino), a mono- or di-C7-16aralkylamino group (e.g., benzylamino, dibenzylamino), a mono- or di-(optionally halogenated C1-6alkyl)-carbonylamino group (e.g., acetylamino, propionylamino), a mono- or di-C6-14aryl- carbonylamino group (e.g., benzoylamino), a mono- or di-C7-16aralkyl-carbonylamino group (e.g., benzylcarbonylamino), a mono- or di-5- to 14-membered aromatic heterocyclylcarbonylamino group (e.g., nicotinoylamino, isonicotinoylamino), a mono- or di-3- to 14-membered non-aromatic heterocyclylcarbonylamino group (e.g., piperidinylcarbonylamino), a mono- or di-C1-6alkoxy-carbonylamino group (e.g., tert-butoxycarbonylamino), a 5- to 14-membered aromatic heterocyclylamino group (e.g., pyridylamino), a carbamoylamino group, a (mono- or di-C1-6alkyl-carbamoyl) amino group (e.g., methylcarbamoylamino), a (mono- or di-C7-16aralkyl- carbamoyl) amino group (e.g., benzylcarbamoylamino), a C1-6alkylsulfonylamino group (e.g., methylsulfonylamino, ethylsulfonylamino), a C6-14arylsulfonylamino group (e.g., phenylsulfonylamino), a (C1-6alkyl)(C1-6alkyl-carbonyl) amino group (e.g., N-acetyl-N-methylamino) and a (C1-6alkyl)(C6-14aryl- carbonyl) amino group (e.g., N-benzoyl-N-methylamino).

[0068] In the present specification, examples of the “optionally substituted carbamoyl group” include a carbamoyl group optionally having “1 or 2 substituents selected from a C1-6alkyl group, a C2-6alkenyl group, a C3-10cycloalkyl group, a C6-14aryl group, a C7-16aralkyl group, a C1-6alkyl-carbonyl group, a C6-14aryl-carbonyl group, a C7-16aralkyl-carbonyl group, a 5- to 14-membered aromatic heterocyclylcarbonyl group, a 3- to 14-membered non-aromatic heterocyclylcarbonyl group, a C1-6alkoxy-carbonyl group, a 5- to 14-membered aromatic heterocyclic group, a carbamoyl group, a mono- or di-C1-6alkyl-carbamoyl group and a mono- or di-C7-16aralkyl-carbamoyl group, each of which optionally has 1 to 3 substituents selected from Substituent Group A”. Preferable examples of the optionally substituted carbamoyl group include a carbamoyl group, a mono- or di-C1-6alkyl- carbamoyl group, a mono- or di-C2-6alkenyl-carbamoyl group (e.g., diallylcarbamoyl), a mono- or di-C3-10cycloalkyl-carbamoyl group (e.g., cyclopropylcarbamoyl, cyclohexylcarbamoyl), a mono- or di- C6-14aryl-carbamoyl group (e.g., phenylcarbamoyl), a mono- or di- C7-16aralkyl-carbamoyl group, a mono- or di-C1-6alkyl-carbonyl- carbamoyl group (e.g., acetylcarbamoyl, propionylcarbamoyl), a mono- or di-C6-14aryl-carbonyl-carbamoyl group (e.g., benzoylcarbamoyl) and a 5- to 14-membered aromatic heterocyclylcarbamoyl group (e.g., pyridylcarbamoyl).

[0069] In the present specification, examples of the “optionally substituted thiocarbamoyl group” include a thiocarbamoyl group optionally having “1 or 2 substituents selected from a C1-6alkyl group, a C2-6alkenyl group, a C3-10cycloalkyl group, a C6-14aryl group, a C7-16aralkyl group, a C1-6alkyl-carbonyl group, a C6-14aryl-carbonyl group, a C7-16aralkyl-carbonyl group, a 5- to 14- membered aromatic heterocyclylcarbonyl group, a 3- to 14-membered non-aromatic heterocyclylcarbonyl group, a C1-6alkoxy-carbonyl group, a 5- to 14-membered aromatic heterocyclic group, a carbamoyl group, a mono- or di-C1-6alkyl-carbamoyl group and a mono- or di-C7-16aralkyl-carbamoyl group, each of which optionally has 1 to 3 substituents selected from Substituent Group A”. Preferable examples of the optionally substituted thiocarbamoyl group include a thiocarbamoyl group, a mono- or di- C1-6alkyl-thiocarbamoyl group (e.g., methylthiocarbamoyl, ethylthiocarbamoyl, dimethylthiocarbamoyl, diethylthiocarbamoyl, N-ethyl-N-methylthiocarbamoyl), a mono- or di-C2-6alkenyl-thiocarbamoyl group (e.g., diallylthiocarbamoyl), a mono- or di- C3-10cycloalkyl-thiocarbamoyl group (e.g., cyclopropylthiocarbamoyl, cyclohexylthiocarbamoyl), a mono- or di-C6-14aryl-thiocarbamoyl group (e.g., phenylthiocarbamoyl), a mono- or di-C7-16aralkyl-thiocarbamoyl group (e.g., benzylthiocarbamoyl, phenethylthiocarbamoyl), a mono- or di-C1-6alkyl-carbonyl-thiocarbamoyl group (e.g., acetylthiocarbamoyl, propionylthiocarbamoyl), a mono- or di-C6-14aryl-carbonyl- thiocarbamoyl group (e.g., benzoylthiocarbamoyl) and a 5- to 14- membered aromatic heterocyclylthiocarbamoyl group (e.g., pyridylthiocarbamoyl).

[0070] In the present specification, examples of the “optionally substituted sulfamoyl group” include a sulfamoyl group optionally having “1 or 2 substituents selected from a C1-6alkyl group, a C2-6alkenyl group, a C3-10cycloalkyl group, a C6-14aryl group, a C7-16aralkyl group, a C1-6alkyl-carbonyl group, a C6-14aryl-carbonyl group, a C7-16aralkyl-carbonyl group, a 5- to 14-membered aromatic heterocyclylcarbonyl group, a 3- to 14-membered non-aromatic heterocyclylcarbonyl group, a C1-6alkoxy-carbonyl group, a 5- to 14-membered aromatic heterocyclic group, a carbamoyl group, a mono- or di-C1-6alkyl-carbamoyl group and a mono- or di-C7-16aralkyl-carbamoyl group, each of which optionally has 1 to 3 substituents selected from Substituent Group A”. Preferable examples of the optionally substituted sulfamoyl group include a sulfamoyl group, a mono- or di-C1-6alkyl- sulfamoyl group (e.g., methylsulfamoyl, ethylsulfamoyl, dimethylsulfamoyl, diethylsulfamoyl, N-ethyl-N-methylsulfamoyl), a mono- or di-C2-6alkenyl-sulfamoyl group (e.g., diallylsulfamoyl), a mono- or di-C3-10cycloalkyl-sulfamoyl group (e.g., cyclopropylsulfamoyl, cyclohexylsulfamoyl), a mono- or di- C6-14aryl-sulfamoyl group (e.g., phenylsulfamoyl), a mono- or di- C7-16aralkyl-sulfamoyl group (e.g., benzylsulfamoyl, phenethylsulfamoyl), a mono- or di-C1-6alkyl-carbonyl-sulfamoyl group (e.g., acetylsulfamoyl, propionylsulfamoyl), a mono- or di- C6-14aryl-carbonyl-sulfamoyl group (e.g., benzoylsulfamoyl) and a 5- to 14-membered aromatic heterocyclylsulfamoyl group (e.g.,pyridylsulfamoyl).

[0071] In the present specification, examples of the “optionally substituted hydroxy group” include a hydroxy group optionally having “a substituent selected from a C1-6alkyl group, a C2-6alkenyl group, a C3-10cycloalkyl group, a C6-14aryl group, a C7-16aralkyl group, a C1-6alkyl-carbonyl group, a C6-14aryl-carbonyl group, a C7-16aralkyl-carbonyl group, a 5- to 14-membered aromatic heterocyclylcarbonyl group, a 3- to 14-membered non-aromatic heterocyclylcarbonyl group, a C1-6alkoxy-carbonyl group, a 5- to 14-membered aromatic heterocyclic group, a carbamoyl group, a mono- or di-C1-6alkyl-carbamoyl group, a mono- or di-C7-16aralkyl- carbamoyl group, a C1-6alkylsulfonyl group and a C6-14arylsulfonyl group, each of which optionally has 1 to 3 substituents selected from Substituent Group A”. Preferable examples of the optionally substituted hydroxy group include a hydroxy group, a C1-6alkoxy group, a C2-6alkenyloxy group (e.g., allyloxy, 2-butenyloxy, 2-pentenyloxy, 3- hexenyloxy), a C3-10cycloalkyloxy group (e.g., cyclohexyloxy), a C6-14aryloxy group (e.g., phenoxy, naphthyloxy), a C7-16aralkyloxy group (e.g., benzyloxy, phenethyloxy), a C1-6alkyl-carbonyloxy group (e.g., acetyloxy, propionyloxy, butyryloxy, isobutyryloxy, pivaloyloxy), a C6-14aryl-carbonyloxy group (e.g., benzoyloxy), a C7-16aralkyl-carbonyloxy group (e.g., benzylcarbonyloxy), a 5- to 14-membered aromatic heterocyclylcarbonyloxy group (e.g., nicotinoyloxy), a 3- to 14-membered non-aromatic heterocyclylcarbonyloxy group (e.g., piperidinylcarbonyloxy), aC1-6alkoxy-carbonyloxy group (e.g., tert-butoxycarbonyloxy), a 5- to 14-membered aromatic heterocyclyloxy group (e.g., pyridyloxy), a carbamoyloxy group, a C1-6alkyl-carbamoyloxy group (e.g., methylcarbamoyloxy), a C7-16aralkyl-carbamoyloxy group (e.g., benzylcarbamoyloxy), a C1-6alkylsulfonyloxy group (e.g., methylsulfonyloxy, ethylsulfonyloxy) and a C6-14arylsulfonyloxy group (e.g., phenylsulfonyloxy).

[0072] In the present specification, examples of the “optionally substituted sulfanyl group” include a sulfanyl group optionallyhaving “a substituent selected from a C1-6alkyl group, a C2-6alkenyl group, a C3-10cycloalkyl group, a C6-14aryl group, a C7-16aralkyl group, a C1-6alkyl-carbonyl group, a C6-14aryl-carbonyl group and a 5- to 14-membered aromatic heterocyclic group, each of which optionally has 1 to 3 substituents selected from Substituent Group A” and a halogenated sulfanyl group. Preferable examples of the optionally substituted sulfanyl group include a sulfanyl (-SH) group, a C1-6alkylthio group, a C2-6alkenylthio group (e.g., allylthio, 2-butenylthio, 2- pentenylthio, 3-hexenylthio), a C3-10cycloalkylthio group (e.g., cyclohexylthio), a C6-14arylthio group (e.g., phenylthio, naphthylthio), a C7-16aralkylthio group (e.g., benzylthio, phenethylthio), a C1-6alkyl-carbonylthio group (e.g., acetylthio, propionylthio, butyrylthio, isobutyrylthio, pivaloylthio), a C6-14aryl-carbonylthio group (e.g., benzoylthio), a 5- to 14-membered aromatic heterocyclylthio group (e.g., pyridylthio) and a halogenated thio group (e.g., pentafluorothio).

[0073] In the present specification, examples of the “optionally substituted silyl group” include a silyl group optionally having “1 to 3 substituents selected from a C1-6alkyl group, a C2-6alkenyl group, a C3-10cycloalkyl group, a C6-14aryl group and a C7- 16 aralkyl group, each of which optionally has 1 to 3 substituents selected from Substituent Group A”. Preferable examples of the optionally substituted silyl group include a tri-C1-6alkylsilyl group (e.g., trimethylsilyl, tert-butyl(dimethyl)silyl).

[0074] In the present specification, examples of the “hydrocarbon ring” include a C6-14aromatic hydrocarbon ring, C3-10cycloalkane and C3-10cycloalkene. In the present specification, examples of the “C6-14aromatic hydrocarbon ring” include benzene and naphthalene. In the present specification, examples of the “C3-10cycloalkane” include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane and cyclooctane.In the present specification, examples of the “C3-10cycloalkene” include cyclopropene, cyclobutene, cyclopentene, cyclohexene, cycloheptene and cyclooctene. In the present specification, examples of the “heterocycle” include an aromatic heterocycle and a non-aromatic heterocycle, each containing, as a ring-constituting atom besides carbon atom, 1 to 4 hetero atoms selected from a nitrogen atom, a sulfur atom and an oxygen atom.

[0075] In the present specification, examples of the “aromatic heterocycle” include a 5- to 14-membered (preferably 5- to 10- membered) aromatic heterocycle containing, as a ring-constituting atom besides carbon atom, 1 to 4 hetero atoms selected from a nitrogen atom, a sulfur atom and an oxygen atom. Preferable examples of the “aromatic heterocycle” include 5- or 6-membered monocyclic aromatic heterocycles such as thiophene, furan, pyrrole, imidazole, pyrazole, thiazole, isothiazole, oxazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, 1,2,4- oxadiazole, 1,3,4-oxadiazole, 1,2,4-thiadiazole, 1,3,4- thiadiazole, triazole, tetrazole, triazine and the like; and 8- to 14-membered fused polycyclic (preferably bi or tricyclic) aromatic heterocycles such as benzothiophene, benzofuran, benzimidazole, benzoxazole, benzisoxazole, benzothiazole, benzisothiazole, benzotriazole, imidazopyridine, thienopyridine, furopyridine, pyrrolopyridine, pyrazolopyridine, oxazolopyridine, thiazolopyridine, imidazopyrazine, imidazopyrimidine, thienopyrimidine, furopyrimidine, pyrrolopyrimidine, pyrazolopyrimidine, oxazolopyrimidine, thiazolopyrimidine, pyrazolopyrimidine, pyrazolotriazine, naphtho[2,3-b]thiophene, phenoxathiin, indole, isoindole, 1H-indazole, purine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, carbazole, β-carboline, phenanthridine, acridine, phenazine, phenothiazine, phenoxazine and the like.

[0076] In the present specification, examples of the “non-aromatic heterocycle” include a 3- to 14-membered (preferably 4- to 10- membered) non-aromatic heterocycle containing, as a ring-constituting atom besides carbon atom, 1 to 4 hetero atoms selected from a nitrogen atom, a sulfur atom and an oxygen atom. Preferable examples of the “non-aromatic heterocycle” include 3- to 8-membered monocyclic non-aromatic heterocycles such as aziridine, oxirane, thiirane, azetidine, oxetane, thietane, tetrahydrothiophene, tetrahydrofuran, pyrroline, pyrrolidine, imidazoline, imidazolidine, oxazoline, oxazolidine, pyrazoline, pyrazolidine, thiazoline, thiazolidine, tetrahydroisothiazole, tetrahydrooxazole, tetrahydroisoxazole, piperidine, piperazine, tetrahydropyridine, dihydropyridine, dihydrothiopyran, tetrahydropyrimidine, tetrahydropyridazine, dihydropyran, tetrahydropyran, tetrahydrothiopyran, morpholine, thiomorpholine, azepane, diazepane, azepine, azocane, diazocane, oxepane and the like; and 9- to 14-membered fused polycyclic (preferably bi or tricyclic) non-aromatic heterocycles such as dihydrobenzofuran, dihydrobenzimidazole, dihydrobenzoxazole, dihydrobenzothiazole, dihydrobenzisothiazole, dihydronaphtho[2,3-b]thiophene, tetrahydroisoquinoline, tetrahydroquinoline, 4H-quinolizine, indoline, isoindoline, tetrahydrothieno[2,3-c]pyridine, tetrahydrobenzazepine, tetrahydroquinoxaline, tetrahydrophenanthridine, hexahydrophenothiazine, hexahydrophenoxazine, tetrahydrophthalazine, tetrahydronaphthyridine, tetrahydroquinazoline, tetrahydrocinnoline, tetrahydrocarbazole, tetrahydro-β-carboline, tetrahydroacridine, tetrahydrophenazine, tetrahydrothioxanthene, octahydroisoquinoline and the like. In the present specification, examples of the “nitrogen- containing heterocycle” include a “heterocycle” containing at least one nitrogen atom as a ring-constituting atom. In the present specification, examples of the “C6-14aromatic hydrocarbon ring” include anthracene, phenanthrene, acenaphthylene, in addition to those exemplified as the above- mentioned “C6-14aromatic hydrocarbon ring”.

[0077] The definition of each symbol in the formula (I) is explained in detail in the following.

[0078] X1is N or CRX1wherein RX1is a hydrogen atom, a halogen atom (e.g., a fluorine atom) or a C1-6alkyl group (e.g., methyl). X1is preferably CH.

[0079] X2, X3and X4are each independently C or N, and one of X2, X3and X4is N, and the other two are C.

[0080] X5is N or CRX5wherein RX5is a hydrogen atom. X5is preferably N.

[0081] X6is N or CRX6wherein RX6is a hydrogen atom. X6is preferably CH.

[0082] The the partial structure represented by the formula:

[0083]

[0084] is specifically represented by the formula (Ia), (Ib) or (Ic):

[0085]

[0086] wherein each symbol is as defined above.

[0087] The partial structure represented by the formula:

[0088]

[0089] is preferably a partial structure represented by the formula (Ia1), (Ib1), (Ic1), (Ia2), (Ib2) or (Ic2):

[0090]

[0091] wherein each symbol is as defined above. In this embodiment, X1is N or CRX1wherein RX1is a hydrogen atom, a halogen atom (e.g., a fluorine atom) or a C1-6alkyl group (e.g., methyl), preferably CH. In this embodiment, RX5is a hydrogen atom. In this embodiment, RX6is a hydrogen atom.

[0092] The partial structure represented by the formula:

[0093]

[0094] is more preferably a partial structure represented by the formula (Ia1), (Ib1), (Ic1) or (Ib2):

[0095]

[0096] wherein each symbol is as defined above, further more preferably a partial structure represented by the formula (Ia1), (Ib1) or (Ic1):

[0097]

[0098] wherein each symbol is as defined above.

[0099] The partial structure represented by the formula:

[0100]

[0101] is still more preferably a partial structure represented by the formula (IIa), (IIb) or (IIc):

[0102] N

[0103] wherein each symbol is as defined above, and specifically represented by the formula (IIa1), (IIb1), (IIc1), (IIa2), (IIb2) or (IIc2):

[0104]

[0105] wherein each symbol is as defined above. In this embodiment, RX1is a hydrogen atom, a halogen atom (e.g., a fluorine atom) or a C1-6alkyl group (e.g., methyl), preferably a hydrogen atom.

[0106] The partial structure represented by the formula:

[0107]

[0108] is still more preferably a partial structure represented by the formula (IIa1), (IIb1), (IIc1) or (IIb2):

[0109]

[0110] wherein each symbol is as defined above, even more preferably a partial structure represented by the formula (IIa1), (IIb1) or (IIc1):

[0111]

[0112] wherein each symbol is as defined above.

[0113] The partial structure represented by the formula:

[0114]

[0115] is particularly preferably a partial structure represented by the formula (IIIa), (IIIb) or (IIIc):

[0116]

[0117] wherein each symbol is as defined above.

[0118] Y1is N or CRY1wherein RY1is a hydrogen atom. Y1is preferably CH.

[0119] Y2is N or CRY2wherein RY2is a hydrogen atom, a halogen atom (e.g., a fluorine atom, a chlorine atom) or a cyano group. Y2is preferably N or CRY2wherein RY2is a hydrogen atom or a halogen atom (e.g., a fluorine atom, a chlorine atom), more preferably CH or CF, particularly preferably CF.

[0120] Y3is N or CRY3wherein RY3is a hydrogen atom or a halogen atom (e.g., a fluorine atom). Y3is preferably CH.

[0121] Y4is N or CRY4wherein RY4is a hydrogen atom or a halogen atom (e.g., a fluorine atom). Y4is preferably CH.

[0122] The partial structure represented by the formula:

[0123]

[0124] is spefifically represented by the formula (Ar-1)-(Ar-12):

[0125]

[0126] wherein each symbol is as defined above. When Y1, Y2, Y3and Y4are all C, then the partial structure is represented by the formula (Ar-1). When at least one of Y1, Y2, Y3and Y4are N, then the partial structure is represented by the formula (Ar-2)-(Ar-12). These partial structures are collectively represented by the formula:

[0127]

[0128] wherein Y1ais N or CRY1awherein RY1ais a hydrogen atom; Y2ais N or CRY2awherein RY2ais a hydrogen atom or a halogen atom (e.g., a fluorine atom); Y3ais N or CRY3awherein RY3ais a hydrogen atom; Y4ais N or CRY4awherein RY4ais a hydrogen atom; and at least one of Y1a, Y2a, Y3aand Y4aare N. Y1ais preferably N. Y2ais preferably CH. Y3ais preferably CH. Y4ais preferably CH.

[0129] The partial structure represented by the formula:

[0130]

[0131] is preferably a partial structure represented by the formula (Ar- 1)-(Ar-11):

[0132]

[0133] wherein each symbol is as defined above. In this embodiment, RY1is a hydrogen atom. In this embodiment, RY2is a hydrogen atom, a halogen atom (e.g., a fluorine atom, a chlorine atom) or a cyano group, preferably is a hydrogen atom or a halogen atom (e.g., a fluorine atom, a chlorine atom), more preferably a hydrogen atom or a fluorine atom, particularly preferably a fluorine atom. In this embodiment, RY3is a hydrogen atom or a halogen atom (e.g., a fluorine atom), preferably a hydrogen atom. In this embodiment, RY4is a hydrogen atom or a halogen atom (e.g., a fluorine atom), preferably a hydrogen atom.

[0134] The partial structure represented by the formula:

[0135]

[0136] is more preferably a partial structure represented by the formula (Ar-1) or (Ar-2):

[0137]

[0138] wherein each symbol is as defined above, further more preferably a partial structure represented by the formula (Ar-1-1) or (Ar-2-1):

[0139]

[0140] wherein each symbol is as defined above. In this embodiment, RY2is a hydrogen atom, a halogen atom (e.g., a fluorine atom, a chlorine atom) or a cyano group, preferably is a hydrogen atom or a halogen atom (e.g., a fluorine atom, a chlorine atom), more preferably a hydrogen atom or a fluorine atom, particularly preferably a fluorine atom.

[0141] The partial structure represented by the formula:

[0142]

[0143] is particularly preferably a partial structure represented by the formula (Ar-1-1):

[0144]

[0145] wherein each symbol is as defined above. In this embodiment, RY2is a hydrogen atom, a halogen atom (e.g., a fluorine atom, a chlorine atom) or a cyano group, preferably is a hydrogen atom or a halogen atom (e.g., a fluorine atom, a chlorine atom), more preferably halogen atom (e.g., a fluorine atom, a chlorine atom), particularly preferably a fluorine atom.

[0146] Ring A1is an optionally further substituted C6-14aromatic hydrocarbon, an optionally further substituted aromatic heterocycle, or an optionally further substituted non-aromatic heterocycle, each of which is optionally fused with an optionally substituted 5- or 6-membered ring.

[0147] The “C6-14aromatic hydrocarbon” of the “optionally further substituted C6-14aromatic hydrocarbon” is preferably a benzene ring. The “aromatic heterocycle” of the “optionally further substituted aromatic heterocycle” is preferably a 5- or 6- membered aromatic heterocycle. The “non-aromatic heterocycle” of the “optionally further substituted non-aromatic heterocycle” is preferably a 5- or 6- membered non-aromatic heterocycle.

[0148] Examples of the “5- or 6-membered ring” of the “optionally substituted 5- or 6-membered ring” include a benzene ring, a C5-6cycloalkene, a 5- or 6-membered aromatic heterocycle and a 5- or 6-membered non-aromatic heterocycle.

[0149] The “C6-14aromatic hydrocarbon” of the “optionally further substituted C6-14aromatic hydrocarbon”, the “aromatic heterocycle” of the “optionally further substituted aromatic heterocycle”, the “non-aromatic heterocycle” of the “optionally further substituted non-aromatic heterocycle” and the “5- or 6-membered ring” of the “optionally substituted 5- or 6-membered ring” optionally further have 1 to 5 (preferably 1 to 3) substituents at substitutable position(s), in addition to the partial structure represented by the formula:

[0150]

[0151] Examples of the substituent include substituents selected from the above-mentioned Substituent Group A. When the number of the substituents is two or more, the respective substituents may be the same or different. In addition, the above-mentioned Substituent Group A is optionally substituted by substituent(s) selected from Substituent Group A. The number of the substituents is, for example, 1 to 3. When the number of the substituents is two or more, the respective substituents may be the same or different.

[0152] Ring A1is preferably Ring A2, i.e., an optionally further substituted benzene ring, an optionally further substituted 5- or 6-membered aromatic heterocycle, or an optionally further substituted 5- or 6-membered non-aromatic heterocycle, each of which is optionally fused with an optionally substituted 5- or 6- membered ring.

[0153] The “5- or 6-membered aromatic heterocycle” of the “optionally further substituted 5- or 6-membered aromatic heterocycle” is preferably a pyridine ring (optionally oxidized), a pyrimidine ring, a pyridazine ring, a pyrazine ring, a pyrazolering, a thiazole ring, an imidazole ring, a thiophene ring or a furan ring. The “5- or 6-membered non-aromatic heterocycle” of the “optionally further substituted 5- or 6-membered non-aromatic heterocycle” is preferably a dihydropyridine ring or a dihydropyrimidine ring.

[0154] Examples of the “5- or 6-membered ring” of the “optionally substituted 5- or 6-membered ring” include a benzene ring, a C5-6cycloalkene, a 5- or 6-membered aromatic heterocycle and a 5- or 6-membered non-aromatic heterocycle.

[0155] The “benzene ring” of the “optionally further substituted benzene ring”, the “5- or 6-membered aromatic heterocycle” of the “optionally further substituted 5- or 6-membered aromatic heterocycle”, the “5- or 6-membered non-aromatic heterocycle” of the “optionally further substituted 5- or 6-membered non-aromatic heterocycle” and the “5- or 6-membered ring” of the “optionally substituted 5- or 6-membered ring” optionally further have 1 to 5 (preferably 1 to 3) substituents at substitutable position(s), in addition to the partial structure represented by the formula:

[0156] N

[0157] Examples of the substituent include substituents selected from the above-mentioned Substituent Group A. When the number of the substituents is two or more, the respective substituents may be the same or different. In addition, the above-mentioned Substituent Group A is optionally substituted by substituent(s) selected from Substituent Group A. The number of the substituents is, for example, 1 to 3. When the number of the substituents is two or more, the respective substituents may be the same or different.

[0158] Ring A2is preferably (1) a benzene ring optionally fused with a 5- to 6-membered monocyclic non-aromatic heterocycle (e.g., dihydrofuran, pyrroline) (i.e., the fused ring is dihydrobenzofuran, isoindoline) optionally substituted by 1 to 3 substituents selected from (a) an oxo group, and (b) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), and optionally further substituted by 1 to 5 substituents selected from (a) a cyano group, (b) a halogen atom (e.g., a fluorine atom, a chlorine atom, a bromine atom), (c) a hydroxy group, (d) a carboxy group, (e) a formyl group, (f) an amino group, (g) a carbamoyl group, (h) a C1-6alkyl group (e.g., methyl, ethyl, isopropyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a hydroxy group, (iii) a C1-6alkoxy group (e.g., methoxy), (iv) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), and (v) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino), (i) a C2-6alkenyl group (e.g., vinyl), (j) a C2-6alkynyl group (e.g., ethynyl), (k) a C1-6alkoxy group (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutyloxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a carboxy group,(iv) a carbamoyl group, (v) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy-C1-6alkoxy group (e.g., methoxyethoxy), and (II) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), (vi) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), (vii) a N-C1-6alkyl-N-C1-6alkyl-carbonylamino group (e.g., N-methyl-N-acetylamino), (viii) a C3-10cycloalkyl group (e.g., cyclopropyl, cyclobutyl), and (ix) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl, azetidinyl, pyrrolidinyl, piperidyl, tetrahydropyranyl) optionally substituted by 1 to 3 substituents selected from (I) an oxo group, and (II) a C1-6alkyl group (e.g., methyl), (l) a C1-6alkyl-carbonyl group (e.g., acetyl), (m) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl), (n) a mono- or di-C1-6alkylamino group (e.g., N-ethylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (o) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino, N-propanoylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (p) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl, N- propylcarbamoyl, N-butylcarbamoyl, N-isobutylcarbamoyl, N- isopentylcarbamoyl, N-neopentylcarbamoyl) optionally substituted by 1 to 3 substituents selected from (i) a hydroxy group, (ii) a C1-6alkoxy group (e.g., methoxy), (iii) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino, N,N-diethylamino),(iv) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), (v) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N,N-diethylcarbamoyl), (vi) a C3-10cycloalkyl group (e.g., cyclopropyl, cyclohexyl), (vii) a C6-14aryl group (e.g., phenyl), (viii) a 5- or 6-membered monocyclic aromatic heterocyclic group (e.g., pyridyl, imidazolyl, triazolyl), and (ix) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., azetidinyl, morpholinyl, pyrrolidinyl, piperidyl, 1,1-dioxidothiomorpholinyl, tetrahydropyranyl) optionally substituted by 1 to 3 substituents selected from (I) a hydroxy group, (II) an oxo group, and (III) a C1-6alkyl group (e.g., methyl), (q) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino), (r) a C3-10cycloalkyloxy group (e.g., cyclohexyloxy) optionally substituted by 1 to 3 substituents selected from (i) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl) optionally substituted by 1 to 3 C1-6alkyl groups (e.g., methyl), (s) a C3-10cycloalkylsulfonyl-carbamoyl group (e.g., cyclopropylsulfonylcarbamoyl), (t) a C6-14aryl-carbamoyl group (e.g., phenylcarbamoyl), (u) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl, piperazinyl) optionally substituted by 1 to 3 C1-6alkyl-carbonyl groups (e.g., acetyl), (v) a 3- to 8-membered monocyclic non-aromatic heterocyclyloxy group (e.g., pyrrolidinyloxy) optionally substituted by 1 to 3 oxo groups, (w) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group (e.g., azetidinylcarbonyl, piperidylcarbonyl, morpholinylcarbonyl) optionally substituted by 1 to 3 substituents selected from(i) a hydroxy group, (ii) a C1-6alkyl group (e.g., methyl), (iii) a C1-6alkoxy group (e.g., methoxy), (iv) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), and (v) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl), (x) a 9- to 14-membered bicyclic non-aromatic heterocyclylcarbonyl group (e.g., tetrahydroimidazopyrazinylcarbonyl tetrahydrotriazolopyrazinylcarbonyl), (y) a 5- or 6-membered monocyclic aromatic heterocyclylcarbamoyl group (e.g., pyrazolylcarbamoyl, pyridylcarbamoyl) optionally substituted by 1 to 3 C1-6alkyl groups (e.g., methyl), (z) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbamoyl group (e.g., azetidinylcarbamoyl, piperidylcarbamoyl, pyrrolidinylcarbamoyl) optionally substituted by 1 to 3 substituents selected from (i) an oxo group, (ii) a C1-6alkyl group (e.g., methyl), (iii) a C1-6alkyl-carbonyl group (e.g., acetyl), and (iv) a C7-16aralkyl group (e.g., benzyl), and (aa) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group (e.g., 1-oxido-thiolan-1- ylidenamino), (2) a 5- or 6-membered aromatic heterocycle (e.g., pyridine (optionally oxidized), pyrimidine, pyridazine, pyrazine, pyrazole, imidazole, thiophene, thiazole, furan) optionally fused with a 5- or 6-membered monocyclic aromatic heterocycle (e.g., imidazole) (i.e., the fused ring is imidazopyridine), and optionally further substituted by 1 to 4 substituents selected from (a) a cyano group, (b) a halogen atom (e.g., a fluorine atom, a chlorine atom), (c) a carboxy group,(d) an amino group, (e) a carbamoyl group, (f) a C1-6alkyl group (e.g., methyl, ethyl, propyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a hydroxy group, (iv) a carboxy group, (v) a C1-6alkoxy group (e.g., methoxy), (vi) a C7-16aralkyloxy-carbonyl group (e.g., benzyloxycarbonyl), (vii) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- ethylcarbamoyl, N-propylcarbamoyl) optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy group (e.g., methoxy), and (II) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl), and (viii) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl), (g) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a C1-6alkoxy group (e.g., methoxy), and (iv) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., oxetanyl), (h) a C3-10cycloalkyl group (e.g., cyclopropyl), (i) a C1-6alkyl-carbonyl group (e.g., acetyl), (j) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (k) a mono- or di-C1-6alkylamino group (e.g., N-methylamino, N,N-dimethylamino, N-ethylamino, N-ethyl-N-methylamino) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (l) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl)optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy group (e.g., methoxy), and (II) a mono- or di-C1-6alkylamino groups (e.g., N,N- diethylamino), (m) a mono- or di-C1-6alkoxy-carbonylamino group (e.g., N- tert-butoxycarbonylamino, N,N-di-tert-butoxycarbonylamino), and (n) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., azetidinyl, pyrrolidinyl), or (3) a 5- or 6-membered non-aromatic heterocycle (e.g., dihydropyridine, dihydropyrimidine) optionally further substituted by 1 to 4 substituents selected from (a) an oxo group, (b) a cyano group, (c) a halogen atom (e.g., a fluorine atom, a chlorine atom), and (d) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from (I) a halogen atom (e.g., a fluorine atom), (II) a cyano group, and (III) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom).

[0159] In another embodiment, Ring A2is preferably (1) a benzene ring optionally fused with a 5- to 6-membered monocyclic non-aromatic heterocycle (e.g., dihydrofuran, pyrroline) (i.e., the fused ring is dihydrobenzofuran, isoindoline) optionally substituted by 1 to 3 substituents selected from (a) an oxo group, and (b) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), and optionally further substituted by 1 to 5 substituents selected from (a) a cyano group, (b) a halogen atom (e.g., a fluorine atom, a chlorine atom, abromine atom), (c) a hydroxy group, (d) a carboxy group, (e) a formyl group, (f) an amino group, (g) a carbamoyl group, (h) a C1-6alkyl group (e.g., methyl, ethyl, isopropyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a hydroxy group, (iii) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), and (iv) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino), (i) a C2-6alkenyl group (e.g., vinyl), (j) a C2-6alkynyl group (e.g., ethynyl), (k) a C1-6alkoxy group (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutyloxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a carboxy group, (iv) a carbamoyl group, (v) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy-C1-6alkoxy group (e.g., methoxyethoxy), and (II) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), (vi) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), (vii) a N-C1-6alkyl-N-C1-6alkyl-carbonylamino group (e.g., N-methyl-N-acetylamino), (viii) a C3-10cycloalkyl group (e.g., cyclopropyl, cyclobutyl), and (ix) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl, azetidinyl,pyrrolidinyl, piperidyl, tetrahydropyranyl) optionally substituted by 1 to 3 substituents selected from (I) an oxo group, and (II) a C1-6alkyl group (e.g., methyl), (l) a C1-6alkyl-carbonyl group (e.g., acetyl), (m) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl), (n) a mono- or di-C1-6alkylamino group (e.g., N-ethylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (o) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino, N-propanoylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (p) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl, N- propylcarbamoyl, N-butylcarbamoyl, N-isobutylcarbamoyl, N- isopentylcarbamoyl, N-neopentylcarbamoyl) optionally substituted by 1 to 3 substituents selected from (i) a hydroxy group, (ii) a C1-6alkoxy group (e.g., methoxy), (iii) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino, N,N-diethylamino), (iv) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), (v) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N,N-diethylcarbamoyl), (vi) a C3-10cycloalkyl group (e.g., cyclopropyl, cyclohexyl), (vii) a C6-14aryl group (e.g., phenyl), (viii) a 5- or 6-membered monocyclic aromatic heterocyclic group (e.g., pyridyl, imidazolyl, triazolyl), and (ix) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., azetidinyl, morpholinyl, pyrrolidinyl, piperidyl, 1,1-dioxidothiomorpholinyl, tetrahydropyranyl) optionally substituted by 1 to 3 substituents selected from (I) a hydroxy group,(II) an oxo group, and (III) a C1-6alkyl group (e.g., methyl), (q) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino), (r) a C3-10cycloalkyloxy group (e.g., cyclohexyloxy) optionally substituted by 1 to 3 substituents selected from (i) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl) optionally substituted by 1 to 3C1-6alkyl groups (e.g., methyl), (s) a C3-10cycloalkylsulfonyl-carbamoyl group (e.g., cyclopropylsulfonylcarbamoyl), (t) a C6-14aryl-carbamoyl group (e.g., phenylcarbamoyl), (u) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl, piperazinyl) optionally substituted by 1 to 3 C1-6alkyl-carbonyl groups (e.g., acetyl), (v) a 3- to 8-membered monocyclic non-aromatic heterocyclyloxy group (e.g., pyrrolidinyloxy) optionally substituted by 1 to 3 oxo groups, (w) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group (e.g., azetidinylcarbonyl, piperidylcarbonyl, morpholinylcarbonyl) optionally substituted by 1 to 3 substituents selected from (i) a hydroxy group, (ii) a C1-6alkyl group (e.g., methyl), (iii) a C1-6alkoxy group (e.g., methoxy), (iv) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), and (v) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl), (x) a 9- to 14-membered bicyclic non-aromatic heterocyclylcarbonyl group (e.g., tetrahydroimidazopyrazinylcarbonyl tetrahydrotriazolopyrazinylcarbonyl), (y) a 5- or 6-membered monocyclic aromatic heterocyclylcarbamoyl group (e.g., pyrazolylcarbamoyl, pyridylcarbamoyl) optionally substituted by 1 to 3 C1-6alkyl groups (e.g., methyl),(z) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbamoyl group (e.g., azetidinylcarbamoyl, piperidylcarbamoyl, pyrrolidinylcarbamoyl) optionally substituted by 1 to 3 substituents selected from (i) an oxo group, (ii) a C1-6alkyl group (e.g., methyl), (iii) a C1-6alkyl-carbonyl group (e.g., acetyl), and (iv) a C7-16aralkyl group (e.g., benzyl), and (aa) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group (e.g., 1-oxido-thiolan-1- ylidenamino), (2) a 5- or 6-membered aromatic heterocycle (e.g., pyridine (optionally oxidized), pyrimidine, pyridazine, pyrazine, pyrazole, imidazole, thiophene, thiazole, furan) optionally fused with a 5- or 6-membered monocyclic aromatic heterocycle (e.g., imidazole) (i.e., the fused ring is imidazopyridine), and optionally further substituted by 1 to 4 substituents selected from (a) a cyano group, (b) a halogen atom (e.g., a fluorine atom, a chlorine atom), (c) a carboxy group, (d) an amino group, (e) a carbamoyl group, (f) a C1-6alkyl group (e.g., methyl, ethyl, propyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a hydroxy group, (iv) a carboxy group, (v) a C1-6alkoxy group (e.g., methoxy), (vi) a C7-16aralkyloxy-carbonyl group (e.g., benzyloxycarbonyl), (vii) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- ethylcarbamoyl, N-propylcarbamoyl) optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy group (e.g., methoxy), and(II) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl), and (viii) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl), (g) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a C1-6alkoxy group (e.g., methoxy), and (iv) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., oxetanyl), (h) a C3-10cycloalkyl group (e.g., cyclopropyl), (i) a C1-6alkyl-carbonyl group (e.g., acetyl), (j) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (k) a mono- or di-C1-6alkylamino group (e.g., N-methylamino, N,N-dimethylamino, N-ethylamino, N-ethyl-N-methylamino) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (l) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl) optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy group (e.g., methoxy), and (II) a mono- or di-C1-6alkylamino groups (e.g., N,N- diethylamino), (m) a mono- or di-C1-6alkoxy-carbonylamino group (e.g., N- tert-butoxycarbonylamino, N,N-di-tert-butoxycarbonylamino), and (n) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., azetidinyl, pyrrolidinyl), or (3) a 5- or 6-membered non-aromatic heterocycle (e.g., dihydropyridine, dihydropyrimidine) optionally further substituted by 1 to 4 substituents selected from (a) an oxo group, (b) a cyano group, (c) a halogen atom (e.g., a fluorine atom, a chlorine atom),and (d) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from (I) a halogen atom (e.g., a fluorine atom), (II) a cyano group, and (III) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom).

[0160] In another embodiment, Ring A2is preferably (1) a benzene ring optionally further substituted by 1 to 5 substituents selected from (a) a cyano group, (b) a halogen atom (e.g., a fluorine atom, a chlorine atom), (c) a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a C1-6alkoxy group (e.g., methoxy), (d) a C1-6alkoxy group (e.g., methoxy) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (2) a 5- or 6-membered aromatic heterocycle (e.g., pyridine (optionally oxidized), pyrimidine, pyridazine, pyrazine, pyrazole, imidazole, thiophene, thiazole, furan) optionally further substituted by 1 to 4 substituents selected from (a) a cyano group, (b) a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), and (c) a C1-6alkoxy group (e.g., methoxy, ethoxy), or (3) a 5- or 6-membered non-aromatic heterocycle (e.g., dihydropyridine, dihydropyrimidine) optionally further substituted by 1 to 4 substituents selected from (a) an oxo group, (b) a cyano group, and (c) a C1-6alkyl group (e.g., methyl).

[0161] Ring A2is more preferably (1) a benzene ringoptionally fused with a 5- to 6-membered monocyclic non-aromatic heterocycle (e.g., dihydrofuran, pyrroline) (i.e., the fused ring is dihydrobenzofuran, isoindoline) optionally substituted by 1 to 3 substituents selected from (a) an oxo group, and (b) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), and optionally further substituted by 1 to 5 substituents selected from (a) a cyano group, (b) a halogen atom (e.g., a fluorine atom, a chlorine atom, a bromine atom), (c) a hydroxy group, (d) a carboxy group, (e) a formyl group, (f) an amino group, (g) a carbamoyl group, (h) a C1-6alkyl group (e.g., methyl, ethyl, isopropyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a hydroxy group, (iii) a C1-6alkoxy group (e.g., methoxy), (iv) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), and (v) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino), (i) a C2-6alkenyl group (e.g., vinyl), (j) a C2-6alkynyl group (e.g., ethynyl), (k) a C1-6alkoxy group (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutyloxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a carboxy group, (iv) a carbamoyl group, (v) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from(I) a C1-6alkoxy-C1-6alkoxy group (e.g., methoxyethoxy), and (II) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), (vi) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), (vii) a N-C1-6alkyl-N-C1-6alkyl-carbonylamino group (e.g., N-methyl-N-acetylamino), (viii) a C3-10cycloalkyl group (e.g., cyclopropyl, cyclobutyl), and (ix) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl, azetidinyl, pyrrolidinyl, piperidyl, tetrahydropyranyl) optionally substituted by 1 to 3 substituents selected from (I) an oxo group, and (II) a C1-6alkyl group (e.g., methyl), (l) a C1-6alkyl-carbonyl group (e.g., acetyl), (m) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl), (n) a mono- or di-C1-6alkylamino group (e.g., N-ethylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (o) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino, N-propanoylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (p) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl, N- propylcarbamoyl, N-butylcarbamoyl, N-isobutylcarbamoyl, N- isopentylcarbamoyl, N-neopentylcarbamoyl) optionally substituted by 1 to 3 substituents selected from (i) a hydroxy group, (ii) a C1-6alkoxy group (e.g., methoxy), (iii) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino, N,N-diethylamino), (iv) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), (v) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N-methylcarbamoyl, N,N-diethylcarbamoyl), (vi) a C3-10cycloalkyl group (e.g., cyclopropyl, cyclohexyl), (vii) a C6-14aryl group (e.g., phenyl), (viii) a 5- or 6-membered monocyclic aromatic heterocyclic group (e.g., pyridyl, imidazolyl, triazolyl), and (ix) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., azetidinyl, morpholinyl, pyrrolidinyl, piperidyl, 1,1-dioxidothiomorpholinyl, tetrahydropyranyl) optionally substituted by 1 to 3 substituents selected from (I) a hydroxy group, (II) an oxo group, and (III) a C1-6alkyl group (e.g., methyl), (q) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino), (r) a C3-10cycloalkyloxy group (e.g., cyclohexyloxy) optionally substituted by 1 to 3 substituents selected from (i) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl) optionally substituted by 1 to 3 C1-6alkyl groups (e.g., methyl), (s) a C3-10cycloalkylsulfonyl-carbamoyl group (e.g., cyclopropylsulfonylcarbamoyl), (t) a C6-14aryl-carbamoyl group (e.g., phenylcarbamoyl), (u) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl, piperazinyl) optionally substituted by 1 to 3 C1-6alkyl-carbonyl groups (e.g., acetyl), (v) a 3- to 8-membered monocyclic non-aromatic heterocyclyloxy group (e.g., pyrrolidinyloxy) optionally substituted by 1 to 3 oxo groups, (w) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group (e.g., azetidinylcarbonyl, piperidylcarbonyl, morpholinylcarbonyl) optionally substituted by 1 to 3 substituents selected from (i) a hydroxy group, (ii) a C1-6alkyl group (e.g., methyl), (iii) a C1-6alkoxy group (e.g., methoxy),(iv) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), and (v) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl), (x) a 9- to 14-membered bicyclic non-aromatic heterocyclylcarbonyl group (e.g., tetrahydroimidazopyrazinylcarbonyl tetrahydrotriazolopyrazinylcarbonyl), (y) a 5- or 6-membered monocyclic aromatic heterocyclylcarbamoyl group (e.g., pyrazolylcarbamoyl, pyridylcarbamoyl) optionally substituted by 1 to 3 C1-6alkyl groups (e.g., methyl), (z) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbamoyl group (e.g., azetidinylcarbamoyl, piperidylcarbamoyl, pyrrolidinylcarbamoyl) optionally substituted by 1 to 3 substituents selected from (i) an oxo group, (ii) a C1-6alkyl group (e.g., methyl), (iii) a C1-6alkyl-carbonyl group (e.g., acetyl), and (iv) a C7-16aralkyl group (e.g., benzyl), and (aa) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group (e.g., 1-oxido-thiolan-1- ylidenamino), (2) a pyridine ring (optionally oxidized) optionally fused with a 5- or 6-membered monocyclic aromatic heterocycle (e.g., imidazole) (i.e., the fused ring is imidazopyridine), and optionally further substituted by 1 to 4 substituents selected from (a) a cyano group, (b) a halogen atom (e.g., a fluorine atom, a chlorine atom), (c) an amino group, (d) a carbamoyl group, (e) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a hydroxy group,(f) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a C1-6alkoxy group (e.g., methoxy), and (iv) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., oxetanyl), (g) a C3-10cycloalkyl group (e.g., cyclopropyl), (h) a C1-6alkyl-carbonyl group (e.g., acetyl), (i) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl), (j) a mono- or di-C1-6alkylamino group (e.g., N-methylamino, N,N-dimethylamino, N-ethylamino, N-ethyl-N-methylamino) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (k) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N-ethylcarbamoyl) optionally substituted by 1 to 3 of mono- or di-C1-6alkylamino groups (e.g., N,N- diethylamino), (l) a mono- or di-C1-6alkoxy-carbonylamino group (e.g., N- tert-butoxycarbonylamino, N,N-di-tert-butoxycarbonylamino), and (m) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., azetidinyl, pyrrolidinyl), (3) a pyrimidine ring optionally further substituted by 1 to 3 substituents selected from (a) a cyano group, (b) an amino group, (c) a C1-6alkoxy group (e.g., methoxy, ethoxy), and (d) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), (4) a pyridazine ring optionally further substituted by 1 to 3 cyano groups, (5) a pyrazine ring optionally further substituted by 1 to 3 substituents selected from (a) a cyano group, (b) a C1-6alkyl group (e.g., methyl), and (c) a C1-6alkoxy group (e.g., methoxy),(6) a pyrazole ring optionally further substituted by 1 to 3 substituents selected from (a) a cyano group, (b) a carboxy group, (c) a C1-6alkyl group (e.g., methyl, ethyl, propyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a hydroxy group, (iv) a carboxy group, (v) a C1-6alkoxy group (e.g., methoxy), (vi) a C7-16aralkyloxy-carbonyl group (e.g., benzyloxycarbonyl), (vii) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- ethylcarbamoyl, N-propylcarbamoyl) optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy group (e.g., methoxy), and (II) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl), and (viii) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl), (d) a C1-6alkoxy-carbonyl group (e.g., propoxycarbonyl, tert- butoxycarbonyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), and (e) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (7) an imidazole ring optionally further substituted by 1 to 3 substituents selected from (a) a cyano group, and (b) a C1-6alkyl group (e.g., methyl), (8) a thiazole ring optionally further substituted by 1 or 2 C1-6alkyl groups (e.g., methyl), (9) a thiophene ring optionally further substituted by 1 to 3 substituents selected from (a) a cyano group,(b) a carboxy group, (c) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl), and (d) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl), (10) a furan ring, (11) a dihydropyridine ring optionally further substituted by 1 to 4 substituents selected from (a) a cyano group, (b) an oxo group, (c) a halogen atom (e.g., a fluorine atom, a chlorine atom), and (d) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from (I) a halogen atom (e.g., a fluorine atom), (II) a cyano group, and (III) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), or (12) a dihydropyrimidine ring optionally further substituted by 1 to 4 substituents selected from (a) a cyano group, and (b) an oxo group.

[0162] In another embodiment, Ring A2is more preferably (1) a benzene ring optionally fused with a 5- to 6-membered monocyclic non-aromatic heterocycle (e.g., dihydrofuran, pyrroline) (i.e., the fused ring is dihydrobenzofuran, isoindoline) optionally substituted by 1 to 3 substituents selected from (a) an oxo group, and (b) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), and optionally further substituted by 1 to 5 substituents selected from (a) a cyano group, (b) a halogen atom (e.g., a fluorine atom, a chlorine atom, a bromine atom),(c) a hydroxy group, (d) a carboxy group, (e) a formyl group, (f) an amino group, (g) a carbamoyl group, (h) a C1-6alkyl group (e.g., methyl, ethyl, isopropyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a hydroxy group, (iii) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), and (iv) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino), (i) a C2-6alkenyl group (e.g., vinyl), (j) a C2-6alkynyl group (e.g., ethynyl), (k) a C1-6alkoxy group (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutyloxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a carboxy group, (iv) a carbamoyl group, (v) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy-C1-6alkoxy group (e.g., methoxyethoxy), and (II) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), (vi) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), (vii) a N-C1-6alkyl-N-C1-6alkyl-carbonylamino group (e.g., N-methyl-N-acetylamino), (viii) a C3-10cycloalkyl group (e.g., cyclopropyl, cyclobutyl), and (ix) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl, azetidinyl, pyrrolidinyl, piperidyl, tetrahydropyranyl) optionallysubstituted by 1 to 3 substituents selected from (I) an oxo group, and (II) a C1-6alkyl group (e.g., methyl), (l) a C1-6alkyl-carbonyl group (e.g., acetyl), (m) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl), (n) a mono- or di-C1-6alkylamino group (e.g., N-ethylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (o) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino, N-propanoylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (p) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl, N- propylcarbamoyl, N-butylcarbamoyl, N-isobutylcarbamoyl, N- isopentylcarbamoyl, N-neopentylcarbamoyl) optionally substituted by 1 to 3 substituents selected from (i) a hydroxy group, (ii) a C1-6alkoxy group (e.g., methoxy), (iii) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino, N,N-diethylamino), (iv) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), (v) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N,N-diethylcarbamoyl), (vi) a C3-10cycloalkyl group (e.g., cyclopropyl, cyclohexyl), (vii) a C6-14aryl group (e.g., phenyl), (viii) a 5- or 6-membered monocyclic aromatic heterocyclic group (e.g., pyridyl, imidazolyl, triazolyl), and (ix) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., azetidinyl, morpholinyl, pyrrolidinyl, piperidyl, 1,1-dioxidothiomorpholinyl, tetrahydropyranyl) optionally substituted by 1 to 3 substituents selected from (I) a hydroxy group, (II) an oxo group, and(III) a C1-6alkyl group (e.g., methyl), (q) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino), (r) a C3-10cycloalkyloxy group (e.g., cyclohexyloxy) optionally substituted by 1 to 3 substituents selected from (i) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl) optionally substituted by 1 to 3 C1-6alkyl groups (e.g., methyl), (s) a C3-10cycloalkylsulfonyl-carbamoyl group (e.g., cyclopropylsulfonylcarbamoyl), (t) a C6-14aryl-carbamoyl group (e.g., phenylcarbamoyl), (u) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl, piperazinyl) optionally substituted by 1 to 3 C1-6alkyl-carbonyl groups (e.g., acetyl), (v) a 3- to 8-membered monocyclic non-aromatic heterocyclyloxy group (e.g., pyrrolidinyloxy) optionally substituted by 1 to 3 oxo groups, (w) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group (e.g., azetidinylcarbonyl, piperidylcarbonyl, morpholinylcarbonyl) optionally substituted by 1 to 3 substituents selected from (i) a hydroxy group, (ii) a C1-6alkyl group (e.g., methyl), (iii) a C1-6alkoxy group (e.g., methoxy), (iv) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), and (v) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl), (x) a 9- to 14-membered bicyclic non-aromatic heterocyclylcarbonyl group (e.g., tetrahydroimidazopyrazinylcarbonyl tetrahydrotriazolopyrazinylcarbonyl), (y) a 5- or 6-membered monocyclic aromatic heterocyclylcarbamoyl group (e.g., pyrazolylcarbamoyl, pyridylcarbamoyl) optionally substituted by 1 to 3 C1-6alkyl groups (e.g., methyl),(z) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbamoyl group (e.g., azetidinylcarbamoyl, piperidylcarbamoyl, pyrrolidinylcarbamoyl) optionally substituted by 1 to 3 substituents selected from (i) an oxo group, (ii) a C1-6alkyl group (e.g., methyl), (iii) a C1-6alkyl-carbonyl group (e.g., acetyl), and (iv) a C7-16aralkyl group (e.g., benzyl), and (aa) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group (e.g., 1-oxido-thiolan-1- ylidenamino), (2) a pyridine ring (optionally oxidized) optionally fused with a 5- or 6-membered monocyclic aromatic heterocycle (e.g., imidazole) (i.e., the fused ring is imidazopyridine), and optionally further substituted by 1 to 4 substituents selected from (a) a cyano group, (b) a halogen atom (e.g., a fluorine atom, a chlorine atom), (c) an amino group, (d) a carbamoyl group, (e) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a hydroxy group, (f) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a C1-6alkoxy group (e.g., methoxy), and (iv) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., oxetanyl), (g) a C3-10cycloalkyl group (e.g., cyclopropyl), (h) a C1-6alkyl-carbonyl group (e.g., acetyl), (i) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl), (j) a mono- or di-C1-6alkylamino group (e.g., N-methylamino, N,N-dimethylamino, N-ethylamino, N-ethyl-N-methylamino)optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (k) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N-ethylcarbamoyl) optionally substituted by 1 to 3 of mono- or di-C1-6alkylamino groups (e.g., N,N- diethylamino), (l) a mono- or di-C1-6alkoxy-carbonylamino group (e.g., N- tert-butoxycarbonylamino, N,N-di-tert-butoxycarbonylamino), and (m) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., azetidinyl, pyrrolidinyl), (3) a pyrimidine ring optionally further substituted by 1 to 3 substituents selected from (a) a cyano group, (b) an amino group, (c) a C1-6alkoxy group (e.g., methoxy, ethoxy), and (d) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), (4) a pyridazine ring optionally further substituted by 1 to 3 cyano groups, (5) a pyrazine ring optionally further substituted by 1 to 3 substituents selected from (a) a cyano group, (b) a C1-6alkyl group (e.g., methyl), and (c) a C1-6alkoxy group (e.g., methoxy), (6) a pyrazole ring optionally further substituted by 1 to 3 substituents selected from (a) a cyano group, (b) a carboxy group, (c) a C1-6alkyl group (e.g., methyl, ethyl, propyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a hydroxy group, (iv) a carboxy group, (v) a C1-6alkoxy group (e.g., methoxy), (vi) a C7-16aralkyloxy-carbonyl group (e.g.,benzyloxycarbonyl), (vii) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- ethylcarbamoyl, N-propylcarbamoyl) optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy group (e.g., methoxy), and (II) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl), and (viii) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl), (d) a C1-6alkoxy-carbonyl group (e.g., propoxycarbonyl, tert- butoxycarbonyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), and (e) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (7) an imidazole ring optionally further substituted by 1 to 3 substituents selected from (a) a cyano group, and (b) a C1-6alkyl group (e.g., methyl), (8) a thiazole ring optionally further substituted by 1 or 2 C1-6alkyl groups (e.g., methyl), (9) a thiophene ring optionally further substituted by 1 to 3 substituents selected from (a) a cyano group, (b) a carboxy group, (c) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl), and (d) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl), (10) a furan ring, (11) a dihydropyridine ring optionally further substituted by 1 to 4 substituents selected from (a) a cyano group, (b) an oxo group, (c) a halogen atom (e.g., a fluorine atom, a chlorine atom), and (d) a C1-6alkyl group (e.g., methyl, ethyl) optionallysubstituted by 1 to 3 substituents selected from (I) a halogen atom (e.g., a fluorine atom), (II) a cyano group, and (III) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), or (12) a dihydropyrimidine ring optionally further substituted by 1 to 4 substituents selected from (a) a cyano group, and (b) an oxo group.

[0163] In another embodiment, Ring A2is more preferably (1) a benzene ring optionally further substituted by 1 to 5 substituents selected from (a) a cyano group, (b) a halogen atom (e.g., a fluorine atom, a chlorine atom), (c) a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a C1-6alkoxy group (e.g., methoxy), (d) a C1-6alkoxy group (e.g., methoxy) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (2) a pyridine ring (optionally oxidized) optionally further substituted by 1 to 4 substituents selected from (a) a cyano group, (b) a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), and (c) a C1-6alkoxy group (e.g., methoxy, ethoxy), (3) a pyrimidine ring optionally further substituted by 1 to 3 substituents selected from (a) a cyano group, and (b) a C1-6alkoxy group (e.g., methoxy), or (4) a dihydropyridine ring optionally further substituted by 1 to 4 substituents selected from (a) a cyano group, (b) an oxo group, and (b) a C1-6alkyl group (e.g., methyl).

[0164] In another embodiment, Ring A2is preferably a benzene ring, a 6-membered aromatic heterocycle, or a 6-membered non- aromatic heterocycle, each of which is further substituted by one cyano group and optionally further substituted.

[0165] The “6-membered aromatic heterocycle” is preferably a pyridine ring (optionally oxidized), a pyrimidine ring, a pyridazine ring or a pyrazine ring, particuarly preferably a pyridine ring. The “6-membered non-aromatic heterocycle” is preferably a dihydropyridine ring or a dihydropyrimidine ring.

[0166] The “benzene ring”, “6-membered aromatic heterocycle” and “6-membered non-aromatic heterocycle” have one cyano group and optionally further have 1 to 5 (preferably 1 to 3) substituents at substitutable position(s), in addition to the partial structure represented by the formula:

[0167]

[0168] Examples of the substituent include substituents selected from the above-mentioned Substituent Group A. When the number of the substituents is two or more, the respective substituents may be the same or different. In addition, the above-mentioned Substituent Group A is optionally substituted by substituent(s) selected from Substituent Group A. The number of the substituents is, for example, 1 to 3. When the number of the substituents is two or more, the respective substituents may be the same or different.

[0169] Ring A2is more preferably (1) a benzene ringfurther substituted by one cyano group, and optionally further substituted by 1 to 5 substituents selected from (a) a cyano group, (b) a halogen atom (e.g., a fluorine atom, a chlorine atom), (c) a hydroxy group, (d) a carboxy group, (e) an amino group, (f) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a C1-6alkoxy group (e.g., methoxy), (g) a C1-6alkoxy group (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutyloxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a carboxy group, (iv) a carbamoyl group, (v) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy-C1-6alkoxy group (e.g., methoxyethoxy), and (II) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), (vi) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), (vii) a N-C1-6alkyl-N-C1-6alkyl-carbonylamino group (e.g., N-methyl-N-acetylamino), (viii) a C3-10cycloalkyl group (e.g., cyclobutyl), and (ix) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl, azetidinyl, pyrrolidinyl, piperidyl, tetrahydropyranyl) optionally substituted by 1 to 3 substituents selected from (I) an oxo group, and (II) a C1-6alkyl group (e.g., methyl), (h) a C1-6alkyl-carbonyl group (e.g., acetyl),(i) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl), (j) a mono- or di-C1-6alkylamino group (e.g., N-ethylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (k) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- propanoylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (l) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non-aromatic heterocyclic groups (e.g., morpholinyl), (m) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino), (n) a C3-10cycloalkyloxy group (e.g., cyclohexyloxy) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non- aromatic heterocyclic groups (e.g., morpholinyl) optionally substituted by 1 to 3 C1-6alkyl groups (e.g., methyl), (o) a 3- to 8-membered monocyclic non-aromatic heterocyclyloxy group (e.g., pyrrolidinyloxy) optionally substituted by 1 to 3 oxo groups, (p) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group (e.g., azetidinylcarbonyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), and (q) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group (e.g., 1-oxido-thiolan-1- ylidenamino), (2) a 6-membered aromatic heterocycle (e.g., pyridine (optionally oxidized), pyrimidine, pyridazine, pyrazine) optionally fused with a 5- or 6-membered monocyclic aromatic heterocycle (e.g., imidazole) (i.e., the fused ring is imidazopyridine), further substituted by one cyano group, and optionally further substituted by 1 to 4 substituents selected from(a) a halogen atom (e.g., a fluorine atom, a chlorine atom), (b) an amino group, (c) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a hydroxy group, (d) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a C1-6alkoxy group (e.g., methoxy), and (iii) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., oxetanyl), (e) a C3-10cycloalkyl group (e.g., cyclopropyl), (f) a C1-6alkyl-carbonyl group (e.g., acetyl), (g) a mono- or di-C1-6alkylamino group (e.g., N-methylamino, N,N-dimethylamino, N-ethylamino, N-ethyl-N-methylamino) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (h) a mono- or di-C1-6alkoxy-carbonylamino group (e.g., N- tert-butoxycarbonylamino, N,N-di-tert-butoxycarbonylamino), and (i) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., azetidinyl, pyrrolidinyl), or (3) a 6-membered non-aromatic heterocycle (e.g., dihydropyridine, dihydropyrimidine) further substituted by one cyano group, and optionally further substituted by 1 to 4 substituents selected from (a) an oxo group, and (b) a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom).

[0170] In another embodiment, Ring A2is more preferably (1) a benzene ring further substituted by one cyano group, and optionally further substituted by 1 to 5 substituents selected from(a) a cyano group, (b) a halogen atom (e.g., a fluorine atom), (c) a hydroxy group, (d) a carboxy group, (e) an amino group, (f) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (g) a C1-6alkoxy group (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutyloxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a carboxy group, (iv) a carbamoyl group, (v) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy-C1-6alkoxy group (e.g., methoxyethoxy), and (II) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), (vi) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), (vii) a N-C1-6alkyl-N-C1-6alkyl-carbonylamino group (e.g., N-methyl-N-acetylamino), (viii) a C3-10cycloalkyl group (e.g., cyclobutyl), and (ix) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl, azetidinyl, pyrrolidinyl, piperidyl, tetrahydropyranyl) optionally substituted by 1 to 3 substituents selected from (I) an oxo group, and (II) a C1-6alkyl group (e.g., methyl), (h) a C1-6alkyl-carbonyl group (e.g., acetyl), (i) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl), (j) a mono- or di-C1-6alkylamino group (e.g., N-ethylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy),(k) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- propanoylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (l) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non-aromatic heterocyclic groups (e.g., morpholinyl), (m) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino), (n) a C3-10cycloalkyloxy group (e.g., cyclohexyloxy) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non- aromatic heterocyclic groups (e.g., morpholinyl) optionally substituted by 1 to 3 C1-6alkyl groups (e.g., methyl), (o) a 3- to 8-membered monocyclic non-aromatic heterocyclyloxy group (e.g., pyrrolidinyloxy) optionally substituted by 1 to 3 oxo groups, (p) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group (e.g., azetidinylcarbonyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), and (q) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group (e.g., 1-oxido-thiolan-1- ylidenamino), (2) a 6-membered aromatic heterocycle (e.g., pyridine (optionally oxidized), pyrimidine, pyridazine, pyrazine) optionally fused with a 5- or 6-membered monocyclic aromatic heterocycle (e.g., imidazole) (i.e., the fused ring is imidazopyridine), further substituted by one cyano group, and optionally further substituted by 1 to 4 substituents selected from (a) a halogen atom (e.g., a fluorine atom, a chlorine atom), (b) an amino group, (c) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and(ii) a hydroxy group, (d) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a C1-6alkoxy group (e.g., methoxy), and (iii) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., oxetanyl), (e) a C3-10cycloalkyl group (e.g., cyclopropyl), (f) a C1-6alkyl-carbonyl group (e.g., acetyl), (g) a mono- or di-C1-6alkylamino group (e.g., N-methylamino, N,N-dimethylamino, N-ethylamino, N-ethyl-N-methylamino) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (h) a mono- or di-C1-6alkoxy-carbonylamino group (e.g., N- tert-butoxycarbonylamino, N,N-di-tert-butoxycarbonylamino), and (i) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., azetidinyl, pyrrolidinyl), or (3) a 6-membered non-aromatic heterocycle (e.g., dihydropyridine, dihydropyrimidine) further substituted by one cyano group, and optionally further substituted by 1 to 4 substituents selected from (a) an oxo group, and (b) a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom).

[0171] In another embodiment, Ring A2is more preferably (1) a benzene ring further substituted by one cyano group, and optionally further substituted by 1 to 5 substituents selected from (a) a halogen atom (e.g., a fluorine atom, a chlorine atom), (b) a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a C1-6alkoxy group (e.g., methoxy), and(c) a C1-6alkoxy group (e.g., methoxy) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (2) a 6-membered aromatic heterocycle (e.g., pyridine, pyrimidine) further substituted by one cyano group, and optionally further substituted by 1 to 4 substituents selected from (a) a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), and (b) a C1-6alkoxy group (e.g., methoxy, ethoxy), or (3) a 6-membered non-aromatic heterocycle (e.g., dihydropyridine) further substituted by one cyano group, and optionally further substituted by 1 to 4 substituents selected from (a) an oxo group, and (b) a C1-6alkyl group (e.g., methyl).

[0172] Ring A2is further more preferably (1) a benzene ring further substituted by one cyano group, and optionally further substituted by 1 to 5 substituents selected from (a) a cyano group, (b) a halogen atom (e.g., a fluorine atom, a chlorine atom), (c) a hydroxy group, (d) a carboxy group, (e) an amino group, (f) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a C1-6alkoxy group (e.g., methoxy), (g) a C1-6alkoxy group (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutyloxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a carboxy group,(iv) a carbamoyl group, (v) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy-C1-6alkoxy group (e.g., methoxyethoxy), and (II) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), (vi) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), (vii) a N-C1-6alkyl-N-C1-6alkyl-carbonylamino group (e.g., N-methyl-N-acetylamino), (viii) a C3-10cycloalkyl group (e.g., cyclobutyl), and (ix) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl, azetidinyl, pyrrolidinyl, piperidyl, tetrahydropyranyl) optionally substituted by 1 to 3 substituents selected from (I) an oxo group, and (II) a C1-6alkyl group (e.g., methyl), (h) a C1-6alkyl-carbonyl group (e.g., acetyl), (i) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl), (j) a mono- or di-C1-6alkylamino group (e.g., N-ethylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (k) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- propanoylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (l) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non-aromatic heterocyclic groups (e.g., morpholinyl), (m) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino), (n) a C3-10cycloalkyloxy group (e.g., cyclohexyloxy) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non- aromatic heterocyclic groups (e.g., morpholinyl) optionallysubstituted by 1 to 3 C1-6alkyl groups (e.g., methyl), (o) a 3- to 8-membered monocyclic non-aromatic heterocyclyloxy group (e.g., pyrrolidinyloxy) optionally substituted by 1 to 3 oxo groups, (p) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group (e.g., azetidinylcarbonyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), and (q) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group (e.g., 1-oxido-thiolan-1- ylidenamino), (2) a pyridine ring (optionally oxidized) optionally fused with a 5- or 6-membered monocyclic aromatic heterocycle (e.g., imidazole) (i.e., the fused ring is imidazopyridine), further substituted by one cyano group, and optionally further substituted by 1 to 4 substituents selected from (a) a halogen atom (e.g., a fluorine atom, a chlorine atom), (b) an amino group, (c) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a hydroxy group, (d) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a C1-6alkoxy group (e.g., methoxy), and (iii) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., oxetanyl), (e) a C3-10cycloalkyl group (e.g., cyclopropyl), (f) a C1-6alkyl-carbonyl group (e.g., acetyl), (g) a mono- or di-C1-6alkylamino group (e.g., N-methylamino, N,N-dimethylamino, N-ethylamino, N-ethyl-N-methylamino) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (h) a mono- or di-C1-6alkoxy-carbonylamino group (e.g., N-tert-butoxycarbonylamino, N,N-di-tert-butoxycarbonylamino), and (i) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., azetidinyl, pyrrolidinyl), (3) a pyrimidine ring further substituted by one cyano group, and optionally further substituted by 1 to 3 substituents selected from (a) an amino group, (b) a C1-6alkoxy group (e.g., methoxy, ethoxy), and (c) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), (4) a pyridazine ring further substituted by one cyano group, (5) a pyrazine ring further substituted by one cyano group, and optionally further substituted by 1 to 3 substituents selected from (a) a C1-6alkyl group (e.g., methyl), and (b) a C1-6alkoxy group (e.g., methoxy), (6) a dihydropyridine ring further substituted by one cyano group, and optionally further substituted by 1 to 4 substituents selected from (a) an oxo group, and (b) a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), or (7) a dihydropyrimidine ring further substituted by one cyano group, and optionally further substituted by 1 or 2 oxo groups.

[0173] In another embodiment, Ring A2is further more preferably (1) a benzene ring further substituted by one cyano group, and optionally further substituted by 1 to 5 substituents selected from (a) a cyano group, (b) a halogen atom (e.g., a fluorine atom),(c) a hydroxy group, (d) a carboxy group, (e) an amino group, (f) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (g) a C1-6alkoxy group (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutyloxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a carboxy group, (iv) a carbamoyl group, (v) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy-C1-6alkoxy group (e.g., methoxyethoxy), and (II) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), (vi) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), (vii) a N-C1-6alkyl-N-C1-6alkyl-carbonylamino group (e.g., N-methyl-N-acetylamino), (viii) a C3-10cycloalkyl group (e.g., cyclobutyl), and (ix) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl, azetidinyl, pyrrolidinyl, piperidyl, tetrahydropyranyl) optionally substituted by 1 to 3 substituents selected from (I) an oxo group, and (II) a C1-6alkyl group (e.g., methyl), (h) a C1-6alkyl-carbonyl group (e.g., acetyl), (i) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl), (j) a mono- or di-C1-6alkylamino group (e.g., N-ethylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (k) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- propanoylamino) optionally substituted by 1 to 3 C1-6alkoxygroups (e.g., methoxy), (l) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non-aromatic heterocyclic groups (e.g., morpholinyl), (m) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino), (n) a C3-10cycloalkyloxy group (e.g., cyclohexyloxy) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non- aromatic heterocyclic groups (e.g., morpholinyl) optionally substituted by 1 to 3 C1-6alkyl groups (e.g., methyl), (o) a 3- to 8-membered monocyclic non-aromatic heterocyclyloxy group (e.g., pyrrolidinyloxy) optionally substituted by 1 to 3 oxo groups, (p) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group (e.g., azetidinylcarbonyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), and (q) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group (e.g., 1-oxido-thiolan-1- ylidenamino), (2) a pyridine ring (optionally oxidized) optionally fused with a 5- or 6-membered monocyclic aromatic heterocycle (e.g., imidazole) (i.e., the fused ring is imidazopyridine), further substituted by one cyano group, and optionally further substituted by 1 to 4 substituents selected from (a) a halogen atom (e.g., a fluorine atom, a chlorine atom), (b) an amino group, (c) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a hydroxy group, (d) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from(i) a halogen atom (e.g., a fluorine atom), (ii) a C1-6alkoxy group (e.g., methoxy), and (iii) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., oxetanyl), (e) a C3-10cycloalkyl group (e.g., cyclopropyl), (f) a C1-6alkyl-carbonyl group (e.g., acetyl), (g) a mono- or di-C1-6alkylamino group (e.g., N-methylamino, N,N-dimethylamino, N-ethylamino, N-ethyl-N-methylamino) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (h) a mono- or di-C1-6alkoxy-carbonylamino group (e.g., N- tert-butoxycarbonylamino, N,N-di-tert-butoxycarbonylamino), and (i) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., azetidinyl, pyrrolidinyl), (3) a pyrimidine ring further substituted by one cyano group, and optionally further substituted by 1 to 3 substituents selected from (a) an amino group, (b) a C1-6alkoxy group (e.g., methoxy, ethoxy), and (c) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), (4) a pyridazine ring further substituted by one cyano group, (5) a pyrazine ring further substituted by one cyano group, and optionally further substituted by 1 to 3 substituents selected from (a) a C1-6alkyl group (e.g., methyl), and (b) a C1-6alkoxy group (e.g., methoxy), (6) a dihydropyridine ring further substituted by one cyano group, and optionally further substituted by 1 to 4 substituents selected from (a) an oxo group, and (b) a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), or(7) a dihydropyrimidine ring further substituted by one cyano group, and optionally further substituted by 1 or 2 oxo groups.

[0174] In another embodiment, Ring A2is further more preferably (1) a benzene ring further substituted by one cyano group, and optionally further substituted by 1 to 5 substituents selected from (a) a halogen atom (e.g., a fluorine atom, a chlorine atom), (b) a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a C1-6alkoxy group (e.g., methoxy), and (c) a C1-6alkoxy group (e.g., methoxy) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (2) a pyridine ring further substituted by one cyano group, and optionally further substituted by 1 to 4 substituents selected from (a) a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), and (b) a C1-6alkoxy group (e.g., methoxy, ethoxy), (3) a pyrimidine ring further substituted by one cyano group, and optionally further substituted by 1 to 4 C1-6alkoxy groups (e.g., methoxy), or (4) a dihydropyridine ring further substituted by one cyano group, and optionally further substituted by 1 to 4 substituents selected from (a) an oxo group, and (b) a C1-6alkyl group (e.g., methyl).

[0175] In another embodiment, Ring A2is more preferably a partial structure represented by the following formula:

[0176]

[0177] wherein Ring A3is an optionally further substituted benzene ring, an optionally further substituted 6-membered nitrogen-containing aromatic heterocycle, or an optionally further substituted 6- membered nitrogen-containing non-aromatic heterocycle. The cyano group is bonded to the carbon atom adjacent to the carbon atom to which the partial structure represented by the formula:

[0178]

[0179] is bonded.

[0180] The “6-membered nitrogen-containing aromatic heterocycle” of the “optionally further substituted 6-membered nitrogen- containing aromatic heterocycle” is preferably a pyridine ring (optionally oxidized), a pyrimidine ring, a pyridazine ring or a pyrazine ring, particuarly preferably a pyridine ring. The “6-membered nitrogen-containing non-aromatic heterocycle” of the “optionally further substituted 6-membered nitrogen-containing non-aromatic heterocycle” is preferably a dihydropyridine ring or a dihydropyrimidine ring.

[0181] The “benzene ring” of the “optionally further substituted benzene ring”, the “6-membered nitrogen-containing aromatic heterocycle” of the “optionally further substituted 6-membered nitrogen-containing aromatic heterocycle” and “6-membered nitrogen-containing non-aromatic heterocycle” of the “optionally further substituted 6-membered nitrogen-containing non-aromatic heterocycle” optionally further have 1 to 3 substituents atsubstitutable position(s), in addition to the cyano group and the partial structure represented by the formula:

[0182]

[0183] Examples of the substituent include substituents selected from the above-mentioned Substituent Group A. When the number of the substituents is two or more, the respective substituents may be the same or different. In addition, the above-mentioned Substituent Group A is optionally substituted by substituent(s) selected from Substituent Group A. The number of the substituents is, for example, 1 to 3. When the number of the substituents is two or more, the respective substituents may be the same or different.

[0184] Ring A3is preferably (1) a benzene ring optionally further substituted by 1 to 5 substituents selected from (a) a cyano group, (b) a halogen atom (e.g., a fluorine atom, a chlorine atom), (c) a hydroxy group, (d) a carboxy group, (e) an amino group, (f) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a C1-6alkoxy group (e.g., methoxy), (g) a C1-6alkoxy group (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutyloxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a carboxy group,(iv) a carbamoyl group, (v) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy-C1-6alkoxy group (e.g., methoxyethoxy), and (II) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), (vi) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), (vii) a N-C1-6alkyl-N-C1-6alkyl-carbonylamino group (e.g., N-methyl-N-acetylamino), (viii) a C3-10cycloalkyl group (e.g., cyclobutyl), and (ix) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl, azetidinyl, pyrrolidinyl, piperidyl, tetrahydropyranyl) optionally substituted by 1 to 3 substituents selected from (I) an oxo group, and (II) a C1-6alkyl group (e.g., methyl), (h) a C1-6alkyl-carbonyl group (e.g., acetyl), (i) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl), (j) a mono- or di-C1-6alkylamino group (e.g., N-ethylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (k) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- propanoylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (l) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non-aromatic heterocyclic groups (e.g., morpholinyl), (m) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino), (n) a C3-10cycloalkyloxy group (e.g., cyclohexyloxy) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non- aromatic heterocyclic groups (e.g., morpholinyl) optionallysubstituted by 1 to 3 C1-6alkyl groups (e.g., methyl), (o) a 3- to 8-membered monocyclic non-aromatic heterocyclyloxy group (e.g., pyrrolidinyloxy) optionally substituted by 1 to 3 oxo groups, (p) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group (e.g., azetidinylcarbonyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), and (q) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group (e.g., 1-oxido-thiolan-1- ylidenamino), (2) a 6-membered aromatic heterocycle (e.g., pyridine (optionally oxidized), pyrimidine, pyridazine, pyrazine) optionally fused with a 5- or 6-membered monocyclic aromatic heterocycle (e.g., imidazole) (i.e., the fused ring is imidazopyridine), and optionally further substituted by 1 to 4 substituents selected from (a) a halogen atom (e.g., a fluorine atom, a chlorine atom), (b) an amino group, (c) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a hydroxy group, (d) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a C1-6alkoxy group (e.g., methoxy), and (iii) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., oxetanyl), (e) a C3-10cycloalkyl group (e.g., cyclopropyl), (f) a C1-6alkyl-carbonyl group (e.g., acetyl), (g) a mono- or di-C1-6alkylamino group (e.g., N-methylamino, N,N-dimethylamino, N-ethylamino, N-ethyl-N-methylamino) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (h) a mono- or di-C1-6alkoxy-carbonylamino group (e.g., N-tert-butoxycarbonylamino, N,N-di-tert-butoxycarbonylamino), and (i) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., azetidinyl, pyrrolidinyl), or (3) a 6-membered non-aromatic heterocycle (e.g., dihydropyridine, dihydropyrimidine) optionally further substituted by 1 to 4 substituents selected from (a) an oxo group, and (b) a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom).

[0185] In another embodiment, Ring A3is preferably (1) a benzene ring optionally further substituted by 1 to 5 substituents selected from (a) a cyano group, (b) a halogen atom (e.g., a fluorine atom), (c) a hydroxy group, (d) a carboxy group, (e) an amino group, (f) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (g) a C1-6alkoxy group (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutyloxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a carboxy group, (iv) a carbamoyl group, (v) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy-C1-6alkoxy group (e.g., methoxyethoxy), and (II) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), (vi) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), (vii) a N-C1-6alkyl-N-C1-6alkyl-carbonylamino group (e.g.,N-methyl-N-acetylamino), (viii) a C3-10cycloalkyl group (e.g., cyclobutyl), and (ix) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl, azetidinyl, pyrrolidinyl, piperidyl, tetrahydropyranyl) optionally substituted by 1 to 3 substituents selected from (I) an oxo group, and (II) a C1-6alkyl group (e.g., methyl), (h) a C1-6alkyl-carbonyl group (e.g., acetyl), (i) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl), (j) a mono- or di-C1-6alkylamino group (e.g., N-ethylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (k) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- propanoylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (l) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non-aromatic heterocyclic groups (e.g., morpholinyl), (m) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino), (n) a C3-10cycloalkyloxy group (e.g., cyclohexyloxy) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non- aromatic heterocyclic groups (e.g., morpholinyl) optionally substituted by 1 to 3 C1-6alkyl groups (e.g., methyl), (o) a 3- to 8-membered monocyclic non-aromatic heterocyclyloxy group (e.g., pyrrolidinyloxy) optionally substituted by 1 to 3 oxo groups, (p) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group (e.g., azetidinylcarbonyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), and (q) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group (e.g., 1-oxido-thiolan-1-ylidenamino), (2) a 6-membered aromatic heterocycle (e.g., pyridine (optionally oxidized), pyrimidine, pyridazine, pyrazine) optionally fused with a 5- or 6-membered monocyclic aromatic heterocycle (e.g., imidazole) (i.e., the fused ring is imidazopyridine), and optionally further substituted by 1 to 4 substituents selected from (a) a halogen atom (e.g., a fluorine atom, a chlorine atom), (b) an amino group, (c) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a hydroxy group, (d) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a C1-6alkoxy group (e.g., methoxy), and (iii) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., oxetanyl), (e) a C3-10cycloalkyl group (e.g., cyclopropyl), (f) a C1-6alkyl-carbonyl group (e.g., acetyl), (g) a mono- or di-C1-6alkylamino group (e.g., N-methylamino, N,N-dimethylamino, N-ethylamino, N-ethyl-N-methylamino) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (h) a mono- or di-C1-6alkoxy-carbonylamino group (e.g., N- tert-butoxycarbonylamino, N,N-di-tert-butoxycarbonylamino), and (i) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., azetidinyl, pyrrolidinyl), or (3) a 6-membered non-aromatic heterocycle (e.g., dihydropyridine, dihydropyrimidine) optionally further substituted by 1 to 4 substituents selected from (a) an oxo group, and (b) a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom).

[0186] In another embodiment, Ring A3is preferably (1) a benzene ring optionally further substituted by 1 to 5 substituents selected from (a) a halogen atom (e.g., a fluorine atom, a chlorine atom), (b) a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a C1-6alkoxy group (e.g., methoxy), and (c) a C1-6alkoxy group (e.g., methoxy) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (2) a 6-membered aromatic heterocycle (e.g., pyridine, pyrimidine) optionally further substituted by 1 to 4 substituents selected from (a) a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), and (b) a C1-6alkoxy group (e.g., methoxy, ethoxy), or (3) a 6-membered non-aromatic heterocycle (e.g., dihydropyridine) optionally further substituted by 1 to 4 substituents selected from (a) an oxo group, and (b) a C1-6alkyl group (e.g., methyl).

[0187] Ring A3is more preferably (1) a benzene ring optionally further substituted by 1 to 5 substituents selected from (a) a cyano group, (b) a halogen atom (e.g., a fluorine atom, a chlorine atom), (c) a hydroxy group, (d) a carboxy group, (e) an amino group, (f) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a C1-6alkoxy group (e.g., methoxy), (g) a C1-6alkoxy group (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutyloxy) optionally substituted by 1 to 3substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a carboxy group, (iv) a carbamoyl group, (v) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy-C1-6alkoxy group (e.g., methoxyethoxy), and (II) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), (vi) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), (vii) a N-C1-6alkyl-N-C1-6alkyl-carbonylamino group (e.g., N-methyl-N-acetylamino), (viii) a C3-10cycloalkyl group (e.g., cyclobutyl), and (ix) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl, azetidinyl, pyrrolidinyl, piperidyl, tetrahydropyranyl) optionally substituted by 1 to 3 substituents selected from (I) an oxo group, and (II) a C1-6alkyl group (e.g., methyl), (h) a C1-6alkyl-carbonyl group (e.g., acetyl), (i) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl), (j) a mono- or di-C1-6alkylamino group (e.g., N-ethylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (k) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- propanoylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (l) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non-aromatic heterocyclic groups (e.g., morpholinyl), (m) a di-C1-6alkylsulfinylidenamino group (e.g., N-dimethylsulfinylidenamino), (n) a C3-10cycloalkyloxy group (e.g., cyclohexyloxy) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non- aromatic heterocyclic groups (e.g., morpholinyl) optionally substituted by 1 to 3 C1-6alkyl groups (e.g., methyl), (o) a 3- to 8-membered monocyclic non-aromatic heterocyclyloxy group (e.g., pyrrolidinyloxy) optionally substituted by 1 to 3 oxo groups, (p) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group (e.g., azetidinylcarbonyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), and (q) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group (e.g., 1-oxido-thiolan-1- ylidenamino), (2) a pyridine ring (optionally oxidized) optionally fused with a 5- or 6-membered monocyclic aromatic heterocycle (e.g., imidazole) (i.e., the fused ring is imidazopyridine), and optionally further substituted by 1 to 4 substituents selected from (a) a halogen atom (e.g., a fluorine atom, a chlorine atom), (b) an amino group, (c) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a hydroxy group, (d) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a C1-6alkoxy group (e.g., methoxy), and (iii) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., oxetanyl), (e) a C3-10cycloalkyl group (e.g., cyclopropyl), (f) a C1-6alkyl-carbonyl group (e.g., acetyl), (g) a mono- or di-C1-6alkylamino group (e.g., N-methylamino, N,N-dimethylamino, N-ethylamino, N-ethyl-N-methylamino)optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (h) a mono- or di-C1-6alkoxy-carbonylamino group (e.g., N- tert-butoxycarbonylamino, N,N-di-tert-butoxycarbonylamino), and (i) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., azetidinyl, pyrrolidinyl), (3) a pyrimidine ring optionally further substituted by 1 to 3 substituents selected from (a) an amino group, (b) a C1-6alkoxy group (e.g., methoxy, ethoxy), and (c) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), (4) a pyridazine ring, (5) a pyrazine ring optionally further substituted by 1 to 3 substituents selected from (a) a C1-6alkyl group (e.g., methyl), and (b) a C1-6alkoxy group (e.g., methoxy), (6) a dihydropyridine ring optionally further substituted by 1 to 4 substituents selected from (a) an oxo group, and (b) a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), or (7) a dihydropyrimidine ring optionally further substituted by 1 or 2 oxo groups.

[0188] In another embodiment, Ring A3is more preferably (1) a benzene ring optionally further substituted by 1 to 5 substituents selected from (a) a cyano group, (b) a halogen atom (e.g., a fluorine atom), (c) a hydroxy group, (d) a carboxy group, (e) an amino group, (f) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (g) a C1-6alkoxy group (e.g., methoxy, ethoxy, propoxy,isopropoxy, isobutyloxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a carboxy group, (iv) a carbamoyl group, (v) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy-C1-6alkoxy group (e.g., methoxyethoxy), and (II) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), (vi) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), (vii) a N-C1-6alkyl-N-C1-6alkyl-carbonylamino group (e.g., N-methyl-N-acetylamino), (viii) a C3-10cycloalkyl group (e.g., cyclobutyl), and (ix) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl, azetidinyl, pyrrolidinyl, piperidyl, tetrahydropyranyl) optionally substituted by 1 to 3 substituents selected from (I) an oxo group, and (II) a C1-6alkyl group (e.g., methyl), (h) a C1-6alkyl-carbonyl group (e.g., acetyl), (i) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl), (j) a mono- or di-C1-6alkylamino group (e.g., N-ethylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (k) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- propanoylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (l) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non-aromatic heterocyclic groups (e.g., morpholinyl),(m) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino), (n) a C3-10cycloalkyloxy group (e.g., cyclohexyloxy) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non- aromatic heterocyclic groups (e.g., morpholinyl) optionally substituted by 1 to 3 C1-6alkyl groups (e.g., methyl), (o) a 3- to 8-membered monocyclic non-aromatic heterocyclyloxy group (e.g., pyrrolidinyloxy) optionally substituted by 1 to 3 oxo groups, (p) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group (e.g., azetidinylcarbonyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), and (q) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group (e.g., 1-oxido-thiolan-1- ylidenamino), (2) a pyridine ring (optionally oxidized) optionally fused with a 5- or 6-membered monocyclic aromatic heterocycle (e.g., imidazole) (i.e., the fused ring is imidazopyridine), and optionally further substituted by 1 to 4 substituents selected from (a) a halogen atom (e.g., a fluorine atom, a chlorine atom), (b) an amino group, (c) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a hydroxy group, (d) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a C1-6alkoxy group (e.g., methoxy), and (iii) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., oxetanyl), (e) a C3-10cycloalkyl group (e.g., cyclopropyl), (f) a C1-6alkyl-carbonyl group (e.g., acetyl), (g) a mono- or di-C1-6alkylamino group (e.g., N-methylamino,N,N-dimethylamino, N-ethylamino, N-ethyl-N-methylamino) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (h) a mono- or di-C1-6alkoxy-carbonylamino group (e.g., N- tert-butoxycarbonylamino, N,N-di-tert-butoxycarbonylamino), and (i) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., azetidinyl, pyrrolidinyl), (3) a pyrimidine ring optionally further substituted by 1 to 3 substituents selected from (a) an amino group, (b) a C1-6alkoxy group (e.g., methoxy, ethoxy), and (c) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), (4) a pyridazine ring, (5) a pyrazine ring optionally further substituted by 1 to 3 substituents selected from (a) a C1-6alkyl group (e.g., methyl), and (b) a C1-6alkoxy group (e.g., methoxy), (6) a dihydropyridine ring optionally further substituted by 1 to 4 substituents selected from (a) an oxo group, and (b) a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), or (7) a dihydropyrimidine ring optionally further substituted by 1 or 2 oxo groups.

[0189] In another embodiment, Ring A3is more preferably (1) a benzene ring optionally further substituted by 1 to 5 substituents selected from (a) a halogen atom (e.g., a fluorine atom, a chlorine atom), (b) a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a C1-6alkoxy group (e.g., methoxy), and (c) a C1-6alkoxy group (e.g., methoxy) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom),(2) a pyridine ring optionally further substituted by 1 to 4 substituents selected from (a) a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), and (b) a C1-6alkoxy group (e.g., methoxy, ethoxy), (3) a pyrimidine ring optionally further substituted by 1 to 4 C1- 6 alkoxy groups (e.g., methoxy), or (4) a dihydropyridine ring optionally further substituted by 1 to 4 substituents selected from (a) an oxo group, and (b) a C1-6alkyl group (e.g., methyl).

[0190] The partial structure represented by the formula;

[0191]

[0192] is preferably a partial structure represented by the formula (A3- 1)-(A3-9);

[0193]

[0194] wherein Q1is N or CRQ1wherein RQ1is (a) a hydrogen atom, (b) a cyano group, (c) a halogen atom, (d) a hydroxy group, (e) a carboxy group, (f) an amino group, (g) an optionally substituted C1-6alkyl group, (h) an optionally substituted C1-6alkoxy group, (i) a C1-6alkyl-carbonyl group, (j) a C1-6alkoxy-carbonyl group, (k) an optionally substituted mono- or di-C1-6alkylamino group, (l) an optionally substituted mono- or di-C1-6alkyl- carbonylamino group, (m) a mono- or di-C1-6alkoxy-carbonylamino group,(n) a mono- or di-C1-6alkyl-carbamoyl group, (o) a di-C1-6alkylsulfinylidenamino group, (p) a C3-10cycloalkyl group, (q) an optionally substituted C3-10cycloalkyloxy group, (r) a 3- to 8-membered monocyclic non-aromatic heterocyclic group, (s) an optionally substituted 3- to 8-membered monocyclic non- aromatic heterocyclyloxy, (t) an optionally substituted 3- to 8-membered monocyclic non- aromatic heterocyclylcarbonyl group, or (u) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group, Q2is N or CRQ2wherein RQ2is (a) a hydrogen atom, (b) a halogen atom, or (c) a C1-6alkoxy group, Q3is N or CRQ3wherein RQ3is (a) a hydrogen atom, (b) a cyano group, (c) a halogen atom, (d) a carboxy group, (e) an optionally substituted C1-6alkyl group, (f) an optionally substituted C1-6alkoxy group, (g) a C1-6alkyl-carbonyl group, (h) a C1-6alkoxy-carbonyl group, (i) a mono- or di-C1-6alkylamino group, (j) an optionally substituted mono- or di-C1-6alkyl-carbamoyl group, (k) a di-C1-6alkylsulfinylidenamino group, or (l) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group, Q4is N or CRQ4wherein RQ4is (a) a hydrogen atom, or (b) a halogen atom, and N of Q1, Q2, Q3and Q4is each optionally oxidized; RN1is a hydrogen atom or a C1-6alkyl group; RN2is a hydrogen atom or a C1-6alkyl group;RN3is a hydrogen atom or a C1-6alkyl group; and RN4is a hydrogen atom or a C1-6alkyl group optionally substituted by 1 to 3 halogen atoms.

[0195] The partial structure represented by the formula;

[0196]

[0197] is more preferably a partial structure represented by the formula (A3-1), (A3-2), (A3-3), (A3-5), (A3-6) or (A3-9);

[0198]

[0199] wherein each symbol is as defined above.

[0200] In the formula (A3-1), Q1is preferably N or CRQ1wherein RQ1is (a) a hydrogen atom, (b) a cyano group, (c) a halogen atom (e.g., a fluorine atom, a chlorine atom), (d) a hydroxy group, (e) a carboxy group, (f) an amino group, (g) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from(i) a halogen atom (e.g., a fluorine atom), and (ii) a C1-6alkoxy group (e.g., methoxy), (h) a C1-6alkoxy group (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutyloxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a carboxy group, (iv) a carbamoyl group, (v) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy-C1-6alkoxy group (e.g., methoxyethoxy), and (II) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), (vi) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), (vii) a N-C1-6alkyl-N-C1-6alkyl-carbonylamino group (e.g., N-methyl-N-acetylamino), (viii) a C3-10cycloalkyl group (e.g., cyclobutyl), and (ix) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl, azetidinyl, pyrrolidinyl, piperidyl, tetrahydropyranyl, oxetanyl) optionally substituted by 1 to 3 substituents selected from (I) an oxo group, and (II) a C1-6alkyl group (e.g., methyl), (i) a C1-6alkyl-carbonyl group (e.g., acetyl), (j) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl), (k) a mono- or di-C1-6alkylamino group (e.g., N-methylamino, N,N-dimethylamino, N-ethylamino, N-ethyl-N-methylamino) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a C1-6alkoxy group (e.g., methoxy), (l) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- propanoylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy),(m) a mono- or di-C1-6alkoxy-carbonylamino group (e.g., N- tert-butoxycarbonylamino, N,N-di-tert-butoxycarbonylamino), (n) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N,N- dimethylcarbamoyl), (o) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino), (p) a C3-10cycloalkyl group (e.g., cyclopropyl), (q) a C3-10cycloalkyloxy group (e.g., cyclohexyloxy) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non- aromatic heterocyclic groups (e.g., morpholinyl) optionally substituted by 1 to 3 C1-6alkyl groups (e.g., methyl), (r) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., azetidinyl, pyrrolidinyl), (s) a 3- to 8-membered monocyclic non-aromatic heterocyclyloxy group (e.g., pyrrolidinyloxy) optionally substituted by 1 to 3 oxo groups, (t) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group (e.g., azetidinylcarbonyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), or (u) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group (e.g., 1-oxido-thiolan-1- ylidenamino).

[0201] In another embodiment, in the formula (A3-1), Q1is preferably N or CRQ1wherein RQ1is (a) a hydrogen atom, (b) a cyano group, (c) a halogen atom (e.g., a fluorine atom, a chlorine atom), (d) a hydroxy group, (e) a carboxy group, (f) an amino group, (g) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (h) a C1-6alkoxy group (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutyloxy) optionally substituted by 1 to 3 substituents selected from(i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a carboxy group, (iv) a carbamoyl group, (v) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy-C1-6alkoxy group (e.g., methoxyethoxy), and (II) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), (vi) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), (vii) a N-C1-6alkyl-N-C1-6alkyl-carbonylamino group (e.g., N-methyl-N-acetylamino), (viii) a C3-10cycloalkyl group (e.g., cyclobutyl), and (ix) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl, azetidinyl, pyrrolidinyl, piperidyl, tetrahydropyranyl, oxetanyl) optionally substituted by 1 to 3 substituents selected from (I) an oxo group, and (II) a C1-6alkyl group (e.g., methyl), (i) a C1-6alkyl-carbonyl group (e.g., acetyl), (j) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl), (k) a mono- or di-C1-6alkylamino group (e.g., N-methylamino, N,N-dimethylamino, N-ethylamino, N-ethyl-N-methylamino) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a C1-6alkoxy group (e.g., methoxy), (l) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- propanoylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (m) a mono- or di-C1-6alkoxy-carbonylamino group (e.g., N- tert-butoxycarbonylamino, N,N-di-tert-butoxycarbonylamino), (n) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N,N- dimethylcarbamoyl), (o) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino),(p) a C3-10cycloalkyl group (e.g., cyclopropyl), (q) a C3-10cycloalkyloxy group (e.g., cyclohexyloxy) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non- aromatic heterocyclic groups (e.g., morpholinyl) optionally substituted by 1 to 3 C1-6alkyl groups (e.g., methyl), (r) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., azetidinyl, pyrrolidinyl), (s) a 3- to 8-membered monocyclic non-aromatic heterocyclyloxy group (e.g., pyrrolidinyloxy) optionally substituted by 1 to 3 oxo groups, (t) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group (e.g., azetidinylcarbonyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), or (u) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group (e.g., 1-oxido-thiolan-1- ylidenamino).

[0202] In another embodiment, in the formula (A3-1), Q1is preferably CRQ1wherein RQ1is (a) a hydrogen atom, (b) a halogen atom (e.g., a fluorine atom, a chlorine atom), (c) a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a C1-6alkoxy group (e.g., methoxy), or (d) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom).

[0203] In the formula (A3-1), Q2is preferably N (optionally oxidized) or CRQ2wherein RQ2is (a) a hydrogen atom, (b) a halogen atom (e.g., a fluorine atom), or (c) a C1-6alkoxy group (e.g., methoxy).

[0204] In another embodiment, in the formula (A3-1), Q2is preferably CRQ2wherein RQ2is(a) a hydrogen atom, or (b) a halogen atom (e.g., a fluorine atom).

[0205] In the formula (A3-1), Q3is preferably N (optionally oxidized) or CRQ3wherein RQ3is (a) a hydrogen atom, (b) a cyano group, (c) a halogen atom (e.g., a fluorine atom, a chlorine atom), (d) a carboxy group, (e) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a hydroxy group, (f) a C1-6alkoxy group (e.g., methoxy) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (g) a C1-6alkyl-carbonyl group (e.g., acetyl), (h) a C1-6alkoxy-carbonyl group (e.g., ethoxycarbonyl), (i) a mono- or di-C1-6alkylamino group (e.g., N-methylamino, N,N-dimethylamino), (j) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N-ethylcarbamoyl) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non-aromatic heterocyclic groups (e.g., morpholinyl), (k) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino), or (l) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group (e.g., 1-oxido-thiolan-1- ylidenamino).

[0206] In another embodiment, in the formula (A3-1), Q3is preferably N (optionally oxidized) or CRQ3wherein RQ3is (a) a hydrogen atom, (b) a cyano group, (c) a halogen atom (e.g., a fluorine atom, a chlorine atom), (d) a carboxy group, (e) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from(i) a halogen atom (e.g., a fluorine atom), and (ii) a hydroxy group, (f) a C1-6alkoxy group (e.g., methoxy), (g) a C1-6alkyl-carbonyl group (e.g., acetyl), (h) a C1-6alkoxy-carbonyl group (e.g., ethoxycarbonyl), (i) a mono- or di-C1-6alkylamino group (e.g., N-methylamino, N,N-dimethylamino), (j) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N-ethylcarbamoyl) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non-aromatic heterocyclic groups (e.g., morpholinyl), (k) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino), or (l) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group (e.g., 1-oxido-thiolan-1- ylidenamino).

[0207] In another embodiment, in the formula (A3-1), Q3is preferably CRQ3wherein RQ3is (a) a hydrogen atom, (b) a halogen atom (e.g., a fluorine atom, a chlorine atom), (c) a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), or (d) a C1-6alkoxy group (e.g., methoxy) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom).

[0208] In the formula (A3-1), Q4is preferably N (optionally oxidized) or CRQ4wherein RQ4is (a) a hydrogen atom, or (b) a halogen atom (e.g., a fluorine atom).

[0209] In another embodiment, in the formula (A3-1), Q4is preferably N (optionally oxidized) or CH.

[0210] In another embodiment, in the formula (A3-1), Q4is preferably N or CRQ4wherein RQ4is (a) a hydrogen atom, or(b) a halogen atom (e.g., a fluorine atom).

[0211] In the formula (A3-2), RN1is preferably a hydrogen atom or a C1-6alkyl group (e.g., methyl), Q3is preferably CH, and Q4is preferably CH.

[0212] In the formula (A3-3), RN2is preferably a hydrogen atom or a C1-6alkyl group (e.g., methyl), Q3is preferably CH, and Q4is preferably N or CH.

[0213] In the formula (A3-5), RN4is preferably a hydrogen atom, Q1is preferably CH, and Q2is preferably CH.

[0214] In the formula (A3-6), RN2is preferably a hydrogen atom or a C1-6alkyl group (e.g., methyl), Q1is preferably CH, and Q4is preferably CH.

[0215] In the formula (A3-9), RN4is preferably a hydrogen atom or a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), Q2is preferably CH, and Q3is preferably CH.

[0216] Ring B1is an optionally further substituted aromatic heterocycle. The “aromatic heterocycle” of the “optionally further substituted aromatic heterocycle” optionally further has 1 to 5 (preferably 1 to 3) substituents at substitutable position(s), inaddition to -V-Z-Ring B1. Examples of the substituent include substituents selected from the above-mentioned Substituent Group A. When the number of the substituents is two or more, the respective substituents may be the same or different. The “aromatic heterocycle” of the “optionally further substituted aromatic heterocycle” is preferably a 5-membered aromatic heterocycle.

[0217] Ring B1is preferably Ring B2, i.e., an optionally further substituted 5-membered aromatic heterocycle. The “5-membered aromatic heterocycle” of the “optionally further substituted 5-membered aromatic heterocycle” optionally further has 1 to 5 (preferably 1 to 3) substituents at substitutable position(s), in addition to -O-CH(R1)-CH2-Ring B2. Examples of the substituent include substituents selected from the above-mentioned Substituent Group A. When the number of the substituents is two or more, the respective substituents may be the same or different. The “5-membered aromatic heterocycle” of the “optionally further substituted 5-membered aromatic heterocycle” is preferably a 5-membered nitrogen-containing aromatic heterocycle. Examples of the 5-membered nitrogen-containing aromatic heterocycle include tetrazole, 1,2,3-triazole, 1,2,4-triazole, pyrazole, imidazole, pyrrole, thiazole, isothiazole, oxazole, isoxazole, 1,2,4-oxadiazole, 1,3,4-oxadiazole, 1,2,4-thiadiazole, 1,3,4-thiadiazole and the like.,

[0218] Ring B2is preferably an optionally further substituted 5-membered nitrogen- containing aromatic heterocycle, more preferably tetrazole or triazole, each of which is optionally further substituted, further more preferably tetrazole or triazole, still more preferably tetrazole or triazole, each of which is bonded at its nitrogen. even more preferably tetrazole or 1,2,4-triazole, each of which is bonded at its nitrogen,particularly preferably tetrazol-1-yl or 1,2,4-triazol-1-yl.

[0219] V is O, S, S(O), S(O)2or N(RV) wherein RVis a hydrogen atom or an optionally substituted C1-6alkyl group. The “C1-6alkyl group” of the “optionally substituted C1-6alkyl group” optionally further has 1 to 5 (preferably 1 to 3) substituents at substitutable position(s). Examples of the substituent include substituents selected from the above- mentioned Substituent Group A. When the number of the substituents is two or more, the respective substituents may be the same or different. V is preferably O.

[0220] Z is an optionally substituted C1-6alkylene group. The “C1-6alkylene group” of the “optionally substituted C1-6alkylene group” optionally further has 1 to 5 (preferably 1 to 3) substituents at substitutable position(s). Examples of the substituent include substituents selected from the above- mentioned Substituent Group A. When the number of the substituents is two or more, the respective substituents may be the same or different. Z is preferably an optionally substituted ethylene group, more preferably -CH(R1)-CH2- wherein R1is a C1-6alkyl group. R1is preferably methyl. Z is particularly preferably -CH(CH3)-CH2-.

[0221] Compound (I) is preferably compound (II), more preferably compound (III).

[0222] Compound (I) contains a compound represented by the formulas (I-1) and (I-2):

[0223]

[0224] wherein each symbol is as defined above. Compound (II) contains a compound represented by the formulas (II-1) and (II-2):

[0225]

[0226] wherein each symbol is as defined above. Compound (III) contains a compound represented by the formulas (III-1) and (III-2):

[0227]

[0228] wherein each symbol is as defined above.

[0229] Preferable compounds (I)-(III) are as follows.

[0230] [Compound A] Compound (II) wherein X1is N or CRX1wherein RX1is a hydrogen atom, a halogen atom (e.g., a fluorine atom) or a C1-6alkyl group (e.g., methyl); X2, X3and X4are each independently C or N, and one of X2, X3and X4is N, and the other two are C; Ring A2is (1) a benzene ring optionally fused with a 5- to 6-membered monocyclic non-aromatic heterocycle (e.g., dihydrofuran, pyrroline) (i.e., the fused ring is dihydrobenzofuran, isoindoline) optionally substituted by 1 to 3 substituents selected from (a) an oxo group, and (b) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), and optionally further substituted by 1 to 5 substituents selected from (a) a cyano group, (b) a halogen atom (e.g., a fluorine atom, a chlorine atom, a bromine atom), (c) a hydroxy group, (d) a carboxy group, (e) a formyl group, (f) an amino group, (g) a carbamoyl group, (h) a C1-6alkyl group (e.g., methyl, ethyl, isopropyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a hydroxy group, (iii) a C1-6alkoxy group (e.g., methoxy), (iv) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), and (v) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino),(i) a C2-6alkenyl group (e.g., vinyl), (j) a C2-6alkynyl group (e.g., ethynyl), (k) a C1-6alkoxy group (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutyloxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a carboxy group, (iv) a carbamoyl group, (v) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy-C1-6alkoxy group (e.g., methoxyethoxy), and (II) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), (vi) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), (vii) a N-C1-6alkyl-N-C1-6alkyl-carbonylamino group (e.g., N-methyl-N-acetylamino), (viii) a C3-10cycloalkyl group (e.g., cyclopropyl, cyclobutyl), and (ix) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl, azetidinyl, pyrrolidinyl, piperidyl, tetrahydropyranyl) optionally substituted by 1 to 3 substituents selected from (I) an oxo group, and (II) a C1-6alkyl group (e.g., methyl), (l) a C1-6alkyl-carbonyl group (e.g., acetyl), (m) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl), (n) a mono- or di-C1-6alkylamino group (e.g., N-ethylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (o) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino, N-propanoylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (p) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N-methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl, N- propylcarbamoyl, N-butylcarbamoyl, N-isobutylcarbamoyl, N- isopentylcarbamoyl, N-neopentylcarbamoyl) optionally substituted by 1 to 3 substituents selected from (i) a hydroxy group, (ii) a C1-6alkoxy group (e.g., methoxy), (iii) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino, N,N-diethylamino), (iv) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), (v) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N,N-diethylcarbamoyl), (vi) a C3-10cycloalkyl group (e.g., cyclopropyl, cyclohexyl), (vii) a C6-14aryl group (e.g., phenyl), (viii) a 5- or 6-membered monocyclic aromatic heterocyclic group (e.g., pyridyl, imidazolyl, triazolyl), and (ix) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., azetidinyl, morpholinyl, pyrrolidinyl, piperidyl, 1,1-dioxidothiomorpholinyl, tetrahydropyranyl) optionally substituted by 1 to 3 substituents selected from (I) a hydroxy group, (II) an oxo group, and (III) a C1-6alkyl group (e.g., methyl), (q) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino), (r) a C3-10cycloalkyloxy group (e.g., cyclohexyloxy) optionally substituted by 1 to 3 substituents selected from (i) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl) optionally substituted by 1 to 3 C1-6alkyl groups (e.g., methyl), (s) a C3-10cycloalkylsulfonyl-carbamoyl group (e.g., cyclopropylsulfonylcarbamoyl), (t) a C6-14aryl-carbamoyl group (e.g., phenylcarbamoyl), (u) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl, piperazinyl) optionally substitutedby 1 to 3 C1-6alkyl-carbonyl groups (e.g., acetyl), (v) a 3- to 8-membered monocyclic non-aromatic heterocyclyloxy group (e.g., pyrrolidinyloxy) optionally substituted by 1 to 3 oxo groups, (w) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group (e.g., azetidinylcarbonyl, piperidylcarbonyl, morpholinylcarbonyl) optionally substituted by 1 to 3 substituents selected from (i) a hydroxy group, (ii) a C1-6alkyl group (e.g., methyl), (iii) a C1-6alkoxy group (e.g., methoxy), (iv) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), and (v) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl), (x) a 9- to 14-membered bicyclic non-aromatic heterocyclylcarbonyl group (e.g., tetrahydroimidazopyrazinylcarbonyl tetrahydrotriazolopyrazinylcarbonyl), (y) a 5- or 6-membered monocyclic aromatic heterocyclylcarbamoyl group (e.g., pyrazolylcarbamoyl, pyridylcarbamoyl) optionally substituted by 1 to 3 C1-6alkyl groups (e.g., methyl), (z) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbamoyl group (e.g., azetidinylcarbamoyl, piperidylcarbamoyl, pyrrolidinylcarbamoyl) optionally substituted by 1 to 3 substituents selected from (i) an oxo group, (ii) a C1-6alkyl group (e.g., methyl), (iii) a C1-6alkyl-carbonyl group (e.g., acetyl), and (iv) a C7-16aralkyl group (e.g., benzyl), and (aa) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group (e.g., 1-oxido-thiolan-1- ylidenamino), (2) a 5- or 6-membered aromatic heterocycle (e.g., pyridine (optionally oxidized), pyrimidine, pyridazine, pyrazine, pyrazole, imidazole, thiophene, thiazole, furan)optionally fused with a 5- or 6-membered monocyclic aromatic heterocycle (e.g., imidazole) (i.e., the fused ring is imidazopyridine), and optionally further substituted by 1 to 4 substituents selected from (a) a cyano group, (b) a halogen atom (e.g., a fluorine atom, a chlorine atom), (c) a carboxy group, (d) an amino group, (e) a carbamoyl group, (f) a C1-6alkyl group (e.g., methyl, ethyl, propyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a hydroxy group, (iv) a carboxy group, (v) a C1-6alkoxy group (e.g., methoxy), (vi) a C7-16aralkyloxy-carbonyl group (e.g., benzyloxycarbonyl), (vii) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- ethylcarbamoyl, N-propylcarbamoyl) optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy group (e.g., methoxy), and (II) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl), and (viii) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl), (g) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a C1-6alkoxy group (e.g., methoxy), and (iv) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., oxetanyl), (h) a C3-10cycloalkyl group (e.g., cyclopropyl), (i) a C1-6alkyl-carbonyl group (e.g., acetyl), (j) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl,propoxycarbonyl, tert-butoxycarbonyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (k) a mono- or di-C1-6alkylamino group (e.g., N-methylamino, N,N-dimethylamino, N-ethylamino, N-ethyl-N-methylamino) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (l) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl) optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy group (e.g., methoxy), and (II) a mono- or di-C1-6alkylamino groups (e.g., N,N- diethylamino), (m) a mono- or di-C1-6alkoxy-carbonylamino group (e.g., N- tert-butoxycarbonylamino, N,N-di-tert-butoxycarbonylamino), and (n) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., azetidinyl, pyrrolidinyl), or (3) a 5- or 6-membered non-aromatic heterocycle (e.g., dihydropyridine, dihydropyrimidine) optionally further substituted by 1 to 4 substituents selected from (a) an oxo group, (b) a cyano group, (c) a halogen atom (e.g., a fluorine atom, a chlorine atom), and (d) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from (I) a halogen atom (e.g., a fluorine atom), (II) a cyano group, and (III) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom); Y1is N or CH; Y2is N or CRY2wherein RY2is a hydrogen atom, a halogen atom (e.g., a fluorine atom, a chlorine atom) or a cyano group; Y3is N or CRY3wherein RY3is a hydrogen atom or a halogen atom (e.g., a fluorine atom); Y4is N or CRY4wherein RY4is a hydrogen atom or a halogen atom(e.g., a fluorine atom); Ring B2is a 5-membered aromatic heterocycle (preferably tetrazole or triazole (preferably 1,2,4-triazole), each of which is preferably bonded at its nitrogen); and R1is a C1-6alkyl group (preferably methyl).

[0231] [Compound B] Compound (III) wherein X2, X3and X4are each independently C or N, and one of X2, X3and X4is N, and the other two are C; Ring A3is (1) a benzene ring optionally further substituted by 1 to 5 substituents selected from (a) a cyano group, (b) a halogen atom (e.g., a fluorine atom, a chlorine atom), (c) a hydroxy group, (d) a carboxy group, (e) an amino group, (f) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a C1-6alkoxy group (e.g., methoxy), (g) a C1-6alkoxy group (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutyloxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a carboxy group, (iv) a carbamoyl group, (v) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy-C1-6alkoxy group (e.g., methoxyethoxy), and (II) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), (vi) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino),(vii) a N-C1-6alkyl-N-C1-6alkyl-carbonylamino group (e.g., N-methyl-N-acetylamino), (viii) a C3-10cycloalkyl group (e.g., cyclobutyl), and (ix) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl, azetidinyl, pyrrolidinyl, piperidyl, tetrahydropyranyl) optionally substituted by 1 to 3 substituents selected from (I) an oxo group, and (II) a C1-6alkyl group (e.g., methyl), (h) a C1-6alkyl-carbonyl group (e.g., acetyl), (i) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl), (j) a mono- or di-C1-6alkylamino group (e.g., N-ethylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (k) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- propanoylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (l) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non-aromatic heterocyclic groups (e.g., morpholinyl), (m) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino), (n) a C3-10cycloalkyloxy group (e.g., cyclohexyloxy) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non- aromatic heterocyclic groups (e.g., morpholinyl) optionally substituted by 1 to 3 C1-6alkyl groups (e.g., methyl), (o) a 3- to 8-membered monocyclic non-aromatic heterocyclyloxy group (e.g., pyrrolidinyloxy) optionally substituted by 1 to 3 oxo groups, (p) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group (e.g., azetidinylcarbonyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), and (q) a 3- to 8-membered monocyclic non-aromaticheterocyclylidenamino group (e.g., 1-oxido-thiolan-1- ylidenamino), (2) a 6-membered aromatic heterocycle (e.g., pyridine (optionally oxidized), pyrimidine, pyridazine, pyrazine) optionally fused with a 5- or 6-membered monocyclic aromatic heterocycle (e.g., imidazole) (i.e., the fused ring is imidazopyridine), and optionally further substituted by 1 to 4 substituents selected from (a) a halogen atom (e.g., a fluorine atom, a chlorine atom), (b) an amino group, (c) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a hydroxy group, (d) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a C1-6alkoxy group (e.g., methoxy), and (iii) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., oxetanyl), (e) a C3-10cycloalkyl group (e.g., cyclopropyl), (f) a C1-6alkyl-carbonyl group (e.g., acetyl), (g) a mono- or di-C1-6alkylamino group (e.g., N-methylamino, N,N-dimethylamino, N-ethylamino, N-ethyl-N-methylamino) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (h) a mono- or di-C1-6alkoxy-carbonylamino group (e.g., N- tert-butoxycarbonylamino, N,N-di-tert-butoxycarbonylamino), and (i) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., azetidinyl, pyrrolidinyl), or (3) a 6-membered non-aromatic heterocycle (e.g., dihydropyridine, dihydropyrimidine) optionally further substituted by 1 to 4 substituents selected from (a) an oxo group, and (b) a C1-6alkyl group (e.g., methyl) optionally substituted by1 to 3 halogen atoms (e.g., a fluorine atom); Y1is N or CH; Y2is N or CRY2wherein RY2is a hydrogen atom or a halogen atom (e.g., a fluorine atom, a chlorine atom); Y3is N or CRY3wherein RY3is a hydrogen atom or a halogen atom (e.g., a fluorine atom); Y4is N or CRY4wherein RY4is a hydrogen atom or a halogen atom (e.g., a fluorine atom); and W is N or CH;

[0232] [Compound C] [Compound B] wherein the partial structure represented by the formula;

[0233]

[0234] is a partial structure represented by the formula (A3-1), (A3-2), (A3-3), (A3-5), (A3-6) or (A3-9);

[0235]

[0236] wherein In the formula (A3-1), Q1is N or CRQ1wherein RQ1is (a) a hydrogen atom,(b) a cyano group, (c) a halogen atom (e.g., a fluorine atom, a chlorine atom), (d) a hydroxy group, (e) a carboxy group, (f) an amino group, (g) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a C1-6alkoxy group (e.g., methoxy), (h) a C1-6alkoxy group (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutyloxy) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), (ii) a cyano group, (iii) a carboxy group, (iv) a carbamoyl group, (v) a C1-6alkoxy group (e.g., methoxy, ethoxy) optionally substituted by 1 to 3 substituents selected from (I) a C1-6alkoxy-C1-6alkoxy group (e.g., methoxyethoxy), and (II) a mono- or di-C1-6alkylamino group (e.g., N,N- dimethylamino), (vi) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- acetylamino), (vii) a N-C1-6alkyl-N-C1-6alkyl-carbonylamino group (e.g., N-methyl-N-acetylamino), (viii) a C3-10cycloalkyl group (e.g., cyclobutyl), and (ix) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., morpholinyl, azetidinyl, pyrrolidinyl, piperidyl, tetrahydropyranyl, oxetanyl) optionally substituted by 1 to 3 substituents selected from (I) an oxo group, and (II) a C1-6alkyl group (e.g., methyl), (i) a C1-6alkyl-carbonyl group (e.g., acetyl), (j) a C1-6alkoxy-carbonyl group (e.g., methoxycarbonyl), (k) a mono- or di-C1-6alkylamino group (e.g., N-methylamino, N,N-dimethylamino, N-ethylamino, N-ethyl-N-methylamino)optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a C1-6alkoxy group (e.g., methoxy), (l) a mono- or di-C1-6alkyl-carbonylamino group (e.g., N- propanoylamino) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), (m) a mono- or di-C1-6alkoxy-carbonylamino group (e.g., N- tert-butoxycarbonylamino, N,N-di-tert-butoxycarbonylamino), (n) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N,N- dimethylcarbamoyl), (o) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino), (p) a C3-10cycloalkyl group (e.g., cyclopropyl), (q) a C3-10cycloalkyloxy group (e.g., cyclohexyloxy) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non- aromatic heterocyclic groups (e.g., morpholinyl) optionally substituted by 1 to 3 C1-6alkyl groups (e.g., methyl), (r) a 3- to 8-membered monocyclic non-aromatic heterocyclic group (e.g., azetidinyl, pyrrolidinyl), (s) a 3- to 8-membered monocyclic non-aromatic heterocyclyloxy group (e.g., pyrrolidinyloxy) optionally substituted by 1 to 3 oxo groups, (t) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group (e.g., azetidinylcarbonyl) optionally substituted by 1 to 3 C1-6alkoxy groups (e.g., methoxy), or (u) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group (e.g., 1-oxido-thiolan-1- ylidenamino); Q2is N (optionally oxidized) or CRQ2wherein RQ2is (a) a hydrogen atom, (b) a halogen atom (e.g., a fluorine atom), or (c) a C1-6alkoxy group (e.g., methoxy); Q3is N (optionally oxidized) or CRQ3wherein RQ3is (a) a hydrogen atom, (b) a cyano group, (c) a halogen atom (e.g., a fluorine atom, a chlorine atom),(d) a carboxy group, (e) a C1-6alkyl group (e.g., methyl, ethyl) optionally substituted by 1 to 3 substituents selected from (i) a halogen atom (e.g., a fluorine atom), and (ii) a hydroxy group, (f) a C1-6alkoxy group (e.g., methoxy) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), (g) a C1-6alkyl-carbonyl group (e.g., acetyl), (h) a C1-6alkoxy-carbonyl group (e.g., ethoxycarbonyl), (i) a mono- or di-C1-6alkylamino group (e.g., N-methylamino, N,N-dimethylamino), (j) a mono- or di-C1-6alkyl-carbamoyl group (e.g., N- methylcarbamoyl, N-ethylcarbamoyl) optionally substituted by 1 to 3 of 3- to 8-membered monocyclic non-aromatic heterocyclic groups (e.g., morpholinyl), (k) a di-C1-6alkylsulfinylidenamino group (e.g., N- dimethylsulfinylidenamino), or (l) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group (e.g., 1-oxido-thiolan-1- ylidenamino); and Q4is N (optionally oxidized) or CRQ4wherein RQ4is (a) a hydrogen atom, or (b) a halogen atom (e.g., a fluorine atom); In the formula (A3-2), RN1is a hydrogen atom or a C1-6alkyl group (e.g., methyl), Q3is CH, and Q4is CH; In the formula (A3-3), RN2is a hydrogen atom or a C1-6alkyl group (e.g., methyl), Q3is CH, and Q4is N or CH; In the formula (A3-5), RN4is a hydrogen atom, Q1is CH, and Q2is CH; In the formula (A3-6), RN2is a hydrogen atom or a C1-6alkyl group (e.g., methyl),Q1is CH, and Q4is CH; and In the formula (A3-9), RN4is a hydrogen atom or a C1-6alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom), Q2is CH, and Q3is CH.

[0237] [Compound D] 2-[6-(4-fluoro-3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]benzonitrile, or a pharmaceutically acceptable salt (Example 121); 2-[6-(4-fluoro-3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]pyridine-3- carbonitrile, or a pharmaceutically acceptable salt (Example 247); 2-[6-(3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]pyridine-3- carbonitrile, or a pharmaceutically acceptable salt (Example 271); 2-[5-(3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2-yl]oxy}phenyl)-3H- imidazo[4,5-b]pyridin-3-yl]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt (Example 284); 4-fluoro-2-[6-(5-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}pyridin-3-yl)imidazo[1,2-b]pyridazin-3-yl]benzonitrile, or a pharmaceutically acceptable salt (Example 288); 4-methoxy-2-[6-(3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]pyridine-3- carbonitrile, or a pharmaceutically acceptable salt (Example 300); 2-[6-(4-fluoro-3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]-4-methoxypyridine-3- carbonitrile, or a pharmaceutically acceptable salt (Example 321);4-fluoro-2-[5-(6-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}pyridin-2-yl)-3H-imidazo[4,5-b]pyridin-3-yl]benzonitrile, or a pharmaceutically acceptable salt (Example 345); 4-fluoro-2-methoxy-6-[6-(6-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}pyrazin-2-yl)imidazo[1,2-b]pyridazin-3-yl]benzonitrile, or a pharmaceutically acceptable salt (Example 392); 4-fluoro-2-methoxy-6-[5-(6-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}pyridin-2-yl)-3H-imidazo[4,5-b]pyridin-3-yl]benzonitrile, or a pharmaceutically acceptable salt (Example 393); and 4-fluoro-2-methoxy-6-[6-(6-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}pyridin-2-yl)imidazo[1,2-b]pyridazin-3-yl]benzonitrile, or a pharmaceutically acceptable salt (Example 410).

[0238] Specific examples of compound (I) include the compounds of Examples 1 to 486.

[0239] When compound (I) is a salt, examples of the salt include metal salts, ammonium salts, salts with organic base, salts with inorganic acid, salts with organic acid, and salts with basic or acidic amino acid. Preferable examples of the metal salt include alkali metal salts such as sodium salts, potassium salts and the like; alkali earth metal salts such as calcium salts, magnesium salts, barium salts and the like; and aluminum salts. Preferable examples of the salt with organic base include salts with trimethylamine, triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, N,N’-dibenzylethylenediamine and the like. Preferable examples of the salt with inorganic acid include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like. Preferable examples of the salt with organic acid include salts with formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p- toluenesulfonic acid and the like. Preferable examples of the salts with basic amino acid include salts with arginine, lysine, ornithine and the like. Preferable examples of the salt withacidic amino acid include salts with aspartic acid, glutamic acid and the like. Among them, a pharmaceutically acceptable salt is preferable. For example, when a compound has an acidic functional group, examples of the salt include inorganic salts such as alkali metal salts (e.g., sodium salt, potassium salt etc.), alkaline earth metal salts (e.g., calcium salt, magnesium salt etc.) and the like, ammonium salt etc., and when a compound has a basic functional group, examples of the salt include salts with inorganic acid such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like, and salts with organic acid such as acetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and the like. When compound (I) contains isomers such as tautomers, optical isomers, stereoisomers, position isomers and rotational isomers, any of isomers or mixture are also encompassed in the compound of the present invention. Further, when compound (I) contains an optical isomer, the optical isomer separated from the racemate is encompassed in compound (I). Compound (I) can be obtained in the crystal form. Either single crystalline form or crystalline mixture can be encompassed in compound (I). Compound (I) can be a pharmaceutically acceptable co- crystal or a co-crystal salt. The co-crystal or co-crystal salt as used herein means a crystalline material composed of two or more unique solids at room temperature, each of which has distinctive physical characteristics such as structure, melting point, and heats of fusion, hygroscopicity, solubility, and stability. A co-crystal or a co-crystal salt can be produced according to co-crystallization method known per se. Compound (I) may be a solvate (e.g., a hydrate) or a non- solvate and both are encompassed in compound (I). Compounds labeled with or substituted by isotopes (e.g.,2H,3H,11C,14C,18F,35S,125I, etc.) are also encompassed in compound (I). The compound labeled with or substituted by isotopes can be used as, for example, a tracer used for PositronEmission Tomography (PET) (PET tracer), and are expected to be useful in the field of medical diagnosis and the like.

[0240] The production method of the compound of the present invention is explained below.

[0241] The raw material compound and reagent used and the compound obtained in each step in the following production method may be each in a form of a salt, and examples of such salt include those similar to the salts of the compound of the present invention and the like.

[0242] When the compound obtained in each step is a free form, it can be converted to the objective salt according to a method known per se. When the compound obtained in each step is a salt, it can be converted to the objective free form or the other salt according to a method known per se.

[0243] The compound obtained in each step can be used directly as the reaction mixture or as a crude product for the next reaction. Alternatively, the compound obtained in each step can be isolated and purified from a reaction mixture according to a method known per se, for example, a separation means such as concentration, crystallization, recrystallization, distillation, solvent extraction, fractional distillation, column chromatography and the like.

[0244] When the raw material compound and reagent used in each step are commercially available, the commercially available product can also be used directly.

[0245] In the reaction in each step, while the reaction time varies depending on the kind of the reagent and solvent to be used, it is generally 1 min -48 hr, preferably 10 min - 8 hr, unless otherwise specified.

[0246] In the reaction in each step, while the reaction temperature varies depending on the kind of the reagent and solvent to be used, it is generally -78°C - 300°C, preferably - 78°C - 150°C, unless otherwise specified.

[0247] In the reaction in each step, while the pressure varies depending on the kind of the reagent and solvent to be used, it is generally 1 atm – 20 atm, preferably 1 atm – 3 atm, unless otherwise specified.

[0248] Microwave synthesizer such as Initiator manufactured by Biotage and the like may be used for the reaction in each step. While the reaction temperature varies depending on the kind of the reagent and solvent to be used, it is generally room temperature - 300°C, preferably 50°C - 250°C, unless otherwise specified. While the reaction time varies depending on the kind of the reagent and solvent to be used, it is generally 1 min -48 hr, preferably 1 min - 8 hr, unless otherwise specified.

[0249] In the reaction in each step, the reagent is used in an amount of 0.5 equivalents – 20 equivalents, preferably 0.8 equivalents – 5 equivalents, relative to the substrate, unless otherwise specified. When the reagent is used as a catalyst, the reagent is used in an amount of 0.001 equivalent – 1 equivalent, preferably 0.01 equivalent - 0.2 equivalent, relative to the substrate. When the reagent is used as a ligand, the reagent is used in an amount of 0.001 equivalent – 1 equivalent, preferably 0.01 equivalent - 0.2 equivalent, relative to the substrate. When the reagent is used as a reaction solvent, the reagent is used in a solvent amount.

[0250] Unless otherwise specified, the reaction in each step is carried out without solvent, or by dissolving or suspending the raw material compound in a suitable solvent. Examples of the solvent include those described in Examples and the following solvents.alcohols: methanol, ethanol, tert-butyl alcohol, 2- methoxyethanol, benzyl alcohol and the like; ethers: diethyl ether, diphenyl ether, tetrahydrofuran, 1,2- dimethoxyethane and the like; aromatic hydrocarbons: chlorobenzene, toluene, xylene and the like; saturated hydrocarbons: cyclohexane, hexane and the like; amides: N,N-dimethylformamide, N-methylpyrrolidone and the like; halogenated hydrocarbons: dichloromethane, carbon tetrachloride and the like; nitriles: acetonitrile and the like; sulfoxides: dimethyl sulfoxide and the like; aromatic organic bases: pyridine and the like; anhydrides: acetic anhydride and the like; organic acids: formic acid, acetic acid, trifluoroacetic acid and the like; inorganic acids: hydrochloric acid, sulfuric acid and the like; esters: ethyl acetate and the like; ketones: acetone, methyl ethyl ketone and the like; water. The above-mentioned solvent can be used in a mixture of two or more kinds thereof in an appropriate ratio.

[0251] When a base is used for the reaction in each step, examples thereof include those described in Examples and the following bases. inorganic bases: sodium hydroxide, magnesium hydroxide, sodium carbonate, calcium carbonate, sodium hydrogen carbonate and the like; organic bases: triethylamine, diethylamine, pyridine, 4- dimethylaminopyridine, N,N-dimethylaniline, 1,4- diazabicyclo[2.2.2]octane, 1,8-diazabicyclo[5.4.0]-7-undecene, imidazole, piperidine and the like; metal alkoxides: sodium ethoxide, potassium tert-butoxide and the like; alkali metal hydrides: sodium hydride and the like;metal amides: sodium amide, lithium diisopropylamide, lithium hexamethyldisilazide and the like; organic lithiums: n-butyllithium and the like.

[0252] When an acid or an acid catalyst is used for the reaction in each step, examples thereof include those described in Examples and the following acids and acid catalysts. inorganic acids: hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, phosphoric acid and the like; organic acids: acetic acid, trifluoroacetic acid, citric acid, p- toluenesulfonic acid, 10-camphorsulfonic acid and the like; Lewis acid: boron trifluoride diethyl ether complex, zinc iodide, anhydrous aluminum chloride, anhydrous zinc chloride, anhydrous iron chloride and the like.

[0253] Unless otherwise specified, the reaction in each step is carried out according to a method known per se, for example, the method described in Jikken Kagaku Kouza, 5th Edition, vol.13-19 (the Chemical Society of Japan ed.); Shin Jikken Kagaku Kouza, vol.14-15 (the Chemical Society of Japan ed.); Fine Organic Chemistry, Revised 2nd Edition (L. F. Tietze, Th. Eicher, Nankodo); Organic Name Reactions, the Reaction Mechanism and Essence, Revised Edition (Hideo Togo, Kodansha); ORGANIC SYNTHESES Collective Volume I-VII (John Wiley & Sons Inc.); Modern Organic Synthesis in the Laboratory A Collection of Standard Experimental Procedures (Jie Jack Li, OXFORD UNIVERSITY); Comprehensive Heterocyclic Chemistry III, Vol.1 - Vol.14 (Elsevier Japan); Strategic Applications of Named Reactions in Organic Synthesis (translated by Kiyoshi Tomioka, Kagakudojin); Comprehensive Organic Transformations (VCH Publishers Inc.), 1989, or the like, or the method described in Examples.

[0254] In each step, the protection or deprotection reaction of a functional group is carried out according to a method known per se, for example, the method described in “Protective Groups in Organic Synthesis, 4th Ed”, Wiley-Interscience, Inc., 2007(Theodora W. Greene, Peter G. M. Wuts); “Protecting Groups 3rd Ed.” Thieme, 2004 (P.J. Kocienski), or the like, or the method described in Examples. Examples of the protecting group for a hydroxy group of an alcohol and the like and a phenolic hydroxy group include ether- type protecting groups such as methoxymethyl ether, benzyl ether, tert-butyldimethylsilyl ether, tetrahydropyranyl ether and the like; carboxylate ester-type protecting groups such as acetate ester and the like; sulfonate ester-type protecting groups such as methanesulfonate ester and the like; carbonate ester-type protecting groups such as tert-butylcarbonate and the like, and the like. Examples of the protecting group for a carbonyl group of an aldehyde include acetal-type protecting groups such as dimethylacetal and the like; cyclic acetal-type protecting groups such as 1,3-dioxane and the like, and the like. Examples of the protecting group for a carbonyl group of a ketone include ketal-type protecting groups such as dimethylketal and the like; cyclic ketal-type protecting groups such as 1,3- dioxane and the like; oxime-type protecting groups such as O- methyloxime and the like; hydrazone-type protecting groups such as N,N-dimethylhydrazone and the like, and the like. Examples of the protecting group for a carboxyl group include ester-type protecting groups such as methyl ester and the like; amide-type protecting groups such as N,N-dimethylamide and the like, and the like. Examples of the protecting group for a thiol include ether- type protecting groups such as benzyl thioether and the like; ester-type protecting groups such as thioacetate ester, thiocarbonate, thiocarbamate and the like, and the like. Examples of the protecting group for an amino group and an aromatic heterocycle such as imidazole, pyrrole, indole and the like include carbamate-type protecting groups such as benzyl carbamate and the like; amide-type protecting groups such as acetamide and the like; alkyl amine-type protecting groups such as N-triphenylmethylamine and the like; sulfonamide-typeprotecting groups such as methanesulfonamide and the like, and the like. The protecting groups can be removed according to a method known per se, for example, by employing a method using acid, base, ultraviolet rays, hydrazine, phenylhydrazine, sodium N- methyldithiocarbamate, tetrabutylammonium fluoride, palladium acetate, trialkylsilyl halide (e.g., trimethylsilyl iodide, trimethylsilyl bromide) and the like, a reduction method, and the like.

[0255] When reduction reaction is carried out in each step, examples of the reducing agent to be used include metal hydrides such as lithium aluminum hydride, sodium triacetoxyborohydride, sodium cyanoborohydride, diisobutylaluminum hydride (DIBAL-H), sodium borohydride, tetramethylammonium triacetoxyborohydride and the like; boranes such as borane tetrahydrofuran complex and the like; Raney nickel; Raney cobalt; hydrogen; formic acid; triethylsilane and the like. When carbon-carbon double bond or triple bond or a nitro group or a benzyloxycarbonyl group is reduced, a method using a catalyst such as palladium-carbon, Lindlar’s catalyst and the like may be employed.

[0256] When oxidation reaction is carried out in each step, examples of the oxidizing agent to be used include peroxides such as m-chloroperbenzoic acid (mCPBA), hydrogen peroxide, tert- butylhydroperoxide and the like; perchlorates such as tetrabutylammonium perchlorate and the like; chlorates such as sodium chlorate and the like; chlorites such as sodium chlorite and the like; periodates such as sodium periodate and the like; hypervalent iodine reagents such as iodosylbenzene and the like; reagents containing manganese such as manganese dioxide, potassium permanganate and the like; leads such as lead tetraacetate and the like; reagents containing chromium such as pyridinium chlorochromate (PCC), pyridinium dichromate (PDC), Jones reagent and the like; halogen compounds such as N- bromosuccinimide (NBS) and the like; oxygen; ozone; sulfur trioxide-pyridine complex; osmium tetroxide; selenium dioxide;2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ), oxone and the like.

[0257] When radical reaction is carried out in each step, examples of the radical initiator to be used include azo compounds such as azobisisobutyronitrile (AIBN) and the like; water-soluble radical initiators such as 4-4’-azobis-4-cyanopentanoic acid (ACPA) and the like; triethylboron in the presence of air or oxygen; benzoyl peroxide and the like. Examples of the radical reagent to be used include tributylstannane, tristrimethylsilylsilane, 1,1,2,2- tetraphenyldisilane, diphenylsilane, samarium iodide and the like.

[0258] When nucleophilic substitution reaction is carried out in each step, examples of the base to be used include organic lithiums (e.g., lithium bis(trimehylsilyl)amide), metal alkoxides (e.g., potassium tert-butoxide), alkali metal hydrides (e.g., sodium hydride), inorganic bases, organic bases and the like.

[0259] When aromatic nucleophilic substitution reaction is carried out in each step, a combination of a nucleophile (e.g., a hydroxy, an amine, imidazole etc.) and a base (e.g., an organic base etc.), or a combination of a nucleophile and an acid (e.g., an organic acid etc.) is used as a reagent.

[0260] When nucleophilic addition reaction by a carbo anion, nucleophilic 1,4-addition reaction (Michael addition reaction) by a carbo anion or nucleophilic substitution reaction by a carbo anion is carried out in each step, and examples of the base to be used for generation of the carbo anion include organic lithiums, metal alkoxides, inorganic bases, organic bases and the like.

[0261] When Grignard reaction is carried out in each step, examples of the Grignard reagent to be used include arylmagnesium halides such as phenylmagnesium bromide and the like; and alkylmagnesium halides such as methylmagnesium bromide and the like. The Grignard reagent can be prepared according to a methodknown per se, for example, by reacting an alkyl halide or an aryl halide with a metal magnesium in an ether or tetrahydrofuran as a solvent.

[0262] When azidation reaction of an alcohol, an alkyl halide or a sulfonate is carried out in each step, examples of the azidating agent to be used include diphenylphosphorylazide (DPPA), trimethylsilylazide, sodium azide and the like. For example, for the azidation reaction of an alcohol, a method using diphenylphosphorylazide and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), a method using trimethylsilylazide and a Lewis acid, and the like are employed.

[0263] When reductive amination reaction is carried out in each step, examples of the reducing agent to be used include sodium triacetoxyborohydride, sodium cyanoborohydride, borane-2- methylpyridine complex, hydrogen, formic acid and the like. When the substrate is an amine compound, examples of the carbonyl compound to be used include paraformaldehyde, aldehydes such as acetaldehyde and the like, and ketones such as cyclohexanone and the like. When the substrate is a carbonyl compound, examples of the amine to be used include ammonia, primary amines such as methylamine and the like; secondary amines such as dimethylamine and the like, and the like.

[0264] When Mitsunobu reaction is carried out in each step, a combination of an azodicarboxylate (e.g., diethyl azodicarboxylate (DEAD), diisopropyl azodicarboxylate (DIAD) etc.) and triphenylphosphine, or a phosphorane reagent (e.g., cyanomethylenetributylphosphorane (Tsunoda reagent) is used as a reagent.

[0265] When esterification reaction, amidation reaction or urea formation reaction is carried out in each step, examples of the reagent to be used include acyl halides such as acid chlorides, acid bromides and the like; activated carboxylic acids such as anhydrides, activated esters, sulfates and the like. Examples ofthe activating agent of the carboxylic acid include carbodiimide condensing agents such as 1-ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride (WSCD) and the like; triazine condensing agents such as 4-(4,6-dimethoxy-1,3,5- triazin-2-yl)-4-methylmorpholinium chloride n-hydrate (DMT-MM) and the like; carbonate condensing agents such as 1,1- carbonyldiimidazole (CDI) and the like; diphenylphosphoryl azide (DPPA); benzotriazol-1-yloxy-trisdimethylaminophosphonium salt (BOP reagent); 2-chloro-1-methyl-pyridinium iodide (Mukaiyama reagent); thionyl chloride; lower alkyl haloformates such as ethyl chloroformate and the like; O-(7-azabenzotriazol-1-yl)- N,N,N’,N’-tetramethyluronium hexafluorophosphorate (HATU); sulfuric acid; combinations thereof and the like. When carbodiimide condensing agent is used, an additive such as 1- hydroxybenzotriazole (HOBt), N-hydroxysuccinimide (HOSu), dimethylaminopyridine (DMAP) and the like may be added to the reaction system.

[0266] When coupling reaction is carried out in each step, examples of the metal catalyst to be used include palladium compounds such as palladium(II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), tris(dibenzylideneacetone)dipalladium(0), [1,1’- bis(diphenylphosphino)ferrocene]dichloropalladium(II), bis(di- tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II), (tri-tert-butylphosphine)palladium(0) and the like; nickel compounds such as tetrakis(triphenylphosphine)nickel(0) and the like; rhodium compounds such as tris(triphenylphosphine)rhodium(III) chloride and the like; cobalt compounds; copper compounds such as copper oxide, copper(I) iodide, copper(II) diacetate and the like; platinum compounds and the like. In addition, a base can be added to the reaction system, and examples thereof include organic bases (e.g., 1,8-diazabicyclo[5.4.0]undec-7-ene, N,N- diisopropylethylamine), inorganic bases and the like. Moreover, a ligand can be added to the reaction system, and examples thereofinclude organic amines such as N,N’-dimethylethylenediamine, N,N’-dimethyl-cyclohexane-1,2-diamine, 2,2-bipyridyl and the like; organophosphorus compounds such as triphenylphosphine, tri- tert-butylphosphine, 1,1'-bis(diphenylphosphino)ferrocene, di- tert-butyl(4-dimethylaminophenyl)phosphine, cataCXium®A (di(1- adamantyl)-n-butylphosphine) and the like; and the like.

[0267] When thiocarbonylation reaction is carried out in each step, phosphorus pentasulfide is typically used as the thiocarbonylating agent. Alternatively, a reagent having a 1,3,2,4-dithiadiphosphetane-2,4-disulfide structure (e.g., 2,4- bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-disulfide (Lawesson reagent) etc.) can also be used instead of phosphorus pentasulfide.

[0268] When halogenation reaction of a hydroxy group is carried out in each step, examples of the halogenating agent to be used include hydrohalic acids and acid halides of inorganic acids, specifically, hydrochloric acid, thionyl chloride, phosphorus oxychloride and the like for chlorination, 48% hydrobromic acid and the like for bromination. In addition, a method of producing an alkyl halide by reacting an alcohol with triphenylphosphine and carbon tetrachloride or carbon tetrabromide or the like can be employed. Alternatively, a method of producing an alkyl halide via two steps comprising converting an alcohol to the corresponding sulfonate, and then reacting the sulfonate with lithium bromide, lithium chloride or sodium iodide can also be employed.

[0269] When sulfonate esterification reaction is carried out in each step, examples of the sulfonating agent to be used include methanesulfonyl chloride, p-toluenesulfonyl chloride, methanesulfonic anhydride, p-toluenesulfonic anhydride and the like.

[0270] When hydrolysis reaction is carried out in each step, an acid or a base is used as a reagent. For acid hydrolysis reactionof tert-butyl ester, formic acid, triethylsilane and the like may be added to reductively-trap tert-butyl cation which is by- produced.

[0271] When dehydration reaction is carried out in each step, examples of the dehydrating agent to be used include sulfuric acid, diphosphorus pentaoxide, phosphorus oxychloride, N,N’- dicyclohexylcarbodiimide, alumina, polyphosphoric acid and the like.

[0272] When cyanation reaction is carried out in each step, examples of the metal catalyst to be used include palladium compounds such as chloro(2-dicyclohexylphosphino-2',4',6'- tri-i- propyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl) palladium(II), palladium(II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), tris(dibenzylideneacetone)dipalladium(0), 1,1’- bis(diphenylphosphino)ferrocene palladium(II) chloride, (tri- tert-butylphosphine)palladium(0) and the like; nickel compounds such as tetrakis(triphenylphosphine)nickel(0) and the like; rhodium compounds such as tris(triphenylphosphine)rhodium(III) chloride and the like; cobalt compounds; copper compounds such as copper oxide, copper(I) iodide, copper(II) diacetate and the like; platinum compounds and the like. Examples of the cyano compound to be used include potassium hexacyanoferrate(II) trihydrate, copper(I) cyanide, zinc cyanide, potassium cyanide, sodium cyanide and the like. In addition, a base can be added to the reaction system, and examples thereof include organic bases, inorganic bases and the like. Moreover, a ligand can be added to the reaction system, and examples thereof include organic amines such as N,N’-dimethylethylenediamine, N,N’-dimethyl-cyclohexane- 1,2-diamine, 2,2-bipyridyl and the like; organophosphorus compounds such as 2-dicyclohexylphosphino-2’,4’,6’- triisopropylbiphenyl, triphenylphosphine, tri-tert- butylphosphine, tricyclohexylphosphine, BINAP (2,2’- bis(diphenylphosphino)-1,1-binaphthyl) and the like; and the like.

[0273] When nitration reaction is carried out in each step, examples of the nitrating agent to be used include mineral acids such as mixed acid, nitric acid and the like; nitrates such as potassium nitrate, sodium nitrate, tetramethylammonium nitrate, silver nitrate and the like.

[0274] When O-alkylation reaction or N-alkylation reaction is carried out in each step, a combination of an alkylating agent (e.g., an alkyl halide, an alkyl sulfonate ester etc.) and a base (e.g., an organic base, an inorganic base, alkali metal hydrides etc.) is used as a reagent.

[0275] Compound (I) of the present invention can be produced according to the methods explained below. A1, B1, V, X1-X6, Y1-Y4and Z in the following schemes are as defined above.

[0276] Compound (I) wherein X2is C, one of X3and X4is N, and the other is C can be produced from compound (2) according to the method shown in Scheme 1-1. [Scheme 1-1]

[0277]

[0278] wherein L1-L4are each independently a leaving group, M1and M2are each independently a metal group, T1is a leaving group or metal group, and the other symbols are as defined above.

[0279] Examples of the “leaving group” for L1-L4and T1include a halogen atom (e.g., a fluorine atom, a chlorine atom, a bromine atom, an iodine atom etc.), an optionally halogenated C1-6alkylsulfonyloxy group (e.g., methanesulfonyloxy, ethanesulfonyloxy, trifluoromethanesulfonyloxy etc.), an optionally substituted C6-14arylsulfonyloxy group [e.g., a C6-14arylsulfonyloxy group optionally having 1 to 3 substituentsselected from a C1-6alkyl group (e.g., methyl, etc.)], an optionally halogenated C1-6alkylsulfide group, an optionally substituted C6-14arylsulfide group, a C1-6alkoxy group (e.g., methoxy, etc.), a nitro group, m-nitrobenzenesulfonyloxy and naphthylsulfonyloxy and the like. Examples of the “metal group” for M1, M2and T1include a boronic acid group (-B(OH)2), or a boronate ester group (-B(OR)2; R is a C1-6alkyl group) or a cyclic group thereof (e.g., a 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl, etc.), or trialkyl stannyl group and the like. Compounds (2), (3), (7) and (9) may be a commercially available product, or can be produced according to a method known per se.

[0280] Compound (I) wherein X1is CH, X2and X4are C, X6is CH, and X3and X5are N, can also be produced from compound (9) according to the method shown in Scheme 1-2. [Scheme 1-2]

[0281]

[0282] wherein T2is a leaving group or a metal group, and the other symbols are as defined above.

[0283] Examples of the “leaving group” for T2include those exemplified as the “leaving group” for T1. Examples of the “metal group” for T2include those exemplified as the “metal group” for T1.Compounds (3’), (9) and (11) may be a commercially available product, or can be produced according to a method known per se.

[0284] Compound (I) wherein X1is CRX1a, X3and X4are C, and X6is CRX6, and X2and X5are N, can be produced from compound (12) according to the method shown in Scheme 1-3. [Scheme 1-3]

[0285] wherein L5is a leaving group, M3is a metal group, RX1ais a hydrogen atom or a C1-2alkyl group, R is a C1-2alkyl group, and the other symbols are as defined above.

[0286] Examples of the “leaving group” for L5include those exemplified as the “leaving group” for L1-L4. Examples of the “metal group” for M3include those exemplified as the “metal group” for M1and M2. Compounds (2), (12), (13) and (16) may be a commercially available product, or can be produced according to a method known per se. Compound (5) can be produced according to Scheme 1-1.

[0287] Compound (2’), which is compound (2) wherein -V-Z-Ring B1is -O-CH(R1)-CH2-Ring B2, can be produced from compound (19) according to the method shown in Scheme 2-1 or a similar method known per se (WO 2018 / 183112 A1 and WO 2020 / 068854 A1). [Scheme 2-1]

[0288]

[0289] wherein L6is a leaving group, and the other symbols are as defined above.

[0290] Examples of the “leaving group” for L6include those exemplified as the “leaving group” for L1-L4. Compounds (19), (20), (22) and (23) may be a commercially available product, or can be produced according to a method known per se.

[0291] The starting compound and / or production intermediate for compound (I) may form a salt. While the salt is not particularly limited as long as the reaction can be performed, examplesthereof include those similar to the salts optionally formed by compound (I) and the like, and the like. As for the configurational isomers (E, Z forms) of compound (I), they can be isolated and purified when isomerization occurs, for example, according to a conventional separation means such as extraction, recrystallization, distillation, chromatography and the like to obtain a pure compound. In addition, the corresponding pure isomer can also be obtained by isomerizing a double bond using heating, an acid catalyst, a transition metal complex, a metal catalyst, a radical catalyst, light irradiation, a strong base catalyst and the like, according to the method described in Shin Jikken Kagaku Kouza 14 (The Chemical Society of Japan ed.), pages 251 to 253, 4th Edition Jikken Kagaku Kouza 19 (The Chemical Society of Japan ed.), pages 273 to 274 or a method analogous thereto.

[0292] Compound (I) contains a stereoisomer depending on the kind of a substituent, and each stereoisomer and a mixture thereof are encompassed in the present invention. Compound (I) may be a hydrate or a non-hydrate. When desired, compound (I) can be synthesized by performing deprotection reaction, acylation reaction, alkylation reaction, hydrogenation reaction, oxidation reaction, reduction reaction, reaction of carbon chain extension, halogenation reaction, substituent exchange reaction, coupling reaction, reductive amination, nucleophilic addition reaction by a carbo anion, Grignard reagent and deoxofluorination reaction singly or two or more thereof in combination. When the objective product is obtained as a free form by the above-mentioned reaction, it can be converted to a salt according to a conventional method, or when the objective product is obtained as a salt, it can be converted to a free form or other salt according to a conventional method. The thus-obtained compound (I) can also be isolated and purified from a reaction mixture according to a known method such as phase transfer, concentration, solvent extraction, distillation, crystallization, recrystallization, chromatography and the like.When compound (I) contains a configurational isomer, a diastereomer, a conformer and the like, each can be isolated according to the above-mentioned separation and purification methods, if desired. In addition, when compound (I) is racemic, d-form and l-form can be isolated according to a conventional optical resolution.

[0293] The thus-obtained compound (I), other reaction intermediate therefor and starting compounds thereof can be isolated and purified from a reaction mixture according to a method known per se, for example, extraction, concentration, neutralization, filtration, distillation, recrystallization, column chromatography, thin layer chromatography, preparative high performance liquid chromatography (preparative HPLC), moderate- pressure preparative liquid chromatography (moderate-pressure preparative LC) and the like.

[0294] A salt of compound (I) can be produced according to a method known per se. For example, when compound (I) is a basic compound, it can be produced by adding an inorganic acid or organic acid, or when compound (I) is an acidic compound, by adding an organic base or inorganic base. When compound (I) contains an optical isomer, each optical isomer and a mixture thereof are encompassed in the scope of the present invention, and these isomers can be subjected to optical resolution or can be produced respectively, according to a method known per se, if desired. When compound (I) contains a configurational isomer, a diastereomer, a conformer and the like, each can be isolated according to the above-mentioned separation and purification methods, if desired. In addition, when compound (I) is racemic, S-form and R-form can be isolated according to a conventional optical resolution. When compound (I) contains a stereoisomer, each isomer and a mixture thereof are encompassed in the present invention.

[0295] Compound (I) may be a prodrug. A prodrug of compound (I)means a compound which is converted to compound (I) with a reaction due to an enzyme, a gastric acid, etc. under the physiological condition in the living body, that is, a compound which is converted to compound (I) with oxidation, reduction, hydrolysis, etc. according to an enzyme; a compound which is converted to compound (I) by hydrolysis etc. due to gastric acid, etc.

[0296] A prodrug for compound (I) may be a compound obtained by subjecting an amino group in compound (I) to an acylation, alkylation or phosphorylation (e.g., a compound obtained by subjecting an amino group in compound (I) to an eicosanoylation, alanylation, pentylaminocarbonylation, (5-methyl-2-oxo-1,3- dioxolen-4-yl)methoxycarbonylation, tetrahydrofuranylation, pyrrolidylmethylation, pivaloyloxymethylation or tert-butylation, etc.); a compound obtained by subjecting a hydroxy group in compound (I) to an acylation, alkylation, phosphorylation or boration (e.g., a compound obtained by subjecting an hydroxy group in compound (I) to an acetylation, palmitoylation, propanoylation, pivaloylation, succinylation, fumarylation, alanylation or dimethylaminomethylcarbonylation, etc.); a compound obtained by subjecting a carboxyl group in compound (I) to an esterification or amidation (e.g., a compound obtained by subjecting a carboxyl group in compound (I) to an ethyl esterification, phenyl esterification, carboxymethyl esterification, dimethylaminomethyl esterification, pivaloyloxymethyl esterification, ethoxycarbonyloxyethyl esterification, phthalidyl esterification, (5-methyl-2-oxo-1,3- dioxolen-4-yl)methyl esterification, cyclohexyloxycarbonylethyl esterification or methylamidation, etc.) and the like. Any of these compounds can be produced from compound (I) by a method known per se. The prodrug of compound (I) may be a compound that converts to compound (I) under physiological conditions as described in Development of Pharmaceutical Products, vol. 7, Molecule Design, 163-198, Hirokawa Shoten (1990).

[0297] Compound (I) or a prodrug thereof (to be abbreviated as thecompound of the present invention) is superior in vivo kinetics (e.g., plasma drug half-life, intracerebral transferability, metabolic stability), shows low toxicity (e.g., more superior as a medicament in terms of liver / hepatotoxicity, acute toxicity, chronic toxicity, genetic toxicity, reproductive toxicity, cardiotoxicity, cytotoxicity, drug interaction, carcinogenicity etc.; especially liver / hepatotoxicity). The compound of the present invention is directly used as a medicament or a pharmaceutical composition mixed with a pharmaceutically acceptable carrier or the like to be orally or parenterally administered to mammals (e.g., humans, monkeys, cows, horses, pigs, mice, rats, hamsters, rabbits, cats, dogs, sheep and goats) in safety. Examples of the “parenteral” include intravenous, intramuscular, subcutaneous, intra-organ, intranasal, intradermal, instillation, intracerebral, intrarectal, intravaginal, intraperitoneal and intratumor administrations, administration to the vicinity of tumor etc. and direct administration to the lesion.

[0298] Since the compound of the present invention has a superior CaMKII inhibitory action, it is expected to be useful for the prophylaxis or treatment of, for example, cardiac diseases (cardiac hypertrophy, acute heart failure and chronic heart failure including congestive heart failure, cardiomyopathy, angina, myocarditis, atrial / ventricular arrhythmia, tachycardia, myocardial infarction, etc.), myocardial ischemia, venous insufficiency, post-myocardial infarction transition to heart failure, hypertension, cor pulmonale, arteriosclerosis including atherosclerosis (aneurysm, coronary arterial sclerosis, cerebral arterial sclerosis, peripheral arterial sclerosis, etc.), vascular thickening, vascular thickening / occlusion and organ damages after intervention (percutaneous coronary angioplasty, stent placement, coronary angioscopy, intravascular ultrasound, coronary thrombolytic therapy, etc.), vascular reocclusion / restenosis after bypass surgery, cardiac hypofunction after artificial heart lung surgery, respiratory diseases (cold syndrome, pneumonia, asthma,pulmonary hypertension, pulmonary thrombus / pulmonary embolism, etc.), bone disorders (nonmetabolic bone disorders such as bone fracture, refracture, bone malformation / spondylosis deformans, osteosarcoma, myeloma, dysostosis and scoliosis, bone defect, osteoporosis, osteomalacia, rickets, osteitis fibrosis, renal osteodystrophy, Paget's disease of bone, myelitis with rigidity, chronic rheumatoid arthritis, gonarthrosis and articular tissue destruction in similar disorders thereof, etc.), inflammatory diseases (diabetic complication such as retinopathy, nephropathy, nerve damage, macroangiopathy etc.; arthritis such as chronic rheumatoid arthritis, osteoarthritis, rheumatoid myelitis, periostitis etc.; inflammation after surgery / trauma; reduction of swelling; pharyngitis; cystitis; pneumonia; atopic dermatitis; inflammatory enteric diseases such as Crohn's disease, ulcerative colitis etc.; meningitis; inflammatory eye diseases; inflammatory pulmonary diseases such as pneumonia, silicosis, pulmonary sarcoidosis, pulmonary tuberculosis etc, and the like), allergic diseases (allergic rhinitis, conjunctivitis, gastrointestinal allergy, pollen allergy, anaphylaxis, etc.), drug dependence, neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, AIDS encephalopathy, etc.), central nervous system damage (disorders such as cerebral hemorrhage and cerebral infarction and aftereffects and complications thereof, head injury, spinal damage, cerebral edema, sensory dysfunction, sensory abnormality, autonomic dysfunction, abnormal autonomic function, multiple sclerosis etc.), dementia, disturbed memory, disturbed consciousness, amnesia, anxiety symptoms, nervous symptoms, unpleasant condition, mental disorders (depression, epilepsy, alcohol dependency, etc.), ischemic peripheral circulatory disorder, deep-vein thrombosis, occlusive peripheral circulatory disorder, arteriosclerosis obliterans (ASO), occlusive thromboangiitis, diabetes (type 1 diabetes, type 2 diabetes, pregnancy diabetes etc.), diabetic complications (nerve damage, nephropathy, retinopathy, cataract, macroangiopathy, osteopenia, diabetic hyperosmolar diabetic coma, infectious diseases, diabetic gangrene, xerostomia, deterioration in hearing, cerebrovasculardamage, peripheral circulatory disorder, etc.), urinary incontinence, metabolic / nutritional disorders (obesity, hyperlipidemia, hypercholesterolemia, diabetes, impaired glucose tolerance, hyperuricemia, hyperkalemia, hypernatremia etc.), metabolic syndrome, vesceral obesity syndrome, male or female sexual dysfunction and the like, and for the prophylaxis or treatment of dysgeusia, smell disturbance, abnormal circadian rhythm of blood pressure, cerebrovascular damage (asymptomatic cerebrovascular damage, transient cerebral ischemia attack, stroke, cerebrovascular dementia, hypertensive encephalopathy, cerebral infarction, etc.), cerebral edema, cerebral circulatory disturbance, recurrence and aftereffects of cerebrovascular damages (neurological symptoms, mental symptoms, subjective symptoms, impairment of activities of daily living, etc.), kidney diseases (nephritis, glomerulonephritis, glomerulosclerosis, renal failure, thrombotic microangiopathy, diabetic nephropathy, nephrotic syndrome, hypertensive nephrosclerosis, complications of dialysis, organ damage including nephropathy by irradiation, etc.), erythrocytosis / hypertension / organ damage / vascular thickening after transplantation、rejection after transplantation, ocular disorders (glaucoma, ocular hypertension, etc.), thrombosis, multiple organ failure, endothelial dysfunction, hypertensive tinnitus, other circulatory diseases (ischemic cerebral circulatory disturbance, Raynaud's disease, Buerger's disease, etc.), chronic occlusive pulmonary diseases, interstitial pneumonia, carinii pneumonia, connective tissue disorders (e.g., systemic erythematosus, scleroderma, polyarteritis, etc.), liver disorders (hepatitis and cirrhosis including chronic types, etc.), portal hypertension, digestive disorders (gastritis, gastric ulcer, gastric cancer, disorder after gastric surgery, poor digestion, esophageal ulcer, pancreatitis, colon polyp, cholelithiasis, hemorrhoidal problem, esophageal and gastric variceal rupture, etc.), hematological / hematopoietic disorders (erythrocytosis, vascular purpura, autoimmune hemolytic anemia, disseminated intravascular coagulation syndrome, multiplemyelosis, etc.), solid tumor, tumors (malignant melanoma, malignant lymphoma, digestive organs (e.g., stomach, intestine, etc.) cancers, etc.), cancers and cachexia associated therewith, cancer metastases, endocrine disorders (Addison's disease, Cushing's syndrome, pheochromocytoma, primary aldosteronism, etc.), Creutzfeldt-Jakob disease, urological / male genital diseases (cystitis, prostatic enlargement, prostate cancer, sexually transmitted diseases, etc.), gynecological disorders (menopausal disorders, pregnancy toxemia, endometriosis, uterine fibroid, ovarian diseases, mammary gland diseases, sexually transmitted diseases, etc.), diseases caused by environmental / occupational factor (e.g., radiation damage, damage from ultraviolet / infrared / laser beam, altitude sickness etc.), infectious diseases (viral infectious diseases of, for example, cytomegalovirus, influenza virus and herpesvirus, rickettsial infectious diseases, bacterial infectious diseases, etc.), toxemia (septicemia, septic shock, endotoxic shock, gram-negative septicemia, toxin shock syndrome, etc.), ear nose throat diseases (Ménière's disease, tinnitus, dysgeusia, vertigo, balance disorder, deglutition disorder etc.), cutaneous diseases (keloid, hemangioma, psoriasis, etc.), dialysis hypotension, myasthenia gravis, systemic diseases such as chronic fatigue syndrome, and the like, particularly cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like, in animals, particularly mammals (e.g., humans, monkeys, cats, pigs, horses, bovines, mice, rats, guinea pigs, dogs, rabbits etc.). Herein, the concept of prophylaxis of cardiac diseases include treatment of prognosis of myocardial infarction, angina attack, cardiac bypass surgery, thrombolytic therapy, coronary revascularization and the like, and the concept of treatment of cardiac diseases include suppress of progress or severity of heart failure (including both contractile failure HFrEF, and heart failure HFpEF with maintained ejection fraction), and maintenance of cardiac function when performing non-drugtherapies (e.g., an implantable defibrillator, resection of cardiac sympathetic nerve, catheter ablation, cardiac pacemaker, intra aortic balloon pumping, auxiliary artificial heart, Batista operation, cell transplantation, gene therapy, heart transplantation and the like) for severe heart failure / arrhythmia, and the like. When the compound of the present invention is applied to prophylaxis or treatment of heart failure, improvement of heart contractility or atonicity is expected to be achieved byshort-time administration, without side effects such as pressure decrease, tachycardia, reduced renal blood flow and the like, regardless of differences in causative diseases such as ischemic cardiac disease, cardiomyopathy, hypertension and the like and symptoms such as contractile failure, diastolic failure and the like. Moreover, long-term improvement of prognosis (survival rate, readmission rate, cardiac event rate etc.) is expected to be achieved, in addition to short-term improvement of cardiac function. When the compound of the present invention is applied to prophylaxis or treatment of arrhythmia, improvement or remission of the symptom is expected to be achieved, regardless of differences in etiology and atrial / ventricular. In addition, long-term improvement of prognosis (survival rate, readmission rate, cardiac event rate etc.) is expected to be achieved.

[0299] While the dose of the compound of the present invention varies depending on the administration route, symptom and the like, when, for example, the compound is orally administered to a patient with cardiac disease (adult, body weight 40 – 80 kg, for example, 60 kg), it is, for example, 0.001 – 1000 mg / kg body weight / day, preferably 0.01 – 100 mg / kg body weight / day, more preferably 0.1 – 10 mg / kg body weight / day. This amount can be administered in 1 to 3 portions per day.

[0300] A medicament containing the compound of the present invention can be used alone or as a pharmaceutical composition containing the compound of the present invention and a pharmaceutically acceptable carrier according to a method knownper se as a production method of a pharmaceutical preparation (e.g., the method described in the Japanese Pharmacopoeia etc.). A medicament containing the compound of the present invention can be safely administered in the form of, for example, tablet (including sugar-coated tablet, film-coated tablet, sublingual tablet, orally disintegrating tablet, buccal and the like), pill, powder, granule, capsule (including soft capsule, microcapsule), troche, syrup, liquid, emulsion, suspension, release control preparation (e.g., immediate-release preparation, sustained- release preparation, sustained-release microcapsule), aerosol, film (e.g., orally disintegrating film, oral mucosa-adhesive film), injection (e.g., subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection), drip infusion, transdermal absorption type preparation, ointment, lotion, adhesive preparation, suppository (e.g., rectal suppository, vaginal suppository), pellet, nasal preparation, pulmonary preparation (inhalant), eye drop and the like, orally or parenterally (e.g., intravenous, intramuscular, subcutaneous, intraorgan, intranasal, intradermal, instillation, intracerebral, intrarectal, intravaginal, intraperitoneal administrations, and administration to the lesion).

[0301] As the aforementioned “pharmaceutically acceptable carrier”, various organic or inorganic carriers conventionally used as preparation materials (starting materials) can be used. For example, excipient, lubricant, binder, disintegrant and the like are used for solid preparations, and solvent, solubilizing agent, suspending agent, isotonicity agent, buffer, soothing agent and the like are used for liquid preparations. Where necessary, preparation additives such as preservative, antioxidant, colorant, sweetening agent and the like can also be used. Examples of the excipient include lactose, sucrose, D- mannitol, starch, corn starch, crystalline cellulose, light anhydrous silicic acid and the like. Examples of the lubricant include magnesium stearate, calcium stearate, talc, colloidal silica and the like.Examples of the binding agent include crystalline cellulose, white sugar, D-mannitol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, starch, sucrose, gelatin, methylcellulose, carboxymethylcellulose sodium and the like. Examples of the disintegrant include starch, carboxymethylcellulose, carboxymethylcellulose calcium, sodium carboxymethyl starch, L-hydroxypropylcellulose and the like. Examples of the solvent include water for injection, alcohol, propylene glycol, Macrogol, sesame oil, corn oil, olive oil and the like. Examples of the solubilizing agent include polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate and the like. Examples of the suspending agent include surfactants such as stearyl triethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzetonium chloride, glycerin monostearate and the like; hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, carboxymethylcellulose sodium, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and the like; and the like. Examples of the isotonic agent include glucose, D-sorbitol, sodium chloride, glycerin, D-mannitol and the like. Examples of the buffering agent include buffer solutions such as phosphates, acetates, carbonates, citrates and the like. Examples of the soothing agent include benzyl alcohol and the like. Examples of the preservative include p-oxybenzoates, chlorobutanol, benzyl alcohol, phenylethyl alcohol, dehydroacetic acid, sorbic acid and the like. Examples of the antioxidant include sulfite, ascorbic acid, α-tocopherol and the like.

[0302] While the pharmaceutical composition varies according to the dosage form, administration method, carrier and the like, it can be produced according to a conventional method by adding thecompound of the present invention in a proportion of generally 0.01 - 100%(w / w), preferably 0.1 - 95%(w / w), of the total amount of the preparation.

[0303] When the compound of the present invention is applied to each of the above-mentioned diseases, it can be used in appropriate combination with a pharmaceutical agent (hereinafter to be abbreviated as a concomitant drug) or a treatment method generally employed for such diseases. For heart failure, for example, it can be used concurrently with angiotensin converting enzyme (ACE) inhibitors (e.g., alacepril, captopril, cilazapril, delapril, enalapril, lisinopril, temocapril, trandolapril, quinapril, imidapril, benazepril, perendopril and the like), angiotensin II receptor antagonists (e.g., losartan, candesartan cillexetil, valsartan, termisartan, irbesartan, forasartan and the like), angiotensin II receptor antagonist / NEP inhibitor combination agent (entresto), β receptor antagonists (e.g., propranolol, nadolol, timolol, nipradilol, bunitorolol, indenolol, penbutolol, carteolol, carvedilol, pindolol, acebutolol, atenolol, bisoprolol, metoprolol, labetalol, amosulalol, arotinolol and the like), Ca antagonists (e.g., manidipine, nicardipine, nilvadipine, nisoldipine, nitrendipine, benidipine, amlodipine, aranidipine and the like), diuretics (e.g., thiazide diuretics such as benzylhydrochlorothiazide, cyclopentiazide, ethiazide, hydrochlorothiazide, hydroflumethiazide, methyclothiazide, penfluthiazide, polythiazide, trichlormethiazide and the like; loop diuretics such as chlorthalidone, clofenamide, indapamide, mefruside, meticrane, sotolazone, tribamide, quinetazone, metolazone, furosemide, mefruside and the like; potassium retention diuretics such as spironolactone, triamterene and the like; and the like), digitalis preparations (e.g., digitoxin, digoxin, methyldigoxin, lanatoside C, proscillaridin and the like), ANP or BNP preparations, Ca sensitizers (e.g., pimobendan and the like), anticoagulants (e.g., warfarin, sodium citrate, activated protein C, tissue factor pathway inhibitor, antithrombin III, dalteparin sodium, aragatroban, gabexate, sodium ozagrel, ethylicosapentate, beraprost sodium, alprostadil, pentoxifyline, tisokinase, streptokinase and the like), antiarrhythmic drugs (e.g., sodium channel blockers such as quinidine, procainamide, disopyramide, ajmaline, cibenzoline, lidocain, diphenylhydantoin, mexiletine, propafenone, flecainide, pilsicainide, phenytoin and the like; potassium channel blockers such as amiodarone and the like; calcium channel blockers such as verapamil, diltiazem and the like; and the like), PDE inhibitors (e.g., amrinone, milrinone, olprinone hydrochloride and the like), therapeutic drugs for diabetes (e.g., sulfonylureas such as tolbutamide, chlorpropamide, glyclopyramide, acetohexamide, tolazamide, glibenclamide, glybuzole and the like; biguanides such as metformin hydrochloride, buformin hydrochloride and the like; α- glucosidase inhibitors such as voglibose, acarbose and the like, insulin sensitizers such as pioglitazone, troglitazone and the like; SGLT2 inhibitors such as ipragliflozin, dapagliflozin, ruseogurifurojin, tofogliflozin, canagliflozin, empagliflozin and the like; insulin, glucagon; therapeutic drugs for diabetic complications such as epalrestat and the like; and the like), anti-obesity drugs and the like, and is also applicable when an implantable artificial heart, an implantable defibrillator, a ventricular pacing, Batista operation, heart transplantation or cell transplantation is performed. In addition, for arrhythmia, for example, it can be used concurrently with other antiarrhythmic drugs (e.g., sodium channel blockers such as flecainide, quinidine, procainamide, disopyramide, ajmaline, cibenzoline, lidocain, diphenylhydantoin, mexiletine, propafenone, pilsicainide, phenytoin and the like; potassium channel blockers such as amiodarone and the like; calcium channel blockers such as verapamil, diltiazem and the like, and the like) and β receptor antagonists, non-drug therapies (e.g., an implantable defibrillator, resection of cardiac sympathetic nerve, catheter ablation, cardiac pacemaker and the like). In addition, after acute myocardial infarction or during myocardial infarction prognosis, for example, the compound can be used in combination with antithrombotics (e.g., anticoagulants such as heparin sodium, heparin calcium, warfarin and the like;thrombolytic agents such as urokinase and the like; anti-platelet drugs such as aspirin, sulfinpyrazone (anturan), dipyridamole (persantin), ticropidine (panaldine), cilostazol (pletal), clopidogrel and the like; and the like), angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, β receptor antagonists, therapeutic drugs for diabetes, therapeutic drugs for hyperlipidemia (e.g., HMG-CoA reductase inhibitors such as pravastatine, fluvastatine, cerivastatine, atorvastatine and the like; fibrate drugs such as sinfibrate, clofibrate aluminum, clinofibrate, fenofibrate and the like; and the like), coronary vessel reconstructive surgery such as PTCA, CABG and the like; and the like. Furthermore, in chronic rheumatoid arthritis, for example, the compound can be used in combination with non- steroidal antiinflammatory agents (e.g., acetaminophen, phenacetin, ethenzamide, sulpyrine, antipyrine, migrenine, aspirin, mefenamic acid, flufenamic acid, diclofenac sodium, loxoprofen sodium, phenylbutazone, indomethacin, ibuprofen, ketoprofen, naproxen, oxaprozin, flurbiprofen, fenbufen, pranoprofen, floctafenine, epirizole, tiaramide hydrochloride, zaltoprofen, gabexate mesilate, camostat mesilate, ulinastatine, colchicine, probenecid, sulfinpyrazone, benzbromarone, allopurinol, sodium aurothiomalate, sodium hyaluronate, sodium salicylate, morphine hydrochloride, salicylic acid, atropine, scopolamine, morphine, pethidine, levorphanol, ketoprofen, naproxen, oxymorphone or a salt thereof and the like), immunomodulators or immunosuppressants (e.g., methotrexate, cyclosporine, tacrolimus, gusperimus, azathioprine, antilymphocyte serum, dried sulfonated immunoglobulin, erythropoietin, colony stimulating factor, interleukin, interferon and the like), steroids (e.g., dexamethasone, hexestrol, methimazole, betamethasone, triamcinolone, triamcinoloneacetonide, fluocinonide, fluocinoloneacetonide, prednisolone, methylprednisolone, cortisone acetate, hydrocortisone, fluorometholone, beclometasone dipropionate, estriol and the like), p38 MAP kinase inhibitors, anti-TNF-α drugs (e.g., etanercept, infliximab, D2E7, CDP-571, PASS TNF-α, soluble TNF-α receptor, TNF-α binding protein, anti-TNF-αantibody and the like), cyclooxygenase inhibitors (e.g., salicylic acid derivatives such as celecoxib, rofecoxib, aspirin and the like, MK-663, valdecoxib, SC-57666, tiracoxib, S-2474, diclofenac, indomethacin, loxoprofen and the like) and the like. Moreover, it is possible to use the compound of the present invention in combination with biological products (e.g.: antibody, vaccine preparation and the like) when applying to the above-mentioned respective diseases, and it is also possible to apply the compound in combination with a gene therapy and the like as a combination therapy. As antibody and vaccine preparation, for example, vaccine preparation to angiotensin II, vaccine preparation to CETP, CETP antibody, TNF α antibody, antibody to other cytokine, amiloid β vaccine preparation, type 1 diabetes vaccine (DIAPEP-277 of Peptor Ltd. and the like), anti- HIV antibody, HIV vaccine preparation and the like, antibody and vaccine preparation to cytokine, renin-angiotensin enzyme and products thereof, antibody and vaccine preparation to enzyme and protein involved in blood lipid metabolism, antibody and vaccine preparation to enzyme and protein involved in blood coagulation- fibrinolytic system, antibody and vaccine preparation to protein involved in glucose metabolism and insulin resistance and the like can be mentioned. In addition, a combined use with biological products involved in growth factors such as GH, IGF and the like is possible. As a gene therapy, for example, a treatment method using a gene relating to cytokine, renin- angiotensin enzyme and products thereof, G protein, G protein- coupled receptor and phosphorylation enzyme thereof, a therapeutic method using a DNA decoy such as NFκB decoy and the like, a therapeutic method using antisense, a therapeutic method using a gene relating to enzyme and protein involved in blood lipid metabolism (e.g., gene relating to metabolism, excretion and absorption of cholesterol or triglyceride or HDL-cholesterol or blood phospholipid, and the like), a therapeutic method using a gene relating to enzyme and protein (e.g., growth factors such as HGF, VEGF and the like, and the like) involved in angiogenetic therapy aiming at obstruction of peripheral vessel and the like, a therapeutic method using a gene relating protein involved inglucose metabolism and insulin resistance, antisense to cytokine such as TNF-α and the like, and the like can be mentioned. In addition, it is possible to use the compound in combination with various organ regeneration methods such as heart regeneration, kidney regeneration, pancreas regeneration, blood vessel regeneration and the like, cell transplantation therapy using bone marrow cells (bone marrow mononuclear cell, bone marrow mesenchymal stem cell and the like), and artificial organs (artificial blood vessels and cardiac muscle cell sheet) using tissue engineering.

[0304] By combining the compound of the present invention and a concomitant drug, a superior effect such as (1) the dose can be reduced as compared to single administration of the compound of the present invention or a concomitant drug, (2) the drug to be combined with the compound of the present invention can be selected according to the condition of patients (mild case, severe case and the like), (3) the period of treatment can be set longer by selecting a concomitant drug having different action and mechanism from the compound of the present invention, (4) a sustained treatment effect can be designed by selecting a concomitant drug having different action and mechanism from the compound of the present invention, (5) a synergistic effect can be afforded by a combined use of the compound of the present invention and a concomitant drug, and the like, can be achieved.

[0305] Hereinafter the compound of the present invention and a concomitant drug used in combination are referred to as the “combination agent of the present invention”. When using the combination agent of the present invention, the administration time of the compound of the present invention and the concomitant drug is not restricted, and the compound of the present invention or a pharmaceutical composition thereof and the concomitant drug or a pharmaceutical composition thereof canbe administered to an administration subject simultaneously, or may be administered at different times. The dosage of the concomitant drug may be determined according to the dose clinically used, and can be appropriately selected depending on an administration subject, administration route, disease, combination and the like. The administration mode of the concomitant drug of the present invention is not particularly restricted, and it is sufficient that the compound of the present invention and the concomitant drug are combined in administration. Examples of such administration mode include the following methods: (1) administration of a single preparation obtained by simultaneously processing the compound of the present invention and the concomitant drug, (2) simultaneous administration of two kinds of preparations of the compound of the present invention and the concomitant drug, which have been separately produced, by the same administration route, (3) administration of two kinds of preparations of the compound of the present invention and the concomitant drug, which have been separately produced, by the same administration route in a staggered manner, (4) simultaneous administration of two kinds of preparations of the compound of the present invention and the concomitant drug, which have been separately produced, by different administration routes, (5) administration of two kinds of preparations of the compound of the present invention and the concomitant drug, which have been separately produced, by different administration routes in a staggered manner (for example, administration in the order of the compound of the present invention and the concomitant drug, or in the reverse order) and the like.

[0306] The combination agent of the present invention exhibits low toxicity. For example, the compound of the present invention or(and) the aforementioned concomitant drug can be combined with a pharmacologically acceptable carrier according to the known method to prepare a pharmaceutical composition such as tablets (including sugar-coated tablet and film-coated tablet), powders, granules, capsules (including soft capsule), liquids, injections,suppositories, sustained-release agents, etc. These compositions can be administered safely orally or non-orally (e.g., topical, rectal, intravenous administration etc.). Injection can be administered intravenously, intramuscularly, subcutaneously, or by intraorgan administration or directly to the lesion. Examples of the pharmacologically acceptable carriers usable for the production of a combination agent of the present invention, various organic or inorganic carrier substances conventionally used as preparation materials can be mentioned. For solid preparations, for example, excipient, lubricant, binder and disintegrant can be used. For liquid preparations, for example, solvent, solubilizing agent, suspending agent, isotonic agent, buffering agent, soothing agent and the like can be used. Where necessary, an appropriate amount of conventional preservative, antioxidant, colorant, sweetening agent, adsorbent, wetting agent and the like can be used as appropriate. Examples of the excipient include lactose, sucrose, D- mannitol, starch, corn starch, crystalline cellulose, light anhydrous silicic acid and the like. Examples of the lubricant include magnesium stearate, calcium stearate, talc, colloidal silica and the like. Examples of the binding agent include crystalline cellulose, white sugar, D-mannitol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, starch, sucrose, gelatin, methylcellulose, carboxymethylcellulose sodium and the like. Examples of the disintegrant include starch, carboxymethylcellulose, carboxymethylcellulose calcium, sodium carboxymethyl starch, L-hydroxypropylcellulose and the like. Examples of the solvent include water for injection, alcohol, propylene glycol, Macrogol, sesame oil, corn oil, olive oil and the like. Examples of the solubilizing agent include polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate and the like. Examples of the suspending agent include surfactants suchas stearyl triethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzetonium chloride, glycerin monostearate and the like; hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, carboxymethylcellulose sodium, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and the like; and the like.

[0307] Examples of the isotonic agent include glucose, D-sorbitol, sodium chloride, glycerin, D-mannitol and the like. Examples of the buffering agent include buffer solutions such as phosphates, acetates, carbonates, citrates and the like. Examples of the soothing agent include benzyl alcohol and the like. Examples of the preservative include p-oxybenzoates, chlorobutanol, benzyl alcohol, phenylethyl alcohol, dehydroacetic acid, sorbic acid and the like. Examples of the antioxidant include sulfite, ascorbic acid, α-tocopherol and the like.

[0308] The mixing ratio of the compound of the present invention to the concomitant drug in the combination agent of the present invention can be appropriately selected depending on an administration subject, administration route, diseases and the like. For example, the content of the compound of the present invention in the combination agent of the present invention differs depending on the form of a preparation, and usually from about 0.01 to about 100 wt%, preferably from about 0.1 to about 50 wt%, further preferably from about 0.5 to about 20 wt%, based on the preparation. The content of the concomitant drug in the combination agent of the present invention differs depending on the form of a preparation, and usually from about 0.01 to about 100 wt%, preferably from about 0.1 to about 50 wt%, further preferably from about 0.5 to about 20 wt%, based on the preparation. The content of additives such as a carrier and the like inthe combination agent of the present invention differs depending on the form of a preparation, and usually from about 1 to about 99.99 wt%, preferably from about 10 to about 90 wt%, based on the preparation. When the compound of the present invention and a concomitant drug are separately formulated into preparations, the contents thereof are similar to the above. Examples

[0309] The present invention is explained in detail in the following by referring to Examples, Experimental Examples and Formulation Examples, which are not to be construed as limitative, and the invention may be changed within the scope of the present invention. In the following Examples, the “room temperature” generally means about 10 °C to about 35 °C. The ratios indicated for mixed solvents are volume mixing ratios, unless otherwise specified. % means wt%, unless otherwise specified. Unless particularly specified, the elution in column chromatography in Example was performed under observation by TLC (Thin Layer Chromatography). For TLC observation, 60F254manufactured by Merck was used as a TLC plate, and the solvent used as an elution solvent for column chromatography was used as a developing solvent. For detection, a UV detector was adopted. In silica gel column chromatography, NH means use of aminopropylsilane-bonded silica gel, and Diol means use of 3- (2,3-dihydroxypropoxy)propylsilane-bonded silica gel. In preparative HPLC (high performance liquid chromatography), C18 means use of octadecyl-bonded silica gel. The ratios indicated for elution solvents are volume mixing ratios, unless otherwise specified. For1H NMR analysis, ACD / SpecManager (trade name) software and the like were used. Peaks of a hydroxy group, an amino group and the like, which having very mild protons, may not be described. MS was measured by LC / MS. As ionization method, ESI method or APCI method was used. The data indicates actual measured value(found). Generally, molecular ion peaks are observed, and may be observed as a fragment ion. In the case of a salt, a molecular ion peak or fragment ion peak of free form is generally observed. The unit of sample concentration (c) for optical rotation ([α]D) is g / 100 mL. Elemental analysis value (Anal.) was described as calculated value (Calcd) and actual measured value (Found). The peak by powder X-RAY diffraction in Example means the peak measured using Cu Kα-ray as a source by Ultima IV (Rigaku Corporation, Japan) at room temperature. The measurement conditions are as follows. Electric pressure / Electric current: 40 kV / 50 mA Scan speed: 6 degree / min Scan range of 2 Theta: 2-35 degree The crystallinity by powder X-RAY diffraction in Example was calculated by Hermans method. In Examples, the following abbreviations are used. mp: melting point MS: mass spectrum M: mol concentration N: normality CDCl3: deuterochloroform DMSO-d6: deuterodimethyl sulfoxide CD3OD: deuteromethanol1H NMR: proton nuclear magnetic resonance LC / MS: liquid chromatograph mass spectrometer TLC: thin-layer chromatography ESI: electrospray ionization, Electron Spray Ionization APCI: atmospheric pressure chemical ionization, atmospheric pressure chemical ionization AcOH: acetic acid Boc: tert-butoxycarbonyl (Boc)2O: di-tert-butyl dicarbonate (Bpin)2: bis(pinacolato)diboron brs: broad singlet n-BuOH: normal butanol n-BuLi: normal butyllithiumtBuXPhos: 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl cataCXium®A: di(1-adamantyl)-n-butylphosphine Cu(OAc)2: copper(II) acetate d: doublet dd: double doublet ddd: double double doublet dt: double triplet DCM: dichloromethane DEAD: diethyl azodicarboxylate Deoxo-Fluor®: bis(2-methoxyethyl)aminosulfur trifluoride DIAD: diisopropyl azodicarboxylate DIPEA: N,N-diisopropylethylamine DMA: N,N-dimethylacetamide DMAP: 4-dimethylaminopyridine DMF: N,N-dimethylformamide DME: 1,2-dimethoxyethane DMSO: dimethyl sulfoxide Et2O: diethyl ether EtOAc: ethyl acetate EtOH: ethanol FA: formic acid HOBt-H2O: 1-Hydroxybenzotriazole monohydrate IPE: diisopropyl ether KOAc: potassium acetate m: multiplet mCPBA: 3-chlorobenzene-1-carboperoxoic acid MeOH: methanol MsCl: methanesulfonyl chloride NaOMe: sodium methoxide NBS: N-bromosuccinimide NMP: N-methylpyrrolidone Pd(OAc)2: palladium(II) acetate Pd(amphos)Cl2: bis(di-tert-butyl(4- dimethylaminophenyl)phosphine)dichloropalladium(II) Pd(tBu3P)2: bis(tri-tert-butylphosphine)palladium(0) Pd2(dba)3: tris(dibenzylideneacetone)dipalladium(0)Pd(dppf)Cl2: [1,1’- bis(diphenylphosphino)ferrocene]dichloropalladium(II) Pd(PPh3)4: tetrakis(triphenylphosphine)palladium(0) Pd(PPh3)2Cl2: bis(triphenylphosphine)palladium(II) dichloride PE: petroleum ether PPh3: triphenylphosphine q: quartet s: singlet SEMCl: 2-(Chloromethoxy)ethyltrimethylsilane t: triplet TBAF: tetrabutylammonium fluoride TBSCl: tert-butyldimethylchlorosilane TEA: triethylamine TFA: trifluoroacetic acid TFE: 2,2,2-trifluoroethanol THF: tetrahydrofuran TMSCl: chlorotrimethylsilane TsCl: p-toluenesulfonyl chloride TsOH-H2O: p-toluenesulfonic acid monohydrate WSC-HCl: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride

[0310] Example 1 3-[5-(4-cyano-3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-N-[2- (diethylamino)ethyl]benzamide

[0311] A) methyl (2S)-2-(5-bromo-2-cyanophenoxy)propanoate To a mixture of 4-bromo-2-hydroxybenzonitrile (14.5 g), methyl (2R)-2-hydroxypropanoate (15.3 g), PPh3(57.6 g) and THF (150 mL) was added 2.2M DEAD toluene solution (120 mL) at 0 °C. The mixture was stirred under nitrogen atmosphere at room temperature overnight. The mixture was diluted with water at room temperature and extracted with EtOAc. The organic layer was separated, washed with water and brine, dried over MgSO4and concentrated under reduced pressure. The residue was purified bysilica gel column chromatography (EtOAc / hexane) to give the titled compound (20.0 g).1H NMR (300 MHz, DMSO-d6) δ 7.72 (d, J = 8.3 Hz, 1H), 7.47 (d, J = 1.6 Hz, 1H), 7.35 (dd, J = 8.3, 1.7 Hz, 1H), 5.40 (q, J = 6.8 Hz, 1H), 3.71 (s, 3H), 1.57 (d, J = 6.8 Hz, 3H).

[0312] B) 4-bromo-2-(((2S)-1-hydroxypropan-2-yl)oxy)benzonitrile To a mixture of methyl (2S)-2-(5-bromo-2- cyanophenoxy)propanoate (72.0 g) in MeOH (200 mL) and THF (100 mL) was added NaBH4(4.76 g) at 0 ºC. The mixture was stirred under nitrogen atmosphere at room temperature for 10 hr. The mixture was quenched with saturated aqueous NH4Cl solution at 0 ºC and concentrated under reduced pressure. The residue was extracted with EtOAc. The organic layer was separated, washed with water and brine, dried over MgSO4and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc / hexane) to give the titled compound (65.0 g).1H NMR (300 MHz, DMSO-d6) δ 7.66 (d, J = 8.3 Hz, 1H), 7.60 (S, 1H), 7.28 (d, J = 8.3 Hz, 1H), 4.97 (t, J = 5.5 Hz, 1H), 4.65- 4.78 (m, 1H), 3.54 (t, J = 5.4 Hz, 2H), 1.24 (d, J = 6.1 Hz, 3H).

[0313] C) (2S)-2-(5-bromo-2-cyanophenoxy)propyl methanesulfonate To a solution of 4-bromo-2-(((2S)-1-hydroxypropan-2- yl)oxy)benzonitrile (21.0 g) and TEA (23 mL) in THF (100 mL) was added MsCl (8.9 mL) at 0 ºC. The mixture was stirred under nitrogen atmosphere at room temperature for 1 hr. The mixture was quenched with water at room temperature and extracted with EtOAc. The organic layer was separated, washed with water and brine, dried over MgSO4and concentrated under reduced pressure. The residue was filtered through an NH silica gel pad and concentrated under reduced pressure to give the titled compound (26.0 g).1H NMR (300 MHz, DMSO-d6) δ 7.70 (d, J = 8.3 Hz, 1H), 7.66 (d, J = 1.6 Hz, 1H), 7.34 (dd, J = 8.3, 1.7 Hz, 1H), 5.07 (td, J = 6.2, 3.0 Hz, 1H), 4.42-4.48 (m, 1H), 4.31-4.39 (m, 1H), 3.22 (s, 3H), 1.33 (d, J = 6.3 Hz 3H); m / z 335.2 [M+H]+.

[0314] D) 4-bromo-2-(((2S)-1-(1H-tetrazol-1-yl)propan-2- yl)oxy)benzonitrile To a mixture of (2S)-2-(5-bromo-2-cyanophenoxy)propyl methanesulfonate (25.0 g), 1H-tetrazole (10.5 g) and DMF (100 mL) was added K2CO3(20.7 g) at room temperature and the mixture was stirred at 80 ºC overnight. The mixture was diluted with water at room temperature and extracted with EtOAc. The organic layer was separated, washed with water and brine, dried over MgSO4and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc / hexane) to give the titled compound (10.3 g).1H NMR (300 MHz, CDCl3) δ 8.88-9.02 (m, 1H), 7.42 (d, J = 8.2 Hz, 1H), 7.21 (dd, J = 8.3, 1.7 Hz, 1H), 7.01 (d, J = 1.6 Hz, 1H), 4.79-4.89 (m, 2H), 4.64-4.77 (m, 1H), 1.44-1.51 (m, 3H); MS m / z 308.2 [M+H]+.

[0315] E) 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(((2S)-1- (1H-tetrazol-1-yl)propan-2-yl)oxy)benzonitrile To a mixture of 4-bromo-2-{[(2S)-1-(1H-tetrazol-1- yl)propan-2-yl]oxy}benzonitrile (5.00 g), (Bpin)2(4.52 g), KOAc (7.93 g) and DMF (50 mL) was added Pd(dppf)Cl2-CH2Cl2(594 mg). After being stirred under nitrogen atmosphere at 100 ºC for 4 hr, the mixture was poured into water and extracted with EtOAc. The organic layer was separated, washed with brine, dried over MgSO4and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc / hexane) to give the titled compound (3.30 g). MS m / z 356.2 [M+H]+.

[0316] F) 4-{pyrazolo[1,5-a]pyrimidin-5-yl}-2-{[(2S)-1-(1H-tetrazol-1- yl)propan-2-yl]oxy}benzonitrile To a solution of 5-chloropyrazolo[1,5-a]pyrimidine (120 mg), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-{[(2S)-1- (1H-tetrazol-1-yl)propan-2-yl]oxy}benzonitrile (666 mg) and Cs2CO3(508 mg) in THF (10 mL) and water (2.0 mL) was added Pd(tBu3P)2(39.9 mg) and the mixture was stirred under nitrogen atmosphereat 70 ºC for 10 hr. The mixture was quenched with water at room temperature and extracted with EtOAc. The organic layer was separated, washed with water and brine, dried over MgSO4and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (NH, EtOAc / hexane) to give the titled compound (80.0 mg).1H NMR (300 MHz, DMSO-d6) δ 9.38 (s, 1H), 9.31 (d, J = 7.4 Hz, 1H), 8.31 (s, 1H), 7.85-7.97 (m, 3H), 7.80 (d, J = 7.2 Hz, 1H), 6.85 (s, 1H), 5.36-5.48 (m, 1H), 4.84-5.01 (m, 2H), 1.39 (d, J = 6.1 Hz, 3H); MS m / z 347.2 [M+H]+.

[0317] G) 4-{3-bromopyrazolo[1,5-a]pyrimidin-5-yl}-2-{[(2S)-1-(1H- tetrazol-1-yl)propan-2-yl]oxy}benzonitrile To a mixture of 4-{pyrazolo[1,5-a]pyrimidin-5-yl}-2-{[(2S)- 1-(1H-tetrazol-1-yl)propan-2-yl]oxy}benzonitrile (180 mg) in DMF (5.0 mL) was added NBS (101 mg) at 0 ºC. The mixture was stirred under nitrogen atmosphere at room temperature for 10 hr. The mixture was quenched with saturated aqueous NaHCO3solution at 0 ºC and extracted with EtOAc. The organic layer was separated, washed with water and brine, dried over MgSO4and concentrated under reduced pressure to give the crude titled compound. The crude product was used for the next step without further purification. MS m / z 425.0 [M+H]+.

[0318] H) methyl 3-[5-(4-cyano-3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)pyrazolo[1,5-a]pyrimidin-3-yl]benzoate To a mixture of 4-{3-bromopyrazolo[1,5-a]pyrimidin-5-yl}-2- {[(2S)-1-(1H-tetrazol-1-yl)propan-2-yl]oxy}benzonitrile (220 mg) and [3-(methoxycarbonyl)phenyl]boronic acid (111 mg) in THF (20 mL) and water (4.0 mL) were added Cs2CO3(252 mg) and Pd(tBu3P)2(26.4 mg) and the mixture was stirred under nitrogen atmosphere at 80 ºC for 14 hr. The mixture was quenched with water at room temperature and extracted with EtOAc. The organic layer was separated, washed with water and brine, dried over MgSO4and concentrated under reduced pressure. The residue was purified bysilica gel column chromatography (NH, EtOAc / hexane) to give the titled compound (160 mg).1H NMR (300 MHz, DMSO-d6) δ 9.36-9.40 (m, 2H), 9.10 (s, 1H), 8.96 (s, 1H), 8.43 (d, J = 8.3 Hz, 1H), 8.05-8.14 (m, 2H), 7.84-8.02 (m, 3H), 7.60-7.70 (m, 1H), 5.45-5.59 (m, 1H), 4.87-5.07 (m, 2H), 3.93 (s, 3H), 1.44 (d, J = 5.8 Hz, 3H); MS m / z 481.2 [M+H]+.

[0319] I) 3-[5-(4-cyano-3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)pyrazolo[1,5-a]pyrimidin-3-yl]benzoic acid To a mixture of methyl 3-[5-(4-cyano-3-{[(2S)-1-(1H- tetrazol-1-yl)propan-2-yl]oxy}phenyl)pyrazolo[1,5-a]pyrimidin-3- yl]benzoate (150 mg) in MeOH (10 mL) and THF (10 mL) was added 2M aqueous NaOH solution (0.16 mL). The mixture was stirred under nitrogen atmosphere at 50 ºC for 10 hr. The mixture was acidified with 6M aqueous HCl solution (pH 2-3). The precipitate was collected by filtration and dried under reduced pressure to give the crude titled compound. The crude product was used for the next step without further purification. MS m / z 467.2 [M+H]+.

[0320] J) 3-[5-(4-cyano-3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-N-[2- (diethylamino)ethyl]benzamide To a mixture of 3-[5-(4-cyano-3-{[(2S)-1-(1H-tetrazol-1- yl)propan-2-yl]oxy}phenyl)pyrazolo[1,5-a]pyrimidin-3-yl]benzoic acid (145 mg), WSC-HCl (178 mg) and HOBt-H2O (125 mg) in DMF (5.0 mL) were added (2-aminoethyl)diethylamine (72.2 mg) and TEA (0.13 mL). The mixture was stirred under nitrogen atmosphere for 16 hr. The mixture was quenched with water at room temperature and extracted with EtOAc. The organic layer was separated, washed with water and brine, dried over MgSO4and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (NH, EtOAc / hexane), and then preparative HPLC (water / CH3CN containing 0.1% TFA). The desired fraction was azeotroped with toluene under reduced pressure. The residue was dissolved in MeOH (5.0 mL) and Amberlyst®A21 was added to the mixture. The mixture was stirred at room temperature for 15 minand then the insoluble material was removed by filtration. The filtrate was concentrated under reduced pressure to give the titled compound (15.0 mg) as a yellow solid.1H NMR (300 MHz, DMSO-d6) δ 9.34-9.40 (m, 2H), 8.91 (s, 1H), 8.87 (s, 1H), 8.46-8.53 (m, 1H), 8.35 (d, J = 7.0 Hz, 1H), 8.15 (s, 1H), 8.03-8.08 (m, 1H), 7.87-7.98 (m, 2H), 7.74 (d, J = 7.3 Hz, 1H), 7.55-7.62 (m, 1H), 5.52-5.65 (m, 1H), 4.87-5.06 (m, 2H), 3.33-3.46 (m, 4H), 2.52-2.67 (m, 4H), 1.43 (d, J = 5.8 Hz, 3H), 0.98 (t, J = 5.8 Hz, 6H); MS m / z 565.4 [M+H]+.

[0321] Example 57 1-[(2S)-2-{2-fluoro-5-[2-methyl-3-(thiophen-2-yl)pyrazolo[1,5- a]pyrimidin-5-yl]phenoxy}propyl]-1H-tetrazole

[0322] A) methyl (2S)-2-(5-bromo-2-fluorophenoxy)propanoate To a solution of 5-bromo-2-fluorophenol (74.0 g), methyl (2R)-2-hydroxypropanoate (80.7 g) and PPh3(152 g) in THF (1000 mL) was added portionwise DIAD (118 g) at 0 °C. The mixture was stirred under nitrogen atmosphere at 25 °C for 12 hr. The mixture was diluted with water (1000 mL) and extracted with EtOAc (800 mL ×3). The combined organic layer was washed with brine (1000 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc / PE) to give the titled compound (85.0 g).1H NMR (400 MHz, CDCl3) δ 6.93-7.07 (m, 3H), 4.76 (q, J = 7.2 Hz, 1H), 3.77 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H).

[0323] B) (2S)-2-(5-bromo-2-fluorophenoxy)propan-1-ol To a solution of methyl (2S)-2-(5-bromo-2- fluorophenoxy)propanoate (85.0 g) in THF (330 mL) and MeOH (660 mL) was added portionwise NaBH4(17.4 g) at 0 °C over 0.5 hr. The mixture was stirred under nitrogen atmosphere at 25 °C for 12 hr. The mixture was diluted with saturated aqueous NH4Cl solution (500 mL) and water (500 mL) at 0 °C. The organic solvent was removed under reduced pressure. The residue was extracted with EtOAc (400 mL ×3). The combined organic layer was washed with brine (800 mL), dried over Na2SO4and concentrated under reduced pressure.The residue was purified by silica gel column chromatography (EtOAc / PE) to give the titled compound (75.0 g).1H NMR (400 MHz, CDCl3) δ 7.16 (dd, J = 7.2, 2.0 Hz, 1H), 7.04- 7.10 (m, 1H), 6.92-6.97 (m, 1H), 4.42-4.46 (m, 1H), 3.74-3.80 (m, 2H), 2.58 (brs, 1H), 1.29 (d, J = 6.0 Hz, 3H).

[0324] C) (2S)-2-(5-bromo-2-fluorophenoxy)propyl methanesulfonate To a solution of (2S)-2-(5-bromo-2-fluorophenoxy)propan-1- ol (75.0 g) and TEA (60.9 g) in THF (1000 mL) was added dropwise MsCl (48.3 g) at 0 °C. The mixture was stirred under nitrogen atmosphere at 25 °C for 1 hr. The mixture was diluted with water (800 mL) and extracted with EtOAc (1000 mL ×3). The combined organic layer was washed with brine (800 mL), dried over Na2SO4and concentrated under reduced pressure to give the titled compound (97.0 g).1H NMR (400 MHz, CDCl3) δ 7.15 (dd, J = 7.2, 2.4 Hz, 1H), 7.06- 7.10 (m, 1H), 6.94-6.99 (m, 1H), 4.59-4.63 (m, 1H), 4.35-4.36 (m, 2H), 3.05 (s, 3H), 1.38 (d, J = 6.4 Hz, 3H).

[0325] D) 1-[(2S)-2-(5-bromo-2-fluorophenoxy)propyl]-1H-tetrazole To a mixture of (2S)-2-(5-bromo-2-fluorophenoxy)propyl methanesulfonate (97.0 g) and 1H-tetrazole (41.5 g) in DMF (1000 mL) was added K2CO3(82.0 g). The mixture was stirred at 80 °C for 12 hr. The mixture was diluted with saturated aqueous NH4Cl solution (600 mL) and extracted with EtOAc (200 mL ×3). The combined organic layer was washed with brine (600 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc / PE) to give the titled compound (31.0 g).1H NMR (400 MHz, CDCl3) δ 8.80 (s, 1H), 7.05-7.17 (m, 1H), 6.90- 7.04 (m, 2H), 4.75-4.85 (m, 1H), 4.65-4.74 (m, 1H), 4.54-4.64 (m, 1H), 1.38 (d, J = 6.4 Hz, 3H).

[0326] E) 1-[(2S)-2-[2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)phenoxy]propyl]-1H-tetrazole A mixture of 1-[(2S)-2-(5-bromo-2-fluorophenoxy)propyl]-1H- tetrazole (29.3 g), (Bpin)2(37.1 g), Pd(dppf)Cl2-CH2Cl2(7.95 g)and KOAc (19.1 g) in DMSO (300 mL) was stirred under nitrogen atmosphere at 100 °C for 2 hr. The mixture was diluted with water (300 mL) and extracted with EtOAc (300 mL ×3). The combined organic layer was washed with brine (300 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc / PE) to give the titled compound (33.0 g).1H NMR (400 MHz, CDCl3) δ 8.44 (s, 1H), 7.33-7.35 (m, 1H), 7.26- 7.29 (m, 1H), 6.94-6.99 (m, 1H), 4.89-4.93 (m, 2H), 4.70-4.76 (m, 1H), 1.35 (d, J = 5.2 Hz, 3H), 1.27 (s, 12H).

[0327] F) 1-[(2S)-2-(2-fluoro-5-{2-methylpyrazolo[1,5-a]pyrimidin-5- yl}phenoxy)propyl]-1H-tetrazole The reaction and purification were performed according to Example 1 Step F to give the titled compound.1H NMR (300 MHz, CDCl3) δ 8.87 (s, 1H), 8.59 (d, J = 7.3 Hz, 1H), 7.72 (dd, J = 2.2, 8.0 Hz, 1H), 7.61 (ddd, J = 2.2, 4.4, 8.5 Hz, 1H), 7.20 (dd, J = 8.5, 10.5 Hz, 1H), 7.08 (d, J = 7.3 Hz, 1H), 6.48 (s, 1H), 4.87-4.95 (m, 1H), 4.80-4.86 (m, 1H), 4.65-4.73 (m, 1H), 2.53 (s, 3H), 1.45 (d, J = 6.2 Hz, 3H); MS m / z 354.3 [M+H]+.

[0328] G) 1-[(2S)-2-(5-{3-bromo-2-methylpyrazolo[1,5-a]pyrimidin-5-yl}- 2-fluorophenoxy)propyl]-1H-tetrazole The reaction and purification were performed according to Example 1 Step G to give the titled compound.1H NMR (300 MHz, CDCl3) δ 8.88 (s, 1H), 8.56 (d, J = 7.3 Hz, 1H), 7.77 (dd, J = 2.2, 7.9 Hz, 1H), 7.69 (ddd, J = 2.2, 4.4, 8.6 Hz, 1H), 7.21 (dd, J = 8.6, 10.5 Hz, 1H), 7.14 (d, J = 7.4 Hz, 1H), 4.81-4.92 (m, 2H), 4.66-4.74 (m, 1H), 2.52 (s, 3H), 1.46 (d, J = 6.2 Hz, 3H); MS m / z 432.2, 434.2 [M+H]+.

[0329] H) 1-[(2S)-2-{2-fluoro-5-[2-methyl-3-(thiophen-2-yl)pyrazolo[1,5- a]pyrimidin-5-yl]phenoxy}propyl]-1H-tetrazole The reaction and purification were performed according to Example 1 Step H to give the titled compound.1H NMR (300 MHz, DMSO-d6) δ 9.43 (s, 1H), 9.14 (d, J = 7.3 Hz, 1H), 8.01-8.10 (m, 1H), 7.97 (ddd, J = 1.9, 4.4, 8.5 Hz, 1H),7.71 (d, J = 7.4 Hz, 1H), 7.53-7.64 (m, 2H), 7.42 (dd, J = 8.7, 10.9 Hz, 1H), 7.22 (dd, J = 3.6, 5.1 Hz, 1H), 5.07-5.18 (m, 1H), 4.89-4.98 (m, 1H), 4.79-4.89 (m, 1H), 2.66 (s, 3H), 1.41 (d, J = 6.2 Hz, 3H); MS m / z 436.4 [M+H]+.

[0330] Example 61 1-[(2S)-2-{3-[3-(thiophen-2-yl)pyrazolo[1,5-a]pyrimidin-5- yl]phenoxy}propyl]-1H-1,2,4-triazole

[0331] A) ((2S)-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenoxy]propan-1-ol To a mixture of (2S)-2-(3-bromophenoxy)propan-1-ol (35.0 g), (Bpin)2(45.9 g) and KOAc (44.3 g) in toluene (100 mL) was added Pd(dppf)Cl2(5.53 g). After being stirred under argon atmosphere at 100 ºC for 3 hr, the mixture was poured into water and extracted with EtOAc. The organic layer was separated, washed with brine, dried over MgSO4and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc / hexane) to give the titled compound (36.0 g). MS m / z 279.1 [M+H]+.

[0332] B) (2S)-2-(3-{pyrazolo[1,5-a]pyrimidin-5-yl}phenoxy)propan-1-ol The reaction and purification were performed according to Example 1 Step F to give the titled compound. MS m / z 270.4 [M+H]+.

[0333] C) (2S)-2-(3-{3-bromopyrazolo[1,5-a]pyrimidin-5- yl}phenoxy)propan-1-ol The reaction and purification were performed according to Example 1 Step G to give the titled compound. MS m / z 348.2 [M+H]+.

[0334] D) (2S)-2-{3-[3-(thiophen-2-yl)pyrazolo[1,5-a]pyrimidin-5- yl]phenoxy}propan-1-ol The reaction and purification were performed according to Example 1 Step H to give the titled compound.MS m / z 352.1 [M+H]+.

[0335] E) (2S)-2-{3-[3-(thiophen-2-yl)pyrazolo[1,5-a]pyrimidin-5- yl]phenoxy}propyl methanesulfonate To a mixture of (2S)-2-{3-[3-(thiophen-2-yl)pyrazolo[1,5- a]pyrimidin-5-yl]phenoxy}propan-1-ol (1.80 g) and TEA (777 mg) in THF (10 mL) was added MsCl (644 mg). The mixture was stirred at room temperature for 30 min. The mixture was poured into water and extracted with EtOAc. The organic layer was separated, washed with brine, dried over MgSO4and concentrated under reduced pressure to give the crude titled compound (2.20 g). The crude product was used for the next step without further purification. MS m / z 430.1 [M+H]+.

[0336] F) 1-[(2S)-2-{3-[3-(thiophen-2-yl)pyrazolo[1,5-a]pyrimidin-5- yl]phenoxy}propyl]-1H-1,2,4-triazole To a mixture of (2S)-2-{3-[3-(thiophen-2-yl)pyrazolo[1,5- a]pyrimidin-5-yl]phenoxy}propyl methanesulfonate (100 mg), K2CO3(64.3 mg) in DMF (5.0 mL) was added 1,2,4-triazole (32.1 mg). The mixture was stirred at 100 ºC for 15 hr. The mixture was poured into water and extracted with EtOAc. The organic layer was separated, washed with brine, dried over MgSO4and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (NH, EtOAc / hexane) to give the titled compound (75.0 mg) as a yellow solid.1H NMR (300 MHz, DMSO-d6) δ 9.20 (d, J = 7.4 Hz, 1H), 8.67 (s, 1H), 8.58 (s, 1H), 7.97 (s, 1H), 7.92 (d, J = 7.9 Hz, 1H), 7.83 (s, 1H) , 7.73 (d, J = 7.4 Hz, 1H) , 7.66 (dd, J = 5.1, 3.6 Hz, 1H), 7.45-7.30 (m, 2H), 7.17 (dd, J = 3.6, 1.1 Hz, 1H), 7.08 (dd, J = 8.1, 2.2 Hz, 1H), 4.95-5.05 (m, 1H), 4.59 (d, J = 5.6 Hz, 2H), 1.36 (d, J = 6.2 Hz, 3H); MS m / z 403.1 [M+H]+.

[0337] Example 121 2-[6-(4-fluoro-3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]benzonitrile

[0338] A) 1-[(2S)-2-(2-fluoro-5-{imidazo[1,2-b]pyridazin-6- yl}phenoxy)propyl]-1H-tetrazole To a solution of 1-[(2S)-2-[2-fluoro-5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]propyl]-1H-tetrazole (33.0 g) and 6-chloroimidazo[1,2-b]pyridazine (14.6 g) in THF (320 mL) and water (80 mL) were added Cs2CO3(61.8 g) and Pd(dppf)Cl2-CH2Cl2(7.74 g). The mixture was stirred under nitrogen atmosphere at 70 °C for 1 hr. The mixture was diluted with water (300 mL) and extracted with EtOAc (400 mL ×3). The combined organic layer was washed with brine (500 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (MeOH / EtOAc) to give the titled compound (13.0 g).1H NMR (400 MHz, CDCl3) δ 8.51 (s, 1H), 7.99-8.01 (m, 2H), 7.79 (s, 1H), 7.55-7.57 (m, 2H), 7.39 (d, J = 8.0 Hz, 1H), 7.16-7.20 (m, 1H), 5.01-5.06 (m, 2H), 4.83-4.85 (m, 1H), 1.51 (d, J = 6.0 Hz, 3H).

[0339] B) 1-[(2S)-2-(5-{3-bromoimidazo[1,2-b]pyridazin-6-yl}-2- fluorophenoxy)propyl]-1H-tetrazole To a mixture of 1-[(2S)-2-(2-fluoro-5-{imidazo[1,2- b]pyridazin-6-yl}phenoxy)propyl]-1H-tetrazole (20.0 g) in DMF (300 mL) was added NBS (10.5 g). The mixture was stirred under nitrogen atmosphere at 25 °C for 12 hr. The mixture was diluted with water (200 mL) and extracted with EtOAc (300 mL ×3). The combined organic layer was washed with brine (200 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc) to give the titled compound (15.1 g).1H NMR (400 MHz, CDCl3) δ 8.54 (s, 1H), 7.99-8.01 (m, 1H), 7.80 (s, 1H),7.62-7.64 (m, 2H), 7.46 (d, J = 6.4 Hz, 1H), 7.21-7.23 (m, 1H), 5.04-5.07 (m, 2H), 4.84-4.86 (m, 1H), 1.52 (d, J = 6.0 Hz, 3H).

[0340] C) 2-[6-(4-fluoro-3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]benzonitrile Pd(PPh3)2Cl2(4.33 mg) was added to a mixture of 1-[(2S)-2-(5-{3-bromoimidazo[1,2-b]pyridazin-6-yl}-2-fluorophenoxy)propyl]- 1H-tetrazole (50.0 mg), (2-cyanophenyl)boronic acid (19.3 mg), Cs2CO3(77.8 mg) in THF (5.0 mL) and water (1.0 mL). The mixture was stirred under nitrogen atmosphere at 70 °C for 1 hr. The mixture was poured into water and extracted with EtOAc. The organic layer was separated, washed with brine, dried over MgSO4and concentrated under reduced pressure. The residue was crystallized from EtOAc to give the titled compound (28.0 mg) as a white solid.1H NMR (300 MHz, DMSO-d6) δ 9.40 (s, 1H), 8.39 (d, J = 5.8 Hz, 1H), 8.23 (s, 1H), 8.07-8.13 (m, 2H), 7.97 (d, J = 5.8 Hz, 1H), 7.90-7.97 (m,1H), 7.81 (dd, J = 5.8, 3.0 Hz, 1H), 7.68-7.72 (m, 2H), 7.35-7.38 (m, 1H), 5.01-5.09 (m, 1H), 4.78-4.94 (m, 2H), 1.36 (d, J = 6.0 Hz, 3H); MS m / z 441.2 [M+H]+.

[0341] Example 150 2-[5-(4-fluoro-3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)-3H-imidazo[4,5-b]pyridin-3-yl]pyridine-3- carbonitrile

[0342] A) 5-chloro-3-{[2-(trimethylsilyl)ethoxy]methyl}-3H-imidazo[4,5- b]pyridine and 5-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H- imidazo[4,5-b]pyridine To a mixture of 5-chloro-3H-imidazo[4,5-b]pyridine (3.90 g) and DIPEA (6.53 g) in DMF (40 mL) was added SEMCl (3.6 mL). After being stirred under nitrogen atmosphere at 80 ºC for 14 hr, additional SEMCl (1.3 mL) was added to the mixture. After being stirred under nitrogen atmosphere at 80 ºC for 4 hr, the mixture was quenched with water at room temperature and extracted with EtOAc. The organic layer was separated, washed with water and brine, dried over MgSO4and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (NH, EtOAc / hexane) to give a mixture of the titled compounds (4.93 g). MS m / z 284.2 [M+H]+.

[0343] B) 1-[(2S)-2-[2-fluoro-5-(3-{[2-(trimethylsilyl)ethoxy]methyl}- 3H-imidazo[4,5-b]pyridin-5-yl)phenoxy]propyl]-1H-tetrazole and 1-[(2S)-2-[2-fluoro-5-(1-{[2-(trimethylsilyl)ethoxy]methyl}-1H- imidazo[4,5-b]pyridin-5-yl)phenoxy]propyl]-1H-tetrazole The reaction and purification were performed according to Example 284 Step D to give the titled compound. MS m / z 470.3 [M+H]+.

[0344] C) 1-[(2S)-2-(2-fluoro-5-{3H-imidazo[4,5-b]pyridin-5- yl}phenoxy)propyl]-1H-tetrazole To a mixture of a mixture of 1-[(2S)-2-[2-fluoro-5-(3-{[2- (trimethylsilyl)ethoxy]methyl}-3H-imidazo[4,5-b]pyridin-5- yl)phenoxy]propyl]-1H-tetrazole and 1-[(2S)-2-[2-fluoro-5-(1-{[2- (trimethylsilyl)ethoxy]methyl}-1H-imidazo[4,5-b]pyridin-5- yl)phenoxy]propyl]-1H-tetrazole (7.48 g) in THF (40 mL) was added 1M TBAF THF solution (14 mL). The mixture was stirred under nitrogen atmosphere at 80 ºC for 4 hr. The mixture was quenched with water at room temperature and extracted with EtOAc. The organic layer was separated, washed with water and brine, dried over MgSO4and concentrated under reduced pressure to give the crude titled compound (2.60 g). The crude product was used for the next step without further purification.1H NMR (300 MHz, DMSO-d6) δ 12.62-13.31 (m, 1H), 9.42 (s, 1H), 8.39-8.51 (m, 1H), 7.98-8.18 (m, 1H), 7.68-7.86 (m, 3H), 7.25- 7.36 (m, 1H), 5.01-5.12 (m, 1H), 4.75-4.93 (m, 2H), 1.36 (d, J = 6.1 Hz, 3H); MS m / z 340.3 [M+H]+.

[0345] D) 2-[5-(4-fluoro-3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)-3H-imidazo[4,5-b]pyridin-3-yl]pyridine-3- carbonitrile A mixture of 1-[(2S)-2-(2-fluoro-5-{3H-imidazo[4,5- b]pyridin-5-yl}phenoxy)propyl]-1H-tetrazole (250 mg), 2- chloropyridine-3-carbonitrile (152 mg), K3PO4(233 mg), tBuXPhos (62.5 mg) and Pd2(dba)3(67.4 mg) in DMA (15 mL) was stirred under microwave irradiation at 100 ºC for 1 hr. The mixture was quenched with water at room temperature and extracted with EtOAc. The organic layer was separated, washed with water and brine, dried over MgSO4and concentrated under reduced pressure. The residue was purified by silica gel column chromatography(EtOAc / hexane) and silica gel column chromatography (NH, EtOAc / hexane) to give the titled compound (8.00 mg) as a white solid.1H NMR (300 MHz, CDCl3) δ 8.91 (s, 1H), 8.83 (dd, J = 1.8, 4.9 Hz, 1H), 8.65 (s, 1H), 8.48 (dd, J = 1.8, 7.8 Hz, 1H), 8.22 (d, J = 8.4 Hz, 1H), 7.97 (dd, J = 2.1, 8.2 Hz, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.61 (dd, J = 4.9, 7.9 Hz, 1H), 7.53-7.58 (m, 1H), 7.18 (dd, J = 8.5, 11 Hz, 1H), 4.92 (dt, J = 2.9, 6.6 Hz, 1H), 4.80-4.87 (m, 1H), 4.65-4.74 (m, 1H), 1.42 (d, J = 6.2 Hz, 3H); MS m / z 442.3 [M+H]+.

[0346] Example 173 4-[5-(4-fluoro-3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-methyl-1H- imidazole-5-carbonitrile

[0347] A) 4-[(6-chloro-3-nitropyridin-2-yl)amino]-1-methyl-1H-imidazole- 5-carbonitrile The reaction and purification were performed according to Example 284 Step A to give the titled compound.1H NMR (300 MHz, DMSO-d6) δ 10.15 (s, 1H), 8.57 (d, J = 8.5 Hz, 1H), 7.72 (s, 1H), 7.13 (d, J = 8.5 Hz, 1H), 3.59 (s, 3H); MS m / z 279.0 [M+H]+.

[0348] B) 4-{5-chloro-3H-imidazo[4,5-b]pyridin-3-yl}-1-methyl-1H- imidazole-5-carbonitrile The reaction and purification were performed according to Example 284 Step B and C to give the titled compound. MS m / z 259.1 [M+H]+.

[0349] C) 4-[5-(4-fluoro-3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-methyl-1H- imidazole-5-carbonitrile The reaction and purification were performed according to Example 284 Step D to give the titled compound.1H NMR (300 MHz, DMSO-d6) δ 9.41 (s, 1H), 8.83 (s, 1H), 8.32 (d, J = 8.4 Hz, 1H), 8.24 (s, 1H), 8.08 (dd, J = 2.0, 8.3 Hz, 1H), 8.03(d, J = 8.4 Hz, 1H), 7.84 (ddd, J = 2.0, 4.4, 8.6 Hz, 1H), 7.32 (dd, J = 8.6, 11 Hz, 1H), 5.08-5.19 (m, 1H), 4.88-4.96 (m, 1H), 4.76-4.87 (m, 1H), 3.97 (s, 3H), 1.37 (d, J = 6.1 Hz, 3H); MS m / z 445.2 [M+H]+.

[0350] Example 239 2-[6-(3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]benzonitrile

[0351] A) methyl (2S)-2-(3-bromophenoxy)propanoate To a mixture of 3-bromophenol (75.0 g), methyl (2R)-2- hydroxypropanoate (90.3 g) and PPh3(171 g) in THF (1000 mL) was added DIAD (131 g) at 0 °C. The mixture was stirred under nitrogen atmosphere at 20 °C for 12 hr. The mixture was diluted with water (1000 mL) and extracted with EtOAc (500 mL ×3). The combined organic layer was washed with brine (1000 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was triturated with 15% EtOAc in PE (500 mL) and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc / PE) to give the titled compound (41.0 g).1H NMR (400 MHz, CDCl3) δ 7.09-7.19 (m, 2H), 7.04 (d, J = 2.0 Hz, 1H), 6.75-6.81 (m, 1H), 4.74 (q, J = 6.8 Hz, 1H), 3.77 (s, 3H), 1.61 (d, J = 6.8 Hz, 3H).

[0352] B) (2S)-2-(3-bromophenoxy)propan-1-ol To a mixture of methyl (2S)-2-(3-bromophenoxy)propanoate (41.0 g) in THF (200 mL) and MeOH (400 mL) was added portionwise NaBH4(8.98 g) at 0 ºC. The mixture was stirred under nitrogen atmosphere at 20 °C for 12 hr. Saturated aqueous NH4Cl solution (500 mL) and water (500 mL) were added to the mixture at 0 °C. The organic solvent was removed under reduced pressure. The residue was extracted with EtOAc (400 mL ×3). The combined organic layer was washed with brine (800 mL), dried over Na2SO4and concentrated under reduced pressure to give the titled compound (35.0 g).1H NMR (400 MHz, CDCl3) δ 7.01-7.16 (m, 3H), 6.80-6.90 (m, 1H), 4.41-4.52 (m, 1H), 3.64-3.75 (m, 2H), 2.06 (brs, 1H), 1.26 (d, J = 6.0 Hz, 3H).

[0353] C) (2S)-2-(3-bromophenoxy)propyl methanesulfonate To a mixture of (2S)-2-(3-bromophenoxy)propan-1-ol (64.0 g) and TEA (56.1 g) in THF (700 mL) was added dropwise MsCl (44.4 g) at 0 °C in 0.5 hr. The mixture was stirred under nitrogen atmosphere at 20 °C for 1 hr. The mixture was diluted with water (1000 mL) and extracted with EtOAc (500 mL ×3). The combined organic layer was washed with brine (1000 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give the titled compound (82.0 g).1H NMR (400 MHz, CDCl3) δ 7.06-7.19 (m, 3H), 6.81-6.92 (m, 1H), 4.59-4.70 (m, 1H), 4.25-4.36 (m, 2H), 3.03 (s, 3H), 1.36 (d, J = 6.0 Hz, 3H).

[0354] D) 1-[(2S)-2-(3-bromophenoxy)propyl]-1H-tetrazole To a mixture of (2S)-2-(3-bromophenoxy)propyl methanesulfonate (82.0 g) in DMF (800 mL) were added K2CO3(73.3 g) and 1H-tetrazole (37.2 g). The mixture was stirred under nitrogen atmosphere at 80 °C for 12 hr. The mixture was concentrated under reduced pressure. The residue was poured into water (1500 mL) and extracted with EtOAc (800 mL ×3). The combined organic layer was washed with brine (1000 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc / PE) to give the titled compound (72.0 g).1H NMR (400 MHz, CDCl3) δ 8.71 (s, 1H), 7.09-7.18 (m, 2H), 6.95- 7.03 (m, 1H), 6.67-6.73 (m, 1H), 4.66-4.79 (m, 2H), 4.53-4.65 (m, 1H), 1.36 (d, J = 6.0 Hz, 3H).

[0355] E) 1-[(2S)-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenoxy]propyl]-1H-tetrazole To a mixture of 1-[(2S)-2-(3-bromophenoxy)propyl]-1H- tetrazole (36.0 g), (Bpin)2(48.4 g) and KOAc (25.0 g) in DMSO (500 mL) was added Pd(dppf)Cl2-CH2Cl2(10.4 g). The mixture wasstirred at 100 °C for 2 hr. The mixture was diluted with water (2000 mL) and extracted with EtOAc (1000 mL ×3). The combined organic layer was washed with water (1000 mL ×2), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc / PE) to give the titled compound (63.0 g).1H NMR (400 MHz, CDCl3) δ 8.75 (s, 1H), 7.43 (d, J = 7.2 Hz, 1H), 7.25-7.34 (m, 2H), 6.90-6.97 (m, 1H), 4.74-4.86 (m, 2H), 4.56- 4.65 (m, 1H), 1.30-1.42 (m, 15H); MS m / z 331.0 [M+H]+.

[0356] F) 1-[(2S)-2-(3-{imidazo[1,2-b]pyridazin-6-yl}phenoxy)propyl]-1H- tetrazole To a solution of 1-[(2S)-2-[3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)phenoxy]propyl]-1H-tetrazole (11.0 g), Cs2CO3(21.7 g) and 6-chloroimidazo[1,2-b]pyridazine (5.12 g) in THF (100 mL) and water (25 mL) was added Pd(dppf)Cl2-CH2Cl2(2.72 g). The mixture was stirred under nitrogen atmosphere at 70 °C for 1 hr. The mixture was diluted with water (100 mL) and extracted with EtOAc (150 mL ×3). The combined organic layer was washed with brine (100 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc / PE) to give the titled compound (8.00 g).1H NMR (400 MHz, CDCl3) δ 8.78 (s, 1H), 7.99-8.05 (m, 2H), 7.83 (s, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.39-7.46 (m, 3H), 6.93 (dd, J = 8.4, 2.8 Hz, 1H), 4.87-4.93 (m, 1H), 4.79-4.83 (m, 1H), 4.62- 4.67 (m, 1H), 1.43 (d, J = 6.0 Hz, 3H).

[0357] G) 1-[(2S)-2-(3-{3-bromoimidazo[1,2-b]pyridazin-6- yl}phenoxy)propyl]-1H-tetrazole To a solution of 1-[(2S)-2-(3-{imidazo[1,2-b]pyridazin-6- yl}phenoxy)propyl]-1H-tetrazole (8.00 g) in DMF (70 mL) was added NBS (4.43 g). The mixture was stirred under nitrogen atmosphere at 25 °C for 12 hr. The mixture was diluted with water (60 mL) and extracted with EtOAc (100 mL ×3). The combined organic layer was washed with brine (100 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gelcolumn chromatography (EtOAc) to give the titled compound (8.75 g).1H NMR (400 MHz, CDCl3) δ 8.79 (s, 1H), 7.98 (d, J = 9.6 Hz, 1H), 7.78 (s, 1H), 7.58 (d, J = 7.6 Hz, 1H), 7.47-7.52 (m, 2H), 7.41 (t, J = 8.0 Hz, 1H), 6.92-6.94 (dd, J = 8.4, 2.0 Hz, 1H), 4.85- 4.91 (m, 1H), 4.78-4.82 (m, 1H), 4.62-4.68 (m, 1H), 1.43 (d, J = 6.4 Hz, 3H).

[0358] H) 2-[6-(3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]benzonitrile The reaction and purification were performed according to Example 121 Step C to give the titled compound.1H NMR (400 MHz, CDCl3) δ 8.76 (s, 1H), 8.18 (s, 1H), 8.13 (d, J = 9.6 Hz, 1H), 7.96 (d, J = 7.6 Hz, 1H), 7.91 (d, J = 7.6 Hz, 1H), 7.74–7.79 (m, 1H), 7.51-7.58 (m, 4H), 7.41 (t, J = 8.0 Hz, 1H), 6.94 (dd, J = 8.4, 2.4 Hz, 1H), 4.86-4.90 (m, 1H), 4.76-4.83 (m, 1H), 4.60-4.70 (m, 1H), 1.41 (d, J = 6.0 Hz, 3H). MS m / z 423.2 [M+H]+.

[0359] Example 244 2-[6-(5-{[(2S)-1-(1H-tetrazol-1-yl)propan-2-yl]oxy}pyridin-3- yl)imidazo[1,2-b]pyridazin-3-yl]benzonitrile

[0360] A) methyl (S)-2-((5-bromopyridin-3-yl)oxy)propanoate The reaction and purification were performed according to Example 57 Step A to give the titled compound.1H NMR (400 MHz, CDCl3) δ 8.26 (d, J = 1.6 Hz, 1H), 8.17 (d, J = 2.4 Hz, 1H), 7.29-7.30 (m, 1H), 4.75 (q, J = 6.8 Hz, 1H), 3.74 (s, 3H), 1.60 (d, J = 6.8 Hz, 3H).

[0361] B) (S)-2-((5-bromopyridin-3-yl)oxy)propan-1-ol The reaction and purification were performed according to Example 57 Step B to give the titled compound.1H NMR (400 MHz, CDCl3) δ 8.25 (d, J = 1.6 Hz, 1H), 8.22 (d, J = 2.8 Hz, 1H), 7.40-7.41 (m, 1H), 4.47-4.54 (m, 1H), 3.75-3.77 (m, 2H), 2.52 (brs, 1H), 1.29 (d, J = 6.4 Hz, 3H).

[0362] C) (S)-2-((5-bromopyridin-3-yl)oxy)propyl methanesulfonate The reaction and purification were performed according to Example 57 Step C to give the titled compound.1H NMR (400 MHz, CDCl3) δ 8.29 (d, J = 1.6 Hz, 1H), 8.22 (d, J = 2.4 Hz, 1H), 7.39-7.40 (m, 1H), 4.66-4.70 (m, 1H), 4.32 (d, J = 5.2 Hz, 2H), 3.02 (s, 3H), 1.37 (d, J = 6.4 Hz, 3H).

[0363] D) 3-bromo-5-{[(2S)-1-(1H-tetrazol-1-yl)propan-2-yl]oxy}pyridine The reaction and purification were performed according to Example 57 Step D to give the titled compound.1H NMR (400 MHz, CDCl3) δ 8.69 (s, 1H), 8.31 (d, J = 1.6 Hz, 1H), 8.14 (d, J = 2.4 Hz, 1H), 7.26 (s, 1H), 4.73-4.82 (m, 2H), 4.58- 4.63 (m, 1H), 1.40 (d, J = 6.0 Hz, 3H).

[0364] E) 3-{imidazo[1,2-b]pyridazin-6-yl}-5-{[(2S)-1-(1H-tetrazol-1- yl)propan-2-yl]oxy}pyridine The reaction and purification were performed according to Example 57 Step E and Example 121 Step A to give the titled compound.1H NMR (300 MHz, CDCl3) δ 8.76-8.82 (m, 2H), 8.37 (d, J = 2.7 Hz, 1H), 8.03-8.12 (m, 2H), 7.85 (s, 1H), 7.74 (d, J = 2.0 Hz, 1H), 7.47 (d, J = 9.6 Hz, 1H), 4.94-5.02 (m, 1H), 4.81-4.88 (m, 1H), 4.65-4.73 (m, 1H), 1.49 (d, J = 6.2 Hz, 3H); MS m / z 323.1 [M+H]+.

[0365] F) 3-{3-bromoimidazo[1,2-b]pyridazin-6-yl}-5-{[(2S)-1-(1H- tetrazol-1-yl)propan-2-yl]oxy}pyridine The reaction and purification were performed according to Example 121 Step B to give the titled compound.1H NMR (300 MHz, CDCl3) δ 8.85 (d, J = 1.4 Hz, 1H), 8.78 (s, 1H), 8.38 (d, J = 2.8 Hz, 1H), 8.06 (d, J = 9.4 Hz, 1H), 7.84 (s, 1H), 7.78-7.83 (m, 1H), 7.53 (d, J = 9.5 Hz, 1H), 4.94-5.03 (m, 1H), 4.80-4.88 (m, 1H), 4.65-4.74 (m, 1H), 1.50 (d, J = 6.1 Hz, 3H); MS m / z 401.1, 403.1 [M+H]+.

[0366] G) 2-[6-(5-{[(2S)-1-(1H-tetrazol-1-yl)propan-2-yl]oxy}pyridin-3- yl)imidazo[1,2-b]pyridazin-3-yl]benzonitrileThe reaction and purification were performed according to Example 121 Step C to give the titled compound.1H NMR (300 MHz, DMSO-d6) δ 9.47 (s, 1H), 8.86 (d, J = 1.7 Hz, 1H), 8.45 (d, J = 9.4 Hz, 1H), 8.40 (d, J = 2.8 Hz, 1H), 8.27 (s, 1H), 8.09-8.14 (m, 2H), 8.04 (d, J = 9.5 Hz, 1H), 7.91-7.99 (m, 2H), 7.70 (dt, J = 1.2, 7.7 Hz, 1H), 5.13 (dt, J = 3.6, 6.6 Hz, 1H), 4.87-4.95 (m, 1H), 4.76-4.85 (m, 1H), 1.35 (d, J = 6.2 Hz, 3H); MS m / z 424.2 [M+H]+.

[0367] Example 247 2-[6-(4-fluoro-3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]pyridine-3- carbonitrile To a mixture of 1-[(2S)-2-(5-{3-bromoimidazo[1,2- b]pyridazin-6-yl}-2-fluorophenoxy)propyl]-1H-tetrazole (400 mg), 2-chloropyridine-3-carbonitrile (238 mg) and CsF (726 mg) in MeOH (10 mL) and water (1.0 mL) was added (Bpin)2(485 mg). After being stirred at room temperature for 10 min, a mixture of Pd(OAc)2(21.4 mg) and cataCXium®A (68.5 mg) in toluene (0.50 mL) was added to the mixture. The mixture was stirred under nitrogen atmosphere at 60 °C for 30 min and then at 90 °C for 14 hr. The insoluble material was removed by filtration and washed with MeOH and THF. The filtrate was concentrated under reduced pressure. The residue was diluted with water and extracted with EtOAc. The organic layer was separated, washed with water and brine, dried over MgSO4and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (NH, EtOAc / hexane), and then preparative HPLC (water / CH3CN containing 0.1% TFA). The desired fraction was neutralized with saturated aqueous NaHCO3solution and extracted with EtOAc. The organic layer was separated, dried over MgSO4and concentrated under reduced pressure. The residue was crystallized from EtOAc / IPE to give the titled compound (42.0 mg) as a white solid.1H NMR (300 MHz, DMSO-d6) δ 9.40 (s, 1H), 9.05 (dd, J = 1.74, 4.86 Hz, 1H), 8.59 (dd, J = 1.70, 7.93 Hz, 1H), 8.43 (d, J = 9.63 Hz, 1H), 8.31 (s, 1H), 8.03 (d, J = 9.63 Hz, 1H), 7.86 (dd, J = 2.02, 8.16 Hz, 1H), 7.68-7.77 (m, 2H), 7.39 (dd, J = 8.57, 11.05 Hz,1H), 5.05 (dt, J = 3.76, 6.56 Hz, 1H), 4.77-4.96 (m, 2H), 1.37 (d, J = 6.14 Hz, 3H); MS m / z 442.1 [M+H]+.

[0368] Example 251 3-[6-(3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]pyridine-4- carbonitrile

[0369] A) 3-(tributylstannyl)pyridine-4-carbonitrile To a solution of 3-bromopyridine-4-carbonitrile (200 mg) in toluene (5.0 mL) were added hexabutylditin (1.27 g) and Pd(PPh3)4(126 mg). The mixture was stirred under nitrogen atmosphere for 110 °C for 16 hr. The mixture was concentrated under reduced pressure to give the crude titled compound (860 mg). The crude product was used for next step without purification.

[0370] B) 3-[6-(3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]pyridine-2- carbonitrile A mixture of 3-(tributylstannyl)pyridine-4-carbonitrile (196 mg), 1-[(2S)-2-(3-{3-bromoimidazo[1,2-b]pyridazin-6- yl}phenoxy)propyl]-1H-tetrazole (200 mg), Pd(PPh3)4 (58.0 mg) and 1,4-dioxane (5.0 mL) was stirred under nitrogen atmosphere at 100 °C for 16 hr. The mixture was diluted with saturated aqueous KF solution (50 mL) and extracted with EtOAc. The organic layer was dried over Na2SO4and concentrated under reduced pressure. The residue was purified by preparative HPLC (water / CH3CN containing 0.05% NH3-H2O). Most of CH3CN was removed under reduced pressure and the remaining solvent was removed by lyophilization to give the titled compound (54.0 mg) as a light yellow solid.1H NMR (400 MHz, CDCl3) δ 9.36 (s, 1H), 8.82 (d, J = 5.2 Hz, 1H), 8.78 (s, 1H), 8.28 (s, 1H), 8.16 (d, J = 9.6 Hz, 1H), 7.79 (d, J = 4.8 Hz, 1H), 7.60 (d, J = 9.6 Hz, 1H), 7.49-7.55 (m, 2H), 7.36- 7.45 (m, 1H), 6.91-6.98 (m, 1H), 4.86-4.90 (m, 1H), 4.76-4.83 (m, 1H), 4.61-4.70 (m, 1H), 1.42 (d, J = 6.0 Hz, 3H). MS m / z 424.2 [M+H]+.

[0371] Example 253 1-methyl-3-[6-(3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]-1,2-dihydropyridin-2- one

[0372] A) 3-[6-(3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]-1,2-dihydropyridin-2- one The reaction and purification were performed according to Example 121 Step C to give the titled compound.1H NMR (400 MHz, DMSO-d6) δ 12.06 (brs, 1H), 9.48 (s, 1H), 8.98 (dd, J = 7.2, 2.0 Hz, 1H), 8.71 (s, 1H), 8.31 (d, J = 9.6 Hz, 1H), 7.87 (d, J = 9.6 Hz, 1H), 7.69 (d, J = 7.6 Hz, 1H), 7.61 (s, 1H), 7.40-7.52 (m, 2H), 7.09 (dd, J = 8.4, 2.4 Hz, 1H), 6.51 (t, J = 7.2 Hz, 1H), 5.01-5.11 (m, 1H), 4.81-4.91 (m, 1H), 4.69-4.79 (m, 1H), 1.36 (d, J = 6.4 Hz, 3H); MS m / z 415.3 [M+H]+.

[0373] B) 1-methyl-3-[6-(3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,...

Claims

CLAIMS 1. A compound represented by the formula (I):wherein X1is N or CRX1wherein RX1is a hydrogen atom, a halogen atom or aC1-6alkyl group; X2, X3and X4are each independently C or N, and one of X2, X3and X4is N, and the other two are C; X5is N or CRX5wherein RX5is a hydrogen atom; X6is N or CRX6wherein RX6is a hydrogen atom; Ring A1is an optionally further substituted C6-14aromatic hydrocarbon, an optionally further substituted aromatic heterocycle, or an optionally further substituted non-aromatic heterocycle, each of which is optionally fused with an optionally substituted 5- or 6-membered ring; Y1is N or CRY1wherein RY1is a hydrogen atom; Y2is N or CRY2wherein RY2is a hydrogen atom, a halogen atom or a cyano group; Y3is N or CRY3wherein RY3is a hydrogen atom or a halogen atom; Y4is N or CRY4wherein RY4is a hydrogen atom or a halogen atom; Ring B1is an optionally further substituted aromatic heterocycle; V is O, S, S(O), S(O)2or N(RV) wherein RVis a hydrogen atom or an optionally substituted C1-6alkyl group; and Z is an optionally substituted C1-6alkylene group; or a pharmaceutically acceptable salt thereof.

2. The compound or pharmaceutically acceptable salt according to claim 1, wherein V is O.

3. The compound or pharmaceutically acceptable salt according to claim 1, wherein Ring B1is an optionally further substituted 5- membered aromatic heterocycle.

4. The compound or pharmaceutically acceptable salt according to claim 1, wherein Z is an optionally substituted ethylene group.

5. The compound or pharmaceutically acceptable salt according to claim 1, wherein X5is N.

6. The compound or pharmaceutically acceptable salt according to claim 1, wherein X6is CH.

7. The compound or pharmaceutically acceptable salt according to claim 1, wherein at least one of Y1, Y2, Y3and Y4are N.

8. The compound or pharmaceutically acceptable salt according to claim 1, which is a compound represented by the formula (I-1):wherein each symbol is as defined in claim 1, or a pharmaceutically acceptable salt thereof.

9. A compound represented by the formula (II):wherein X1is N or CRX1wherein RX1is a hydrogen atom, a halogen atom or a C1-6alkyl group; X2, X3and X4are each independently C or N, and one of X2, X3and X4is N, and the other two are C; Ring A2is an optionally further substituted benzene ring, an optionally further substituted 5- or 6-membered aromatic heterocycle, or an optionally further substituted 5- or 6- membered non-aromatic heterocycle, each of which is optionally fused with an optionally substituted 5- or 6-membered ring; Y1is N or CRY1wherein RY1is a hydrogen atom; Y2is N or CRY2wherein RY2is a hydrogen atom, a halogen atom or a cyano group; Y3is N or CRY3wherein RY3is a hydrogen atom or a halogen atom; Y4is N or CRY4wherein RY4is a hydrogen atom or a halogen atom; Ring B2is an optionally further substituted 5-membered aromatic heterocycle; and R1is a C1-6alkyl group; or a pharmaceutically acceptable salt thereof.

10. The compound or pharmaceutically acceptable salt according to claim 9, wherein X1is CH.

11. The compound or pharmaceutically acceptable salt according to claim 9, wherein Ring B2is tetrazole or triazole, each of which is bonded at its nitrogen.

12. The compound or pharmaceutically acceptable salt according to claim 9, wherein R1is methyl.

13. The compound or pharmaceutically acceptable salt according to claim 9, wherein Ring A2is a benzene ring, a 6-membered aromatic heterocycle, or a 6-membered non-aromatic heterocycle, each of which is further substituted by one cyano group and optionally further substituted.

14. The compound or pharmaceutically acceptable salt according to claim 9, wherein at least one of Y1, Y2, Y3and Y4are N.

15. The compound or pharmaceutically acceptable salt according to claim 9, which is a compound represented by the formula (II-1):wherein each symbol is as defined in claim 9, or a pharmaceutically acceptable salt thereof.

16. A compound represented by the formula (III):X2, X3and X4are each independently C or N, and one of X2, X3and X4is N, and the other two are C; Ring A3is an optionally further substituted benzene ring, an optionally further substituted 6-membered nitrogen-containingaromatic heterocycle, or an optionally further substituted 6- membered nitrogen-containing non-aromatic heterocycle; Y1is N or CRY1wherein RY1is a hydrogen atom; Y2is N or CRY2wherein RY2is a hydrogen atom, a halogen atom or a cyano group; Y3is N or CRY3wherein RY3is a hydrogen atom or a halogen atom; Y4is N or CRY4wherein RY4is a hydrogen atom or a halogen atom; and W is N or CH; or a pharmaceutically acceptable salt thereof.

17. The compound or pharmaceutically acceptable salt according to claim 16, wherein the partial structure represented by the formula;is a partial structure represented by the formula (A3-1)-(A3-9);wherein Q1is N or CRQ1wherein RQ1is (a) a hydrogen atom, (b) a cyano group, (c) a halogen atom, (d) a hydroxy group, (e) a carboxy group, (f) an amino group, (g) an optionally substituted C1-6alkyl group, (h) an optionally substituted C1-6alkoxy group, (i) a C1-6alkyl-carbonyl group, (j) a C1-6alkoxy-carbonyl group, (k) an optionally substituted mono- or di-C1-6alkylamino group, (l) an optionally substituted mono- or di-C1-6alkyl- carbonylamino group, (m) a mono- or di-C1-6alkoxy-carbonylamino group, (n) a mono- or di-C1-6alkyl-carbamoyl group, (o) a di-C1-6alkylsulfinylidenamino group, (p) a C3-10cycloalkyl group, (q) an optionally substituted C3-10cycloalkyloxy group, (r) a 3- to 8-membered monocyclic non-aromatic heterocyclic group, (s) an optionally substituted 3- to 8-membered monocyclic non- aromatic heterocyclyloxy, (t) an optionally substituted 3- to 8-membered monocyclic non- aromatic heterocyclylcarbonyl group, or (u) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group, Q2is N or CRQ2wherein RQ2is (a) a hydrogen atom, (b) a halogen atom, or (c) a C1-6alkoxy group, Q3is N or CRQ3wherein RQ3is (a) a hydrogen atom, (b) a cyano group, (c) a halogen atom,(d) a carboxy group, (e) an optionally substituted C1-6alkyl group, (f) an optionally substituted C1-6alkoxy group, (g) a C1-6alkyl-carbonyl group, (h) a C1-6alkoxy-carbonyl group, (i) a mono- or di-C1-6alkylamino group, (j) an optionally substituted mono- or di-C1-6alkyl-carbamoyl group, (k) a di-C1-6alkylsulfinylidenamino group, or (l) a 3- to 8-membered monocyclic non-aromatic heterocyclylidenamino group, Q4is N or CRQ4wherein RQ4is (a) a hydrogen atom, or (b) a halogen atom, and N of Q1, Q2, Q3and Q4is each optionally oxidized; RN1is a hydrogen atom or a C1-6alkyl group; RN2is a hydrogen atom or a C1-6alkyl group; RN3is a hydrogen atom or a C1-6alkyl group; and RN4is a hydrogen atom or a C1-6alkyl group optionally substituted by 1 to 3 halogen atoms.

18. The compound or pharmaceutically acceptable salt according to claim 16, wherein at least one of Y1, Y2, Y3and Y4are N.

19. The compound or pharmaceutically acceptable salt according to claim 16, which is a compound represented by the formula (III-1):wherein each symbol is as defined in claim 16, or a pharmaceutically acceptable salt thereof.

20. A compound selected from the group consisting of 2-[6-(4-fluoro-3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]benzonitrile, 2-[6-(4-fluoro-3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]pyridine-3- carbonitrile, 2-[6-(3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]pyridine-3- carbonitrile, 2-[5-(3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2-yl]oxy}phenyl)-3H- imidazo[4,5-b]pyridin-3-yl]pyridine-3-carbonitrile, 4-fluoro-2-[6-(5-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}pyridin-3-yl)imidazo[1,2-b]pyridazin-3-yl]benzonitrile, 4-methoxy-2-[6-(3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]pyridine-3- carbonitrile, 2-[6-(4-fluoro-3-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}phenyl)imidazo[1,2-b]pyridazin-3-yl]-4-methoxypyridine-3- carbonitrile, 4-fluoro-2-[5-(6-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}pyridin-2-yl)-3H-imidazo[4,5-b]pyridin-3-yl]benzonitrile, 4-fluoro-2-methoxy-6-[6-(6-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}pyrazin-2-yl)imidazo[1,2-b]pyridazin-3-yl]benzonitrile, 4-fluoro-2-methoxy-6-[5-(6-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}pyridin-2-yl)-3H-imidazo[4,5-b]pyridin-3-yl]benzonitrile, and 4-fluoro-2-methoxy-6-[6-(6-{[(2S)-1-(1H-tetrazol-1-yl)propan-2- yl]oxy}pyridin-2-yl)imidazo[1,2-b]pyridazin-3-yl]benzonitrile, or a pharmaceutically acceptable salt.

21. A medicament comprising the compound or pharmaceutically acceptable salt according to claim 1.

22. The medicament according to claim 21, which is a calcium / calmodulin-dependent protein kinase II inhibitor.

23. The medicament according to claim 21, which is an agent for the prophylaxis or treatment of cardiac diseases.

24. The medicament according to claim 23, wherein the cardiac disease is selected from catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure and fatal arrhythmia.

25. The compound or pharmaceutically acceptable salt according to claim 1 for use in the prophylaxis or treatment of cardiac diseases.

26. The compound or pharmaceutically acceptable salt according to claim 25, wherein the cardiac disease is selected from catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure and fatal arrhythmia.

27. A method for inhibiting calcium / calmodulin-dependent protein kinase II in a mammal, which comprises administering an effective amount of the compound or pharmaceutically acceptable salt according to claim 1 to the mammal.

28. A method for preventing or treating cardiac diseases in a mammal, which comprises administering an effective amount of the compound or pharmaceutically acceptable salt according to claim 1 to the mammal.

29. The method according to claim 28, wherein the cardiac disease is selected from catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure and fatal arrhythmia.

30. Use of the compound or pharmaceutically acceptable salt according to claim 1 for the production of an agent for the prophylaxis or treatment of cardiac diseases.

31. The use according to claim 30, wherein the cardiac disease is selected from catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure and fatal arrhythmia.